{'breast cancer': {'January': 4, 'September': 2, 'bisphosphonates': 1, 'denosumab': 1, 'Actinomyces': 4, 'chemotherapy': 50, 'estradiol': 8, 'testosterone': 1, 'progesterone': 2, 'AKT inhibitor': 1, 'paclitaxel': 8, 'FoundationOne': 1, 'PUPOSE': 1, 'multitesting': 1, 'MSH6': 1, 'MSH2': 1, 'amino acid ( amino acid': 1, 'amino acid': 5, 'deregulation': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'Tamoxifen': 18, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 9, 'glutathione peroxidase ( GSH - Px )': 1, 'trastuzumab': 14, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'cisplatin': 4, 'nanogels': 2, 'curcumin': 7, 'anticancer': 3, 'glutathione ( GSH )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 11, 'ovulation': 1, 'letrozole': 12, 'clomiphene citrate': 3, 'clomiphene': 6, 'livebirth': 5, 'Takeda': 1, 'Roche': 1, 'estrogen receptor / progesterone receptor / human epidermal growth factor receptor': 1, 'fasting insulin': 2, 'insulin': 3, 'tamoxifen': 16, 'antineoplastic': 1, 'Chemotherapy': 7, 'suramin': 3, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'Ursolic acid ( Ursolic acid': 1, 'Ursolic acid': 6, 'artemisinin': 1, 'dihydroartemisinin': 3, 'neoadjuvant chemotherapy': 8, 'PARP inhibitor': 1, 'PARP inhibitors': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'Kyoto': 1, 'compound Kushen': 2, 'November': 1, 'chemotherapies': 1, 'nomogram': 1, 'CRISPR': 2, 'progesterone receptor (PR ( progesterone receptor )': 2, 'estrogen receptor': 3, 'Herceptin': 13, 'dimerization blocker , Stattic ( S )': 1, 'nanocarrier': 1, 'Stattic': 5, 'PLGA nanoparticles': 1, "progesterone receptor (PR status . Rates of high Wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'steroid': 2, 'prednisolone': 1, 'Prednisolone': 1, 'progesterone receptor': 1, 'eribulin': 1, 'Fulvestrant': 1, 'EC': 1, 'capecitabine': 1, 'docetaxel': 4, 'nivolumab': 3, 'anastrozole': 2, 'epirubicin': 5, 'cyclophosphamide': 6, 'fructose': 1, 'pertuzumab': 5, 'fluorouracil': 5, 'NeoSphere': 1, 'TRYPHAENA': 1, 'imatinib': 4, 'fulvestrant': 2, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'antifungal': 1, 'chemotherapy(TC)and': 1, 'chemo': 2, 'bevacizumab': 4, 'fulvestrant)was': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'ICG': 1, 'October': 2, 'intratumorally': 1, 'photodynamic': 1, 'aromatase inhibitors': 1, 'CDK4/6 inhibitors': 1, 'glucocorticoid': 1, 'anthracycline': 1, 'Progesterone receptor (PR membrane component': 1, 'Progesterone receptor membrane component': 7, 'FPR2': 1, 'GPR37': 1, 'CCR5': 1, 'radioactive iodine ( radioactive iodine ) treatment increased markedly . radioactive iodine': 1, 'radioactive iodine treatment': 2, 'radioactive iodine ( yes v no or unknown ) using Poisson regression among > /= 5-': 1, 'radioactive iodine treatment ( 45': 1, 'nonsignificantly': 1, 'radioactive iodine': 2, 'carboplatin': 3, 'blebbing': 1, 'psychotropics': 1, 'doxycycline': 1, 'citrate ions': 1, 'anticancer compounds': 1, 'herceptin': 1, 'PSN': 1, 'CAncer': 1, 'progesterone receptor ) receptor (PR - negative human breast cancer (BC . Here , we show that reverting the high LIP': 1, 'NMYC': 1, 'PsycINFO': 1, 'hormone binding globulin ( sex hormone binding globulin )': 1, 'hormone binding globulin': 1, 'hormone binding globulin by suppression status . Conclusions : There were no differences in FE2 but significantly lower E2 and higher sex hormone binding globulin among women with HIV versus without HIV . Further research is merited in a large contemporary sample': 1, 'Adjuvant': 1, 'bisphosphonate': 6, 'ibandronate': 1, 'zoledronic acid': 1, 'glutathione peroxidase': 2, 'iRGD': 1, 'ferroptosis': 1, 'postmastectomy': 1, 'Clinicopathological': 1, 'progesterone receptor (PR ( PgR ) status , in which ER-/PgR + tended to present the worst prognosis . CONCLUSION : This study revealed profound heterogeneity associated with hazard ratios status in the clinical outcomes of human epidermal growth factor receptor 2 - positive breast cancer (BC regarding clinicopathological': 1, 'Ado - trastuzumab emtansine ( T - DM1 )': 1, 'monoclonal antibody': 1, 'microtubule inhibitor emtansine': 1, 'L1CAM': 1, 'shRNA': 1, 'Oncomine': 1, 'Aurein': 1, 'aromatase inhibitors ( aromatase inhibitors )': 1, 'NSAIDs': 1, '2012.PURPOSE': 1, '12,907': 1, 'CHOP': 1, 'pAMPK': 2, 'GRP78': 2, 'Bax': 2, 'valrubicin': 1, 'antibiotics': 1, 'steroids': 2, 'leuprorelin': 1, 'Fluorouracil': 2}, 'tumor': {'FOLFIRINOX': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'January': 1, 'somatostatin': 1, 'bisphosphonates': 1, 'denosumab': 1, 'Actinomyces': 4, 'chemotherapy': 35, 'rapamycin': 5, 'Pancreaticoduodenectomy': 2, 'Linifanib': 1, 'HDAC': 1, 'chemo': 1, 'interleukin-2': 61, 'IL-2': 56, 'docetaxel': 5, 'gemcitabine': 1, 'nab - paclitaxel against B16F10': 1, 'covalent inhibitor': 1, 'GSH': 1, 'Astragalus polysaccharides': 1, 'Astragalus polysaccharides )': 1, 'catla': 2, 'Catla catla )': 1, 'Albumin': 1, 'malondialdehyde': 1, 'glutathione peroxidase ( glutathione peroxidase': 1, 'nitric oxide synthase ( nitric oxide synthase )': 1, 'hydrogen peroxides ( H2O2 )': 1, 'Astragalus polysaccharides diets on week': 1, 'Astragalus polysaccharides enriched diets revealed significant improved tumor necrosis factor ( TNF)-alpha and tumor necrosis factor receptor - associated factor-6 ( TNF receptor-associated factor-6 ) mRNA expression on week': 1, 'Paclitaxel': 4, 'praziquantel': 1, 'PD-1': 1, 'pemetrexed': 1, 'cisplatin': 5, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - Pancreaticoduodenectomy - L1 therapy (PDT': 1, 'OPTN': 1, 'photothermal': 6, 'AECII': 1, 'spirulina': 2, 'atezolizumab': 1, 'AKT inhibitor': 1, 'paclitaxel': 2, 'FoundationOne': 1, 'taxane': 2, 'Cobas': 1, 'osimertinib': 1, 'fluorouracil': 1, 'leucovorin': 1, 'irinotecan': 8, 'oxaliplatin': 1, 'serine hydrolase carboxylesterase': 1, 'PDGFRA': 1, 'NCTN': 1, 'amino acid ( amino acid': 1, 'amino acid': 5, 'O2': 1, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'Electrodynamic': 2, 'zeolite imidazole': 1, 'single amino acid mutations': 1, 'Mmp8': 1, 'eotaxin': 1, 'Tgfrbeta': 1, 'Mmp2': 1, 'phosphodiesterase-5 inhibitors': 1, 'Metformin': 1, 'metformin': 10, 'neoadjuvant immunotherapy': 1, 'nivolumab': 1, 'ipilimumab': 2, 'Chemotherapy': 1, 'Pembrolizumab': 1, 'September': 2, 'pembrolizumab': 4, 'beta - hydroxybutyrate ( beta-hydroxybutyrate )': 1, 'fatty acid': 4, 'insulin': 3, 'beta-hydroxybutyrate': 1, 'quantitative insulin sensitivity check index RQUICKI - beta-hydroxybutyrate': 1, 'SUVmean': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'fatty acids': 1, 'hexadecenoic acid': 1, 'IL-2 hydroxy octadecanoic acid': 1, 'dienes': 1, 'phytosphingosine': 1, 'doxorubicin': 3, 'ceramide B ( 2 )': 2, 'sertoliomas': 1, 'aprepitant': 1, 'Clinicopathological': 1, 'clinicopathological': 1, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'nanogels': 2, 'curcumin': 2, 'Annexin': 1, 'p38 inhibitor': 1, 'JNK inhibitor': 1, 'PKLR': 1, 'furosemide': 3, 'cimetidine': 2, 'para - amino hippuric acid': 1, 'saline': 1, 'OAT inhibitor': 1, 'superoxide dismutase': 1, 'lavage': 3, 'conatumumab': 1, 'quercetin': 1, 'glucocorticoid receptor interactions in normal tissues and tumor is crucial': 1, 'glucocorticoid receptor antagonists RU486 ( mifepristone )': 1, 'dexamethasone': 1, 'antagonist': 1, 'glucocorticoid receptor interactions can be measured in vivo with (': 1, 'glucocorticoid receptor antagonists': 1, 'C5aR antagonist blocked': 1, 'Ductal': 2, 'acinar': 1, 'clonally': 1, 'uracil': 1, 'cytarabine': 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide ( 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide )": 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide": 1, 'miR-133b': 7, 'Wilcoxon': 1, 'shrewd immunohistochemical': 1, 'anisole': 1, 'receptor alpha immunohistochemical expression .': 1, 'receptor alpha immunohistochemical expression , respectively . Thus , enhancer of zeste homolog 2': 1, 'TFEB': 2, 'intratumoral': 1, 'beta receptor (': 1, 'beta receptor )': 1, 'beta receptor in': 1, 'beta receptor': 1, 'Lymphotoxin': 1, 'beta receptor activated the non - canonical NF - kappaB signaling pathway in NIH3T3 cells': 1, 'Lymphotoxin-beta receptor - NIH3T3 cells': 1, 'beta receptor - NIH3T3 cells': 1, 'November': 1, 'lumbosacral': 1, 'lactic acid bacteria ( lactic acid bacteria )': 1, 'lactic acid bacteria': 1, 'streptozotocin': 4, 'curcumin nanoparticles ( curcumin nanoparticles': 1, 'nitric oxide ( nitric oxide': 1, 'curcumin nanoparticles': 1, 'immunoblotting': 1, 'sorafenib': 9, 'lenvatinib': 6}, 'cancer': {'urapidil': 1, 'January': 7, 'September': 5, 'bisphosphonates': 1, 'denosumab': 1, 'Actinomyces': 4, 'chemotherapy': 43, 'intratumoral': 1, 'Corynoline': 1, 'acetylcorynoline': 2, 'rapamycin': 4, 'mercapturic acid': 1, 'multivalency': 1, 'Linifanib': 1, 'Cytosponge': 1, 'Rosetrees': 1, 'Stoneygate': 1, 'cisplatin': 11, 'gemcitabine': 9, 'pemetrexed': 2, 'bevacizumab': 4, 'demethylase': 6, 'higenamine': 1, 'HDAC': 1, 'MAGL': 1, 'pharmacokinetics': 1, 'chemoradiotherapy': 4, 'carboplatin': 5, 'paclitaxel': 7, 'trametinib': 2, '-1/1/2/3': 1, 'PD-1 monoclonal antibody treatment . Collectively , these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral': 1, 'PD-1 monoclonal antibody can be an efective reagent': 1, 'chemo': 1, 'docetaxel': 5, 'nab - paclitaxel against B16F10': 1, 'Paeoniaceae': 1, 'p70S6 K signaling': 1, 'imidazoquinoline agonists': 1, 'covalent inhibitor': 1, 'GSH': 1, 'Cytotoxic': 1, 'photothermal': 5, 'iron oxide': 1, 'chemotherapies': 1, 'chloroisopropyl': 2, 'phosphate': 1, 'Organophosphate': 1, 'Paclitaxel': 4, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - PD - L1 therapy (PDT': 1, 'OPTN': 1, 'chemokine ligand': 1, 'LR': 1, 'RBC folate': 3, 'RBC': 1, 'RBC folate concentration': 1, 'normal folate status is important for reducing the risk of cervical intraepithelial': 1, 'propofol': 3, 'sevoflurane': 2, 'Propofol': 1, 'anesthesia': 1, 'ICNB': 3, 'ASA': 1, 'anesthetics': 1, 'estradiol': 1, 'testosterone': 1, 'progesterone': 1, 'nicotine': 2, 'imatinib': 2, 'erlotinib': 1, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 1, 'Imatinib': 1, 'scopolamine': 1, 'Allyl isothiocyanate ( Allyl isothiocyanate )': 1, 'Allyl isothiocyanate': 4, 'Allyl isothiocyanate action': 1, 'intragastrically': 1, 'Irrespectively': 1, 'Allyl isothiocyanate considerably lowered thyroid hormones ( fT4 , fT3 )': 1, 'Allyl isothiocyanate at': 2, 'hydroxybutyric acid': 1, 'insulin': 1, 'blood insulin': 1, 'atezolizumab': 1, 'nomogram': 1, 'AKT inhibitor': 1, 'FoundationOne': 1, 'taxane': 2, 'Cobas': 1, 'osimertinib': 1, 'PUPOSE': 1, 'multitesting': 1, 'MSH6': 1, 'MSH2': 1, 'NCTN': 1, 'amino acid ( amino acid': 1, 'amino acid': 1, 'anticoagulation': 1, 'Glyco disulfide acted as reducing and capping agents of gold ions': 1, 'O2': 1, 'CRISPR': 1, 'phosphodiesterase-5 inhibitors': 1, 'Metformin': 1, 'metformin': 10, 'Lewis acid as additive': 1, 'trifluridine': 1, 'tipiracil': 2, 'FTD': 1, 'fluorouracil': 2, 'October': 2, 'June': 1, 'Trifluridine': 1, 'deregulation': 1, 'oxaliplatin': 3, 'supplementation': 1, 'ceramides': 1, 'FDI': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 1, 'ipilimumab': 2, 'CCRT': 1, 'IQR': 2, 'Chemotherapy': 1, 'Pembrolizumab': 1, 'pembrolizumab': 4, 'lignans': 1, 'adenosine triphosphate': 2, 'linalool oxide': 1, 'fatty acid biosynthesis': 1, 'phosphatidic acid': 1, 'cholesteryl esters distinguished amino acid': 1, 'SUVmean': 1, 'flavonoids chemical': 1, 'superoxide anion radicals': 1, 'Arthrocnemum indicum (Willd.) Moq. indicum shoot ethanolic extract': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'Isavuconazole': 6, 'Mucormycosis': 1, 'antifungal': 2, 'corticosteroids': 1, 'Tamoxifen': 16, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 1, 'glutathione peroxidase ( GSH - Px )': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'Characella': 1, 'GNPS': 1, 'cyanocobalamin': 1, 'vitamin B12': 1, 'Nivolumab': 3, 'Undaria': 1, 'Lerdsin': 1, 'mirtazapine': 6, 'Mirtazapine': 1, 'chemoradiation': 1, 'niraparib': 2, 'haematological': 1, 'trastuzumab': 3, 'PD-1': 5, 'PD-1 inhibitors in combination': 1, 'PD-1 inhibitor': 1, 'Adjuvant chemotherapy': 1, 'neoadjuvant chemotherapy': 1, 'irinotecan': 1, 'Akaike': 1, 'alectinib': 2, 'CBDCA': 3}, 'polycystic ovarian syndrome': {'letrozole': 29, 'clomiphene citrate': 6, 'clomiphene': 34, 'livebirth': 5, 'Takeda': 1, 'Roche': 1, 'folic acid': 1, 'folic acid (PFHxS , and a control group ( group 3': 1, 'folic acid (PFHxS from 1 month': 1, 'insulin': 93, 'impaired insulin secretion': 1, 'metformin': 49, 'Metformin': 18, 'Letrozole': 5, 'normal saline water ( 0.9': 1, 'malondialdehyde': 7, 'Choline': 1, 'choline': 2, 'Omega-3': 2, 'Omega-3 ( 10.78 + /- 1.71 )': 1, 'estradiol': 17, 'progesterone': 18, 'Gpx3': 1, 'tamoxifen': 2, 'Tamoxifen': 1, 'glucose': 5, 'Ellagic acid treatment restored them to levels seen in the control group . Ellagic acid reduced the days': 1, 'dehydroepiandrosterone': 5, 'estrogen receptor (LHR ( estrogen receptor )': 1, 'Ellagic acid treatment': 1, 'Ellagic acid improved glucose intolerance and insulin intolerance': 1, 'Ellagic acid groups': 1, 'Ellagic acid': 4, 'carbamazepine': 1, 'ovarian insulin resistance in polycystic ovarian syndrome remain elusive . METHODS : Follicular fluid': 1, 'vitamin D': 5, 'Antimullerian hormone (FSH levels , antral follicle': 1, 'luteinizing hormone (FSH / choriogonadotropin receptor (LHR ; CYP17A1 : cytochrome P450 family 17 subfamily A member': 1, 'fasting insulin ( FINS : WMD -3.40': 1, 'lithium': 4, 'Steroid hormone (FSH profiles were compared between patients with and without follicle-stimulating hormone receptor - autoantibodies or luteinizing hormone receptor - autoantibodies . Signal linearity and detection ranges were characterized and both methods': 1, 'steroid': 9, 'Scopus': 2, 'Embase': 2, 'LKB1': 1, 'rapamycin': 11, 'January': 9, 'September': 3, 'ventriculo': 1, 'superoxide dismutase ( superoxide dismutase )': 2, 'PAPASH': 1, 'GSH': 1, 'CINAHL': 2, 'Insulin': 3, 'amino acid (PFHxS residues crucial': 1, 'shRNA': 1, 'aspirin': 2, 'nonsteroidal': 1, 'hyperandrogenism': 3, 'Sildenafil': 1, 'diuretics': 1, 'diuretic': 1, 'anorexigenic': 1, 'Serum insulin': 2, 'steroidal hormones': 1, 'luteinizing hormone': 3, 'Anethum': 1, 'Kurz': 1, 'tilatailam': 3, 'gonadotropins': 2, 'Kyoto': 4, 'clomiphene citrate ( clomiphene citrate': 2, 'Fibroscan': 1, 'fasting insulin': 2, 'acetylcysteine': 1, 'Antioxidants': 1, 'CV-6': 1, 'SP-6': 1, 'body insulin sensitivity measured by the clamp': 1, 'chemerin': 4, 'normal progesterone secretion with lower concentrations in polycystic ovarian syndrome human luteinised granulosa cells': 1, 'serum insulin': 3, 'Unani': 1, 'Lashansky': 1, 'SPORTDiscus': 1, 'rat': 1, 'SF': 4, 'aromatase inhibitors ( aromatase inhibitors )': 1, 'aromatase inhibitors': 3, 'aromatase inhibitors treatment . Polycystic ovary syndrome ( polycystic ovarian syndrome )': 1, 'chemotherapy': 3, 'October': 1, 'herbicides': 1, 'oestrogen': 1, 'Masashi': 1, 'curcumin': 5, 'oogenesis': 1, 'intracytoplasmic sperm injection': 1, 'kisspeptin hormone (FSH - release kinetics . It highlighted the recently identified ligands': 1, 'pioglitazone': 1, 'nitric oxide': 3, 'dehydroepiandrosterone - sulfate': 1, 'vitamin D supplementation': 1, 'perfluorooctanesulfonic acid )': 1, 'perfluorohexane sulfonic acid': 2, 'genistein': 6, 'estrogen receptor': 1, 'exaggerated insulin': 1, 'Clomiphene citrate': 1, 'progesterone metabolite allopregnanolone ( allopregnanolone )': 1, 'benzodiazepines': 1, 'Sepranolone': 1, 'probiotics': 2, 'synbiotics': 1, 'parasitome': 1, 'Curcumin': 1, 'Ellagic acid (PFHxS ( Ellagic acid )': 1, 'cholesterol': 1, 'Ellagic acid ( P < 0.05 )': 1, 'Ellagic acid supplementation can be helpful as a diet supplement in women with polycystic ovarian syndrome through improvement in insulin resistance': 1, 'statin': 1, 'blood glucose': 1, 'statins': 1, 'Vitamin D': 2, 'acarbose': 1, 'myoinositol': 1, 'AUCglucagon': 1, 'Valproate': 3, 'lamotrigine': 6, 'LD)-VPA': 1, 'tPA': 1, 'spironolactone': 5, 'F1 formulation': 1, 'flotillin': 5, 'STARBASE': 1, 'hormone replacement cycles protocols ( 86': 1, 'hormone replacement cycles protocols . Subsequent multivariate logistic regression analysis also yielded similar results . Conclusion : stimulated cycles': 1, 'hormone replacement cycles protocols . Evidence is available': 1, 'hormone replacement cycles': 1, 'GnRH receptor autoantibody': 3, 'GnRH receptor autoantibody activity in polycystic ovarian syndrome patients compared with control subjects ; and 2 ) effectiveness of gonadotrophin-releasing hormone antagonist in suppressing GnRH receptor autoantibody': 1, 'GnRH receptor autoantibody activity levels in the polycystic ovarian syndrome group were significantly higher than in the control group . With cetrorelix': 1, 'mRNAs': 3, 'atropine': 1, 'theophylline': 2, 'azithromycin': 1, 'dexamethasone': 1, 'melatonin': 1, 'Melatonin': 1, 'leptin': 2, 'insulin receptor (LHR ( insulin receptor )': 1, 'uterine insulin receptor': 1, 'testosterone': 2, 'chenodeoxycholic acid (PFHxS ( chenodeoxycholic acid )': 1, 'antibiotic': 1, 'chenodeoxycholic acid treatment': 1, 'chenodeoxycholic acid improved glucose metabolism': 1, 'SKBZ': 1, 'Wilcoxon': 1, 'aromatase inhibitor': 1, 'venepuncture': 1, 'Col6a5': 1, 'contraceptives': 1, 'lipid profle': 1, 'Indonesia': 1, 'Vitex': 9, 'homeopathic medicines': 1, 'fasting insulin ( r = -0.324 , P <': 1, 'free testosterone': 1, 'dehydroepiandrosterone sulfate': 1, 'vitamin C': 3, 'androgen receptor extract': 1, 'androgen receptor with vitamin C': 1, 'glutathione': 1, 'adipocytokines': 1, 'single nucleotide polymorphisms ( single nucleotide polymorphisms )': 1, 'adiponectin': 1}, 'tumors': {'somatostatin': 1, 'epoetin alpha ( Retacrit(R ) )': 1, 'chemotherapy': 34, 'iron': 3, 'epoetin': 1, 'epoetin alpha biosimilar were reported': 1, 'January': 3, 'September': 3, 'intratumoral': 2, 'antibiotics': 1, 'diuretics': 1, 'cisplatin': 7, 'biotherapeutic cocktail': 1, 'HDAC': 1, 'chemo': 6, 'docetaxel': 2, 'gemcitabine': 2, 'nab - paclitaxel against B16F10': 1, 'photothermal': 6, 'ICNB': 3, 'ASA': 1, 'anesthetics': 2, 'nomogram': 1, 'AKT inhibitor': 1, 'paclitaxel': 15, 'FoundationOne': 1, 'PDGFRA': 1, 'PFS': 3, 'amino acid ( amino acid': 1, 'amino acid': 3, 'O2': 1, 'phosphodiesterase-5 inhibitors': 1, 'trifluridine': 1, 'tipiracil': 2, 'FTD': 1, 'fluorouracil': 2, 'October': 1, 'June': 1, 'Trifluridine': 1, 'Chemotherapy': 1, 'Pembrolizumab': 1, 'pembrolizumab': 6, 'ipilimumab': 1, 'phosphatidic acid': 1, 'cholesteryl esters distinguished amino acid': 1, 'sertoliomas': 1, 'chemoradiation': 1, 'aprepitant': 1, 'biocompatible iron oxide nanoparticle': 1, 'iron oxide': 2, 'iron oxide nanomaterials': 1, 'furosemide': 3, 'cimetidine': 2, 'para - amino hippuric acid': 1, 'saline': 1, 'OAT inhibitor': 1, 'carboplatin': 2, 'albumin': 1, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'Ductal': 2, 'acinar': 1, 'clonally': 1, 'overexpressing': 1, 'uracil': 1, 'doxorubicin': 8, 'cytarabine': 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide ( 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide )": 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide": 1, 'Oxaliplatin': 6, 'oxaliplatin': 2, 'Liposomal Oxaliplatin': 1, 'shrewd immunohistochemical': 1, 'anisole': 1, 'TFEB': 3, 'alizarin red stainings': 1, 'osteopontin': 1, 'myomatous': 1, '95%CI': 1, 'intracytoplasmic': 1, 'vacuolation': 1, 'Taxol': 3, 'taxane': 1, 'Kirsten rat sarcoma viral oncogene proto - oncogene GTPase ( Kirsten rat sarcoma viral oncogene )': 1, 'ameloblastomas': 2, 'unerupted': 2, 'steroid hormone biosynthesis , bile acid biosynthesis': 1, 'estrogen biosynthesis': 1, 'heterotypic': 1, 'palisading': 1, 'histopathological': 1, 'CRISPR': 1, 'tetracycline': 1, 'doxycycline': 1, 'COX-2': 1, 'microsomal prostaglandin E': 1, 'Ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mPGES-1': 2, 'Cisplatin': 1, 'Paclitaxel': 1, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'purine nucleoside monophosphate metabolic process': 1, 'interferon genes agonists': 1, 'antagonists': 1, 'anesthesia': 3, 'CNKI': 1, 'Wanfang': 1, 'chemoradiotherapy': 1, 'SOX': 2, 'bevacizumab': 3, 'IRIS': 1, 'imatinib': 5, 'trastuzumab': 2, 'ramucirumab': 1, 'nivolumab': 2, 'irinotecan': 1, 'steroid': 2, 'gammadelta T cells': 1, 'VIP152': 1, 'somatostatin analogs ( somatostatin analogs': 1, 'radiolabeled somatostatin analogs': 1, 'capecitabine': 1, 'nab - paclitaxel plus ramucirumab . The tumor marker levels decreased , the lymph nodes shrank , and PR': 1, 'erythropoietin': 1}, 'infertility': {'syngeneic': 1, 'taurine transporter ( TauT /': 1, 'guanidinoacetic acid (GAA ( guanidinoacetic acid )': 1, 'probenecid': 1, 'estradiol': 9, 'progesterone': 8, 'January': 2, 'October': 1, 'progestin': 9, 'levonorgestrel': 1, 'etomidate': 4, 'analgesic': 1, 'propofol': 2, 'intraperitoneally': 1, 'Propofol': 1, 'detortion': 1, 'ovulation': 1, 'letrozole': 20, 'clomiphene citrate': 6, 'clomiphene': 12, 'livebirth': 5, 'Takeda': 1, 'Roche': 1, 'hormone agonist': 2, 'CAncer': 1, 'CINAHL': 1, 'amino acid (GAA sequence in testis-specific protein Y-encoded 1 protein': 1, 'Noninterventional': 1, 'Merck': 18, 'Darmstadt': 6, 'Germany': 2, 'Theramex': 1, 'Ferring Pharmaceuticals A / S , grant': 1, 'chemotherapy': 5, 'Oocyte': 1, 'Adalimumab': 1, 'malondialdehyde': 6, 'inactivators': 1, 'Zika': 1, 'intracytoplasmic sperm injection ( intracytoplasmic sperm injection': 1, 'intracytoplasmic sperm injection': 5, 'Vitamin E': 1, 'vitamin E': 2, 'vitamin E (': 2, 'oestradiol': 1, 'endometritis': 1, 'antibiotics': 1, 'hormones': 1, 'isotretinoin': 1, 'benzodiazepines': 1, 'statins': 1, 'tetracyclines': 1, 'irisin': 1, 'thyroid replacement therapy . The association between Body mass index and Subclinical hypothyroidism': 1, 'sperm': 1, 'insulin': 8, 'multivitamins': 1, 'folic acid (GAA supplements': 1, 'Kindara.com': 1, 'Berberis': 1, 'berberine': 2, 'contraceptives': 1, 'Blaschko': 1, 'circulating insulin': 1, 'metformin': 2, 'intracytoplasmic sperm': 1, 'Antisperm': 12, 'gonadotropins': 2, 'Aase': 1, 'Ejner': 1, 'miR-193a-5p': 1, 'Artificial insemination': 1, 'HSALT': 1, 'normoxia': 1, 'O2': 1, 'spermatocytes': 1, 'spermatids': 2, 'globozoospermia': 1, 'bromocriptine': 5, 'dopamine': 2, 'Jinfeng': 3, 'September': 3, 'Latinx': 1, 'Ceftriaxone': 2, 'doxycycline': 2, 'penicillin': 2, 'moxifloxacin': 2, 'nitroimidazoles': 1, 'metronidazole': 1, 'chromatin': 1, 'fatty acid (GAA oxidation': 1, 'CRISPR': 1, 'Cct6b': 1, 'glucose': 2, 'Scopus': 2, 'Embase': 2, 'bibliographies': 1, 'Letrozole': 2, 'hydroxybutyryllysine': 1, 'lysinecrotonyllysine': 1, 'methyllysine': 1, 'Kac': 1, 'lysineacetyllysine': 1, 'Kpr': 1, 'Metformin': 2, 'normal saline water ( 0.9': 1, 'IL-6': 1, 'synthetic oestrogen diethylstilbestrol ( diethylstilbestrol )': 1, 'diethylstilbestrol': 7, 'CRY1': 4, 'PER2': 1, 'BMAL1': 1, 'Ferring': 2, 'Pharmasure': 1, 'Bessins': 1, 'dermatomyositis': 1, 'methotrexate': 1, 'salazopyrine': 1, 'cyclophosphamide': 1, 'vitamin C ( vitamin C )': 1, 'antioxidant supplements': 1, 'vitamin C ( 600 microM )': 2, 'hyperoside': 3, 'vitamin C': 3, 'Shanghai Municipal Science': 1, 'Shanghai': 5, 'Shuguang': 1, 'Phosphoglycerate': 1, 'Busulfan': 3, 'Loboob': 3, 'genistein': 4, 'steroid': 3, 'Choline': 1, 'choline': 2, 'Omega-3': 2, 'Omega-3 ( 10.78 + /- 1.71 )': 1, 'transmembrane protease serine': 1, 'Transcriptional': 1, 'artificial insemination': 1, 'ashwagandha': 1, 'estrogen': 1, 'tamoxifen': 2, 'Tamoxifen': 1, 'FASLG': 3, 'coincubation': 3, 'mRNAs': 1, 'Hyperlipidemic': 1, 'intratesticular': 1, 'hysterosalpingography': 1, 'gonadotropin': 1, 'Subfertile': 1, 'clomiphene citrate ( clomiphene citrate': 1, 'Bagcilar': 1, 'Istanbul': 1, 'August': 1, 'Clomiphene': 1, 'MAXQDA': 1, 'Vandhyatva': 1, 'MEDLINE': 1, 'CREM': 6, 'protamine': 1, 'Activator': 1, 'LR': 1}, 'toxicity': {'January': 3, 'September': 1, 'insulin': 1, 'hoxy)phenoxy)acetic acid ( lead compound': 1, 'intraperitoneally': 1, 'mercapturic acid': 1, 'Quercetin': 2, 'quercetin': 4, 'Pb+ Quercetin group was fed with ration supplemented': 1, 'blood urea nitrogen ( blood urea nitrogen': 1, 'quercetin supplementation': 4, 'Pb': 3, 'malondialdehyde': 13, 'glutathione peroxidase': 2, 'HDAC': 1, 'histone deacetylase': 4, 'analgesic': 2, 'anesthetics': 1, 'isoflurane': 3, 'stereological': 1, 'methylimidazolium nitrate': 1, 'Gossypium': 1, 'dreg': 2, 'antibiotic': 7, 'coelomocytes': 1, 'aromatic amino acids )': 1, 'Sulfonamides ( Sulfonamides )': 1, 'Sulfonamides': 1, 'ecotoxicity': 1, 'antibiotics': 5, 'sulfadiazine': 1, 'sulfamethoxazole': 1, 'sulfamethazine': 1, 'arsenic trioxide ( arsenic trioxide )': 1, 'arsenic trioxide': 2, 'rapamycin': 1, 'antimalarials': 1, 'sixteen compounds': 1, 'carbamazepine': 1, 'ibuprofen': 3, 'triclosan': 1, 'antifungal': 1, 'Zinc': 1, 'Chlorobutanol': 5, 'cadmium': 2, 'imatinib': 7, 'erlotinib': 2, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 2, 'Imatinib': 1, 'amiodarone': 1, 'diclofenac': 3, 'transcriptomics': 1, 'ciguatoxin': 1, 'Lactobacillus': 1, 'Bifidobacterium': 1, 'Fumonisin': 9, 'intragastrically': 1, 'platelets': 1, 'necroinflammation': 1, 'fumonisins': 1, 'metformin': 6, 'fluoroquinolone': 2, 'ciprofloxacin': 8, 'cometabolism': 1, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'carbapenems': 1, 'chemotherapy': 31, 'trifluridine': 1, 'tipiracil': 2, 'FTD': 1, 'fluorouracil': 2, 'October': 1, 'June': 1, 'Trifluridine': 1, 'oxaliplatin': 4, 'amenability': 1, 'phosphatidylcholine': 1, 'CPx': 1, 'SpHMA7': 1, 'Helichrysum': 1, 'Arsenic': 5, 'Peganum': 1, 'ellagic acid derivatives ( 3 ,': 1, 'gallic acid derivatives ( 5 ,': 1, 'phosphofructokinase': 1, 'ADMET': 1, 'mVOCs': 2, 'Ganoderma': 1, 'nitric oxide': 1, 'amino acid residues': 1, 'Ericaria': 2, 'linoleamide': 1, 'palmitamide': 1, 'oleamide': 1, 'erucamide': 1, 'Folin': 1, 'anticancer': 7, 'antifouling compounds': 1, 'red alga Sphaerococcus coronopifolius': 2, 'bromosphaerol': 4, 'calcium salts': 1, 'levulinic acid': 2, 'calcium carbonate': 1, 'Murashige': 1, 'analogs': 2, 'tansy': 1, 'mirtazapine': 6, 'Mirtazapine': 1, 'Potassium dichromate (': 1, 'selenium': 4, 'IL-2': 1, 'CBD2': 1, 'Celluclast': 1, 'Faggion': 1, 'alectinib': 2, 'carboplatin': 1, 'CBDCA': 3, 'cisplatin': 5, 'aprepitant': 1, 'docetaxel': 4, 'Nanosponges': 1, 'dexamethasone': 4, 'antifouling': 1, 'antifouling sol - gel': 1, 'Fe(III': 2, 'glutathione ( GSH )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 2, 'conatumumab': 1, 'irinotecan': 3, 'gemcitabine': 10, 'capecitabine': 5, 'PD.Acute fish toxicity ( PD.Acute fish toxicity )': 1, 'pure compounds': 1, 'microg': 3, 'octanol': 1, 'decanol': 1, 'Bifenthrin': 1, 'Caenorhabditis': 1, 'Oscillospiraceae': 1, 'Lachnoclostridium': 1, 'Oxaliplatin': 6, 'Liposomal Oxaliplatin': 1, 'mesalazine': 2, 'adlay': 1, 'brittanica': 1, 'Gailardia': 1, 'antioxidant compounds': 1, 'free chlorine': 1, 'Artemia': 1, 'Lliver': 1, 'lactic acid': 1, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'Baclofen': 1, 'baclofen': 4, 'Selenium ( selenium ) supplementation can restrict metal uptake by roots and translocation to shoots , which is one': 1, 'citrate': 2, 'amino acids': 1, 'subtoxic': 3, 'intracerebroventricular': 1, 'cysteine protease': 1, 'gefitinib': 8, 'pemetrexed': 1, 'Hematological': 1, 'chemoradiation': 1, 'radiosensitizing': 1, 'microCi': 2, 'VIP152': 1, 'meclofenamate': 6, 'nonsteroidal': 1, 'copper chelating abilities': 1, 'steroid': 1, 'rifampicin': 1, 'isoniazid': 1, 'quinolone': 1, 'linezolid': 5, 'TB medicines': 1, 'Linezolid': 1, 'honokiol': 1, 'curcumin nanoparticles ( curcumin - nanoparticles ) against copper oxide nanoparticle ( CuO - NP)-mediated hepatorenal effects on behavioral performance , biochemical markers , antioxidants , inflammation , apoptosis , and histopathology in rats . STUDY DESIGN : Twenty Wistar adult male rats were randomly divided into four groups ( n=5 )': 1, 'IotaIota': 1, 'gavaged': 1, 'curcumin - nanoparticles (': 1, 'curcumin - nanoparticles': 1, 'histopathological': 2, 'uric acid': 1, 'Tamoxifen': 1, 'genistein': 1, 'apigenin': 1, 'nicotinic acetylcholine receptors': 3, 'Rituximab': 1, 'cyclophosphamide': 1, 'vincristine': 1, 'prednisolone': 1, 'R - CHOP . METHODS : We developed a predictive model ( Tolerability of R - CHOP in Aggressive Lymphoma [ TRAIL ] ) on the basis of a training data set from the phase III GOYA trial ( obinutuzumab with CHOP v R - CHOP in 1L diffuse large B-cell lymphoma ) using a composite binary end point , identifying patients who prematurely stopped or required reductions of R - CHOP . Candidate predictive variables were selected on the basis of known baseline characteristics that contribute to patient frailty , comorbidity , and/or chemotherapy toxicity . TRAIL was developed using an iterative trial - and - error modeling process to fit a logistic regression model . The final model was evaluated for robustness using a GOYA holdout data set and the phase III MAIN ( R - CHOP with or without bevacizumab': 1, 'spiro heterocycles were synthesized via': 1, 'isatoic anhydride': 1, 'barbituric acid / thiobarbituric acid': 1, 'etoposide': 1, 'oleic acid , tocopherol , methyl ester , diterpene alcohol , triterpene and fatty acid ester': 1, 'Wasmann': 1, 'ethyl acetate': 1, 'photodynamic': 1, 'paclitaxel': 1, 'porphyrin prodrugs are synthesized': 1, 'chemo': 1, 'illudane glycosides ptesculentoside': 1, 'ptaquiloside': 2, 'nickel nanoparticles nanoparticles': 1, 'urothelial': 1, 'pembrolizumab': 1, 'enfortumab vedotin': 3, 'GHB': 8, 'Exogenously': 1, 'pharmacokinetics': 2, 'GABAergic': 1, 'analogues': 1, 'herceptin': 4, 'tryptophan': 1, 'amino acid supplements': 2, 'probucol': 7, 'glutathione peroxidase ( glutathione peroxidase': 1, 'Prx5': 1, 'manganese': 1, 'Curcuma': 1, 'ethylene glycol': 1, 'propylene glycol': 1, 'tetradentate': 1, 'chelating ligands': 1, 'cobalt(II': 1, 'nonnatural analogs': 1, 'panitumumab': 1, 'cannabidiol': 5, 'COX-2 inhibitor': 1, 'Ecuphar': 1, 'Microplastic': 1, 'Chromium': 9, 'alanine amino transferase': 1, 'Selenium ( selenium )': 1, 'selenate': 1, 'polygalacturonase': 1, 'superoxidase': 1, 'beta - galactosidase )': 1, 'hydrogen peroxide': 2, 'nanomaterial': 1, 'Tempol conjugated beta - cyclodextrin and Genistein': 1, 'sulfated steroids': 1, 'sulfatase': 2, 'polylactic acid': 1, 'plastics': 1, 'bioavailability': 1, 'methotrexate': 6, 'methacrylic acid': 1, 'methylene bis acrylamide ( methylene bis acrylamide )': 1, 'albino rabbits': 1, 'curcumin': 6, 'Tyrosine kinase inhibitors ( Tyrosine kinase inhibitors ) are molecular - targeted anticancer drugs': 1, 'Tyrosine kinase inhibitors': 1, 'keratinocyte': 2, 'regorafenib': 1, 'pazopanib': 1, 'thrombogenicity': 1, 'binimetinib': 3, 'Adjuvant': 1, 'bisphosphonate': 6, 'ibandronate': 1, 'zoledronic acid': 1, 'beta - lactam antibiotics ( amoxicillin and amoxicillin - clavulanate': 1, 'cefditoren': 1, 'macrolide': 1, 'fluoroquinolones': 1, 'Curcumin': 1, 'polyphenolic compound': 1, 'curcumin exhibits immobilizing action on sperms , and at': 1, 'chemotherapeutic': 1, 'Oocyte': 1, 'isovalent substitution': 1, 'cupric ions': 1, 'Ado - trastuzumab emtansine ( T - DM1 )': 1, 'monoclonal antibody': 1, 'trastuzumab': 1, 'microtubule inhibitor emtansine': 1, 'valproic acid ( valproic acid )': 1, 'valproic acid analogues': 1, 'gadolinium': 1, 'Ferulic acid': 1, 'Ferulic acid exhibits various therapeutic actions by modulation of various signal transduction pathways such as Nrf2': 1, 'ferulic acid include anti - apoptosis , antioxidant , anti - inflammatory , antidiabetic': 1, 'ferulic acid': 1, 'polyacrylic acid ( polyacrylic acid': 1, 'Flavonoids': 1, 'chemopreventive': 1, '-9.0': 1, 'SETAC': 1}, 'gastric cancer': {'clinicopathological': 1, 'chemotherapy': 84, 'October': 1, 'paclitaxel': 10, 'antifungal': 1, 'anticancer': 2, 'BRD4': 1, 'Paclitaxel': 1, 'oxaliplatin': 44, 'nivolumab': 16, 'unresectable': 4, 'steroid': 4, 'Adachi': 3, 'docetaxel': 23, 'trastuzumab': 4, 'ramucirumab': 1, 'irinotecan': 1, 'Chemotherapy': 3, 'January': 6, 'capecitabine': 3, 'cisplatin': 3, 'Ventriculoperitoneal': 1, 'nab - paclitaxel': 1, 'Peptidyl arginine deiminase': 1, 'Nivolumab': 4, 'Adjuvant chemotherapy': 1, 'trastuzumab(Tmab)and': 1, 'Tmab': 1, 'chemotherapy(TC)and': 1, 'chemo': 2, 'anastrozole': 1, 'bevacizumab': 1, 'fulvestrant)was': 1, 'response(CR)after': 1, 'nab - paclitaxel plus ramucirumab . The tumor marker levels decreased , the lymph nodes shrank , and pathological response was achieved again with the fourth - line treatment . The treatment is still ongoing 2 year and 8 months': 1, 'iron': 1, 'erythropoietin': 1, 'FOLFOX': 3, 'Ramucirumab': 1, 'azithromycin': 1, 'oxygen': 1, 'Oxaliplatin': 1, 'nab - paclitaxel plus ramucirumab , then treated with nivolumab': 1, 'fluorouracil': 20, 'leucovorin': 19, 'LCV': 1, 'histone deacetylase': 3, 'antiemetic': 3, 'doxorubicin': 4, 'cyclophosphamide': 1, 'aprepitant': 1, 'tricarboxylic acid': 1, 'dexamethasone': 1, 'AHCY': 1, 'CHDH': 1, 'Docetaxel': 1, 'antimitotic chemotherapy medication': 1, 'Labeled docetaxel': 1, 'Alvotere': 4, 'NanoAlvand': 1, 'anthracyclines': 1, 'chemotherapeutic': 2, 'miR-96': 1, 'immunoblotting': 1, 'H3 lysine 4': 1, 'H3 lysine': 1, 'Kyoto': 3, 'Actinobacteria': 1, 'Leptotrichia': 1, 'Lachnospiraceae': 1, 'Megasphaera': 1, 'F16': 1, 'Moryella': 1, 'Filifactor': 1, 'deregulation': 1, 'antibiotic': 4, 'clarithromycin': 1, 'metronidazole': 1, 'levofloxacin': 1, 'amoxicillin': 1, 'hsa': 1, 'podoplanin': 1, 'circRNA': 1, 'miR-637': 1, 'pepsinogen': 1, 'TFF1': 1, 'LBC MKN45 cells': 1, 'amino acid residues in the saccharide primers': 1, 'amino acid selectivity': 1, 'Apatinib': 1, 'pembrolizumab': 3, 'polyethylene glycol - poly(epsilon - caprolactone ) ( PEG - PCL ) nanoparticles ( nanoparticles )': 1, 'Alvoxal': 2, 'Immunohistochemistry': 1, 'Preoperative': 1, 'euro22': 1, 'lactulose': 1, 'fresh frozen plasma': 1, 'hemodiafiltration': 1, 'ProQuest': 1, 'probiotics': 1, 'antibiotics': 3, 'ASA': 2, 'Cochrane Library databases': 1, 'extraction': 1, 'February': 1, 'Sargassum': 1, 'senescore': 4, 'immunotherapeutic': 1, 'aspirin': 5, 'metachronous': 1, 'Aspirin': 1, 'deacetylase inhibitors entinostat': 1, 'pracinostat': 2, 'mocetinostat': 2, 'vorinostat': 1, 'deacetylase inhibitors': 1, 'neoantigens': 3, 'neoepitope': 1, 'sphingolipid': 2, 'autophagy inhibitor': 1, 'chloroquine': 1, 'endocytosis inhibitors chlorpromazine': 1, 'sphingosine kinase 1 inhibitor': 1, 'Metformin': 4, 'biguanide': 1, 'gastriccell': 1, 'metformin': 2, 'vitamin B12': 1, 'vitamin B12 capsule': 5, 'celecoxib': 4, 'Embase': 1, 'CNKI': 1, 'November': 1, 'nomogram': 1, 'August': 1, 'OGDH': 1, 'citric acid': 1, 'Blautia': 1, 'Bifidobacterium': 1, 'Butyricicoccus': 1, 'Fibronectin': 1, 'Azaadenosine': 1, 'FAMCE': 1, 'copper oxide nanoparticles': 6, 'glutamic acid ( copper oxide nanoparticles': 1, 'glutamic acid )': 1, 'conjugated with thiosemicarbazone ( copper oxide nanoparticles': 1, 'glutamic acid / TSC nanoparticles': 2, 'glutamic acid nanoparticles': 1, 'glutamic acid / TSC nanoparticles efficiently inhibited the proliferation of AGS cells': 1, 'glutamic acid / TSC treated cells': 1, 'glutamic acid / TSC as an efficient anticancer against gastric cancer (LBC cells': 1}, 'CDF': {'Curcumin': 2, 'curcumin': 10, 'difluorinated curcumin (CDF ( cylindrical diffuser fibers )': 2, 'insulin': 3, 'metformin': 1, 'normal saline': 1, 'citrate': 1, 'glucose': 2, 'CDF analogs': 1, 'antifungals': 1, 'difluorinated curcumin (CDF ( cylindrical diffuser fibers': 1, 'TIMML': 2, 'Ubiquitin': 1, 'MGF': 1, 'quercetin ( quercetin )': 1, 'hyaluronic acid': 1, 'microneedles': 1, 'amino acids': 1, 'Stickland': 1, 'amino acid catabolism': 1, 'amino acid': 1, 'chia protein hydrolysates )': 1, 'Alcalase': 3, 'Serum Sodium': 2, 'metals': 1, 'vacuolar': 2, 'ACE inhibitory peptides': 1, 'durvalumab': 1, 'Hydrogen peroxide ( Hydrogen peroxide': 1, 'Hydrogen peroxide': 3, 'Chlamydophila': 1, 'Minco': 1, 'chemotherapy': 6, 'CAIX inhibitor acetazolamide ( acetazolamide )': 1, 'gentamicin': 8, 'diafiltration': 2, 'pharmacokinetics': 1, 'Embase': 1, 'CINAHL': 1, 'Scopus': 1, 'February': 1, 'nomogram': 1, 'Poland': 1, 'Russia': 1, 'indole acetic acid ( Aux / IAAs )': 1, 'abscisic acid': 1, 'malondialdehyde': 8, 'GSSG': 2, 'dermatophytes': 1, 'plantarflexion': 4, 'interactions': 2, 'dexamethasone': 8, 'DEX': 3, 'Thioalbus': 1, 'Defluviimonas': 1, 'confers zinc and manganese': 1, '5-(and-6)-carboxy-2': 1, 'taurocholate acid': 1, 'rosuvastatin': 1, 'propionic acid': 1, 'ABTS': 2, 'phenolic compounds': 1, 'chemo': 1, 'nivolumab': 2, 'docetaxel': 3, 'Nivolumab': 1, 'glutamine': 1, 'asparagine': 1, 'Cangfudaotan': 5, 'suppresses insulin resistance': 1, 'carbamazepine': 1, 'polyvinylpyrrolidone': 1, 'saccharin': 1, 'tryptophan': 1, 'crystalline excipients to polymeric Amorphous solid dispersions': 1, 'salvianolic acid B ( salvianolic acid B )': 1, 'iodinated contrast agent ( iodinated contrast agent ) , human urine , or deionized water ( diffusion-weighted )': 1, 'GradePro': 1, 'hsCRP': 1, 'canakinumab': 1, 'triamcinolone': 1, 'APID': 1, 'VLXT': 1, 'Firmicutes': 1, 'Bacteroidetes': 2, 'congener': 1, 'progesterone': 1, 'free dye': 1, 'mixotrophic': 1, 'Reintervention': 2, 'opioid': 5, 'Opioid': 1, 'morphine': 1, 'ASA': 1, 'magnesium': 1, 'ACDF': 1, 'indoxyl sulfate': 3, 'dialysate': 1, 'Deltaproteobacteria': 2, 'mamB': 1, 'biomineralization': 1, 'Alphaproteobacteria': 1, 'delignification': 1, 'vasopressors': 1, 'Holmium': 1, 'Superpulsed Thulium Fiber': 1, 'equiangular': 1, 'Bacteraemia': 1, 'antibiotic': 2, 'January': 1, 'Cupriavidus': 1, 'flusilazole': 1, 'ACE': 1, 'Firmicute': 1, 'estrogens': 2, 'progestogen': 1, 'estradiol': 1, 'lipidated': 1, 'metribuzin': 2, 'phytotoxic compounds': 1, 'zinc efflux transporters': 1, 'Mrp2 fluorescent': 1, 'probenecid': 2, 'Higuchi': 1, 'Korsmeyer - Peppas model': 1, 'Karhunen-Loeve Tansform using Sufficient statistics proves to be perfectly reliable even for one degree of freedom . An example of experimental measurement is given . Human hepatoma cell lines are useful for evaluation of drug': 1, 'canaliculi': 1, 'Matrigel': 1, 'ZnCu': 1, 'CuCd': 1, 'datasets': 1, 'I(2)=0.0': 1, 'diphenylurea': 1, 'tetracycline': 3, 'tisagenlecleucel': 4, 'clofarabine': 1, 'pound27,732': 1, 'pound29,501': 1, 'urothelial': 1}, 'Cancer': {'urapidil': 1, 'January': 7, 'September': 5, 'bisphosphonates': 1, 'denosumab': 1, 'Actinomyces': 4, 'chemotherapy': 43, 'intratumoral': 1, 'Corynoline': 1, 'acetylcorynoline': 2, 'rapamycin': 4, 'mercapturic acid': 1, 'multivalency': 1, 'Linifanib': 1, 'Cytosponge': 1, 'Rosetrees': 1, 'Stoneygate': 1, 'cisplatin': 11, 'gemcitabine': 9, 'pemetrexed': 2, 'bevacizumab': 4, 'demethylase': 6, 'higenamine': 1, 'HDAC': 1, 'MAGL': 1, 'pharmacokinetics': 1, 'chemoradiotherapy': 4, 'carboplatin': 5, 'paclitaxel': 7, 'trametinib': 2, '-1/1/2/3': 1, 'PD-1 monoclonal antibody treatment . Collectively , these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral': 1, 'PD-1 monoclonal antibody can be an efective reagent': 1, 'chemo': 1, 'docetaxel': 5, 'nab - paclitaxel against B16F10': 1, 'Paeoniaceae': 1, 'p70S6 K signaling': 1, 'imidazoquinoline agonists': 1, 'covalent inhibitor': 1, 'GSH': 1, 'Cytotoxic': 1, 'photothermal': 5, 'iron oxide': 1, 'chemotherapies': 1, 'chloroisopropyl': 2, 'phosphate': 1, 'Organophosphate': 1, 'Paclitaxel': 4, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - PD - L1 therapy (PDT': 1, 'OPTN': 1, 'chemokine ligand': 1, 'LR': 1, 'RBC folate': 3, 'RBC': 1, 'RBC folate concentration': 1, 'normal folate status is important for reducing the risk of cervical intraepithelial': 1, 'propofol': 3, 'sevoflurane': 2, 'Propofol': 1, 'anesthesia': 1, 'ICNB': 3, 'ASA': 1, 'anesthetics': 1, 'estradiol': 1, 'testosterone': 1, 'progesterone': 1, 'nicotine': 2, 'imatinib': 2, 'erlotinib': 1, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 1, 'Imatinib': 1, 'scopolamine': 1, 'Allyl isothiocyanate ( Allyl isothiocyanate )': 1, 'Allyl isothiocyanate': 4, 'Allyl isothiocyanate action': 1, 'intragastrically': 1, 'Irrespectively': 1, 'Allyl isothiocyanate considerably lowered thyroid hormones ( fT4 , fT3 )': 1, 'Allyl isothiocyanate at': 2, 'hydroxybutyric acid': 1, 'insulin': 1, 'blood insulin': 1, 'atezolizumab': 1, 'nomogram': 1, 'AKT inhibitor': 1, 'FoundationOne': 1, 'taxane': 2, 'Cobas': 1, 'osimertinib': 1, 'PUPOSE': 1, 'multitesting': 1, 'MSH6': 1, 'MSH2': 1, 'NCTN': 1, 'amino acid ( amino acid': 1, 'amino acid': 1, 'anticoagulation': 1, 'Glyco disulfide acted as reducing and capping agents of gold ions': 1, 'O2': 1, 'CRISPR': 1, 'phosphodiesterase-5 inhibitors': 1, 'Metformin': 1, 'metformin': 10, 'Lewis acid as additive': 1, 'trifluridine': 1, 'tipiracil': 2, 'FTD': 1, 'fluorouracil': 2, 'October': 2, 'June': 1, 'Trifluridine': 1, 'deregulation': 1, 'oxaliplatin': 3, 'supplementation': 1, 'ceramides': 1, 'FDI': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 1, 'ipilimumab': 2, 'CCRT': 1, 'IQR': 2, 'Chemotherapy': 1, 'Pembrolizumab': 1, 'pembrolizumab': 4, 'lignans': 1, 'adenosine triphosphate': 2, 'linalool oxide': 1, 'fatty acid biosynthesis': 1, 'phosphatidic acid': 1, 'cholesteryl esters distinguished amino acid': 1, 'SUVmean': 1, 'flavonoids chemical': 1, 'superoxide anion radicals': 1, 'Arthrocnemum indicum (Willd.) Moq. indicum shoot ethanolic extract': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'Isavuconazole': 6, 'Mucormycosis': 1, 'antifungal': 2, 'corticosteroids': 1, 'Tamoxifen': 16, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 1, 'glutathione peroxidase ( GSH - Px )': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'Characella': 1, 'GNPS': 1, 'cyanocobalamin': 1, 'vitamin B12': 1, 'Nivolumab': 3, 'Undaria': 1, 'Lerdsin': 1, 'mirtazapine': 6, 'Mirtazapine': 1, 'chemoradiation': 1, 'niraparib': 2, 'haematological': 1, 'trastuzumab': 3, 'PD-1': 5, 'PD-1 inhibitors in combination': 1, 'PD-1 inhibitor': 1, 'Adjuvant chemotherapy': 1, 'neoadjuvant chemotherapy': 1, 'irinotecan': 1, 'Akaike': 1, 'alectinib': 2, 'CBDCA': 3}, 'PD': {'intratumoral': 1, 'January': 2, 'attapulgite': 2, 'Pseudogymnoascus': 26, 'EXERPD': 2, 'SEDPD': 2, 'Stereotaxic': 1, 'pemetrexed': 7, 'cisplatin': 3, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - Parkinson disease - L1 therapy': 1, 'OPTN': 1, '28,525': 1, 'pharmacokinetics': 12, 'pharmacodynamics': 4, 'CCL5': 1, 'chemotherapy': 52, 'Veronica': 1, 'antifungal': 4, 'stereodivergent': 1, 'stereoinduction': 1, 'carboplatin': 3, 'albumin': 1, 'paclitaxel': 4, 'linezolid': 4, 'Linezolid': 1, 'RhCl(CO)2': 1, 'AuCl': 1, 'apomorphine': 2, 'subgingival': 3, 'antibiotic': 2, 'Porphyromonas': 2, 'Gemella': 1, 'Fusobacterium': 1, 'Desulfobulbaceae': 1, 'Mycoplasmataceae': 1, 'Campylobacteraceae': 1, 'Muribaculaceae': 1, 'Streptococcaceae': 1, 'Gemellaceae': 1, 'Lactobacillus': 1, 'Bifidobacterium': 1, 'Megasphaera': 1, 'Romboutsia': 1, 'Rothia': 1, 'supragingival': 1, 'chemo': 1, 'pembrolizumab': 10, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'GEPIA': 1, 'Sd': 2, 'levodopa': 18, 'Wilcoxon': 1, 'amantadine': 1, 'selegiline': 1, 'benserazide': 1, 'carbidopa': 1, 'Yahr': 2, 'dopamine': 6, 'Clinicopathological': 1, 'durvalumab': 7, 'antibiotics': 2, 'clarithromycin': 1, 'ethambutol': 1, 'rifampicin': 1, 'amikacin': 1, 'macrolide': 2, 'Methotrexate': 1, 'prednisolone': 1, 'iguratimod': 1, 'DKS': 1, 'gemcitabine': 1, 'gammadelta T cells (ICs selectively': 1, 'neoadjuvant chemotherapy': 2, 'FOLFOX': 1, 'nivolumab': 4, 'docetaxel(DTX)as': 1, 'capecitabine': 1, 'oxaliplatin': 1, 'nab - paclitaxel plus ramucirumab . The tumor marker levels decreased , the lymph nodes shrank , and PR': 1, 'Atezolizumab': 2, 'bevacizumab': 4, 'atezolizumab': 2, 'lenvatinib': 1, 'sorafenib': 1, 'Ramucirumab': 1, 'Nivolumab': 3, 'steroid': 3, 'azithromycin': 1, 'oxygen': 1, 'Metabolomics': 1, 'mycobiome': 1, 'Kazachstania': 1, 'Tremellaceae': 1, 'Torulaspora': 1, 'MPTP': 5, 'multiphysics': 1, 'nanovesicles': 1, 'thrombolytic': 1, 'pentyne': 1, 'desorb': 1, 'azetidines': 1, 'indoles': 1, 'quinolines': 1, 'Alloying': 1, 'dextran sulfate sodium': 1, 'functionalized nucleoside analogues': 1, 'histone deacetylase': 3, 'acetic acid ( pH 2.9 )': 1, 'electrogenerated adsorbed hydrogen ( H ads': 1, 'aryl alpha - diazoamides': 1, 'allenes': 1, 'Leiws acid': 1, 'carboxylic acid': 1, 'liraglutide': 2, 'MEST(high)BRCA1(high': 1, 'Ubiquitin': 1, 'bismuth sulfide nanorods': 1, 'urothelial': 1, 'anesthesia': 2, 'ceftolozane': 1, 'ceftazidime': 1, 'avibactam': 1, 'Pmetrics': 1, 'cephalosporins': 1, 'beta - lactamase inhibitors': 1, 'TOL': 1, 'Electrocatalysis': 1, 'nanocatalyst': 1, 'Yangchengdianmao': 1, 'rotenone': 6, 'Mogroside V': 2, 'adenosine triphosphate ( adenosine triphosphate ) production in a dose': 1, 'superoxide dismutase': 2, 'chloroquine': 1, 'PDL-1 inhibitor': 1, 'levo': 1, 'Chromobacterium': 1, 'Cyphos': 1, 'dissolved': 1, 'Chemoradiation': 3, 'coinhibitory': 1, 'Fibrillary': 1, 'February': 1, 'antipsychotics': 1, 'sugemalimab': 10, 'CStone Pharmaceuticals': 1, 'toxin': 2, 'adenosine triphosphate synthesis': 1, 'checkpoint inhibitor': 1, 'lesioned': 1, 'chemotherapies': 1, 'PARP inhibitors': 1, 'September': 1, 'follistatin': 1, 'aryl': 1, 'vinyl sulfonates / halides': 1, 'dubamine': 1, 'tamoxifen': 1, 'agrochemicals': 1, 'unsaturated alkynes': 1, '0.816': 1}, 'death': {'FOLFIRINOX': 1, 'immunoglobulin': 1, 'methylprednisolone': 2, 'pharmacodynamics': 14, 'intratumoral': 1, 'antibiotics': 6, 'diuretics': 1, 'cisplatin': 8, 'biotherapeutic cocktail': 1, 'Paeoniaceae': 1, 'Antiepileptic': 1, 'pemetrexed': 6, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - pharmacodynamics - L1 therapy': 1, 'OPTN': 1, 'Pixantrone': 2, 'PFS': 1, 'insulin': 2, 'steroid': 5, 'Dexamethasone': 1, 'dexamethasone': 2, 'carbamazepine': 1, 'ibuprofen': 2, 'triclosan': 1, 'amiodarone': 1, 'diclofenac': 3, 'transcriptomics': 1, 'receptor ligand': 1, 'chemotherapy': 18, 'reoxygenation': 5, 'statin': 4, 'lysophosphatidylcholines': 1, 'hydroxysphingomyelins': 2, 'peroxynitrite': 1, 'August': 1, 'antifungal': 10, 'trimethoprim': 1, 'sulfamethoxazole ( TMP - SMX': 1, 'clindamycin': 2, 'February': 1, 'lactic acid': 1, 'Chemotherapy': 1, 'Pembrolizumab': 1, 'September': 3, 'pembrolizumab': 9, 'ipilimumab': 1, 'Cardiomatics': 1, 'Cracow': 1, 'amino acid': 1, 'Annexin': 1, 'nonesterifed fatty acids , phospholipids and carnitines in blood serum using liquid chromatography - tandem mass spectrometry': 1, 'nitric oxide': 1, 'divalent cations ( magnesium , zinc': 1, 'carotenoid astaxanthin in the course': 1, 'astaxanthin': 1, 'Taiwan': 1, 'January': 9, 'lactic acid dehydrogenase ( lactic acid dehydrogenase )': 1, 'hydrolysates': 1, 'acetic acid ( acetic acid )': 1, 'acetic acid inhibits yeast fermentation and triggers a regulated cell': 1, 'acetic acid - regulated cell': 4, 'zinc supplementation': 1, 'vacuolar zinc transporter Zrt3': 1, 'acetic acid (': 1, 'pneumocystosis': 1, 'corticosteroids': 1, 'pharmacokinetics': 2, 'antifungal compounds': 1, 'Streptomyces': 1, 'amino acid tryptophan': 1, 'carboplatin': 1, 'CBDCA': 3, 'biocompatible iron oxide nanoparticle': 1, 'photothermal': 1, 'iron oxide': 2, 'iron oxide nanomaterials': 1, 'Embase': 2, 'Covishield': 3, 'anticancer': 1, 'malondialdehyde': 5, 'glutathione': 3, 'Ginsenoside': 5, 'superoxide dismutase ( superoxide dismutase )': 2, 'doxorubicin': 1, 'arsenic trioxide': 1, 'retinoic acid': 2, 'arsenic trioxide combined': 1, 'anthracycline': 1, 'd1': 1, 'd18': 1, 'Macrolides': 1, 'Mongolia': 1, 'lactic acid dehydrogenase 736 IU ( 482 - 1744 )': 1, 'CINAHL': 1, 'ketamine': 4, 'thiopental': 2, 'intraperitoneally': 1, 'Thiopental': 1, 'alpha-2 adrenergic agonist is generally considered to be safe in rats , we propose that studies utilizing protocols requiring repeated anaesthesia': 1, 'dermatomyositis': 2, 'November': 3, 'electroconvulsive': 5, 'Wilcoxon': 1, 'red blood cells (B16F10 ( red blood cells': 1, 'AUCs': 1, 'RVEDVI': 1, 'RVESVI': 1, 'Quercetin': 3, 'vitamin E': 2, 'spectrophotometrically': 1, 'vitamin E treatment reversed these effects , suggestive of their anti - apoptotic effect': 1, 'antineoplastic': 2, 'fluid': 1, 'hyperkalaemia': 1, 'chemo': 1, 'ligands': 1, 'glutathione peroxidase': 1, 'NOD2': 1, 'phosphate buffered saline . Anti - cancer effects of extracts': 1, 'artemisinin': 1, 'dihydroartemisinin': 3, 'steroids': 3, 'immunosuppressants': 2, 'vitamin stores': 1, 'hemostatics': 1, 'Cyclophosphamide': 2, 'rituximab': 3, 'antibiotic': 1, 'Carbapenem': 1, 'quinolone': 1, 'Oncologia': 1, 'Multidrug': 1, 'intravitreally': 1, 'Cisplatin': 1, 'chemotherapeutic': 1, 'Tripterygium': 1, 'ginsenoside': 5, 'Clinicopathological': 1, 'durvalumab': 3, 'complexation': 1, 'SCFAs': 1, 'opioids': 1, 'cause(s)and': 1, 'neoadjuvant chemotherapy': 1, 'folic acid': 1, 'ticagrelor': 3, 'October': 1}, 'cardiotoxicity': {'anthracyclines': 12, 'paclitaxel': 1, 'cisplatin': 8, 'amidinourea': 2, 'R - CHOP regimen of pegylated liposomal': 1, 'doxorubicin': 174, 'chemotherapy': 55, 'Resveratrol ( Resveratrol )': 1, 'Resveratrol': 1, 'antibiotic': 3, 'steroid': 2, 'diuretics': 2, 'azacitidine': 1, 'Osimertinib': 4, 'oxygen': 1, 'Doxorubicin': 73, 'pyroptosis': 2, 'nigericin': 2, 'Calycosin': 1, 'antipyroptotic': 1, 'adenosine triphosphate': 3, 'superoxide dismutase': 2, 'Anthracycline': 1, 'phthalate': 2, 'acyl hydrazine': 1, 'thiourea': 1, 'humanized monoclonal antibody': 1, 'nanoforms': 1, 'Loperamide': 1, 'opioid': 2, 'methadone': 1, 'Opioid': 1, 'naloxone': 1, 'loperamide': 4, 'trastuzumab': 67, 'carboplatin': 1, 'oxaliplatin': 1, 'anticancer': 7, 'January': 1, 'November': 1, 'Bortezomib': 6, 'normal saline': 1, 'receptor agonist': 1, 'bupivacaine': 3, 'BW373U86': 1, 'PEGylated': 1, 'adriamycin': 2, 'isoproterenol': 5, 's.c': 1, 'anesthesia': 1, 'tamoxifen': 2, 'paroxetine': 3, 'lapatinib': 2, 'Tamoxifen': 1, 'Lapatinib': 2, 'BCL': 1, 'cyclophosphamide': 3, 'Chrysin': 1, 'malondialdehyde': 22, 'acetylcholinesterase': 6, 'chemotherapies': 1, 'imatinib': 1, 'ponatinib': 2, 'transporter inhibitors in different cell lines': 1, 'Paclitaxel': 1, 'IL-2': 1, 'IFNgamma': 1, 'immunomodulatory monoclonal antibodies endowed with more potent anti - cancer activity on triple negative breast cancer and lower cardiotoxic side effects than the combination of atezolizumab': 1, 'ipilimumab': 4, 'Fondazione Italiana Linfomi )': 1, 'liposomal': 1, 'doxorubicine': 1, 'reinduction': 1, 'anthracycline': 31, 'clofarabine': 1, 'vinorelbine': 1, 'thiotepa': 1, 'Loulu': 3, 'GAPDH': 1, 'Nicotinamide': 1, 'Coumarin': 1, 'Parthenolide': 1, 'Ligustilide': 1, 'AIHF': 2, 'Arenobufagin': 9, 'analgesic': 2, 'free radicals': 1, 'Dawley': 1, 'hyaluronate': 1, 'nanocarrier': 1, 'hyaluronic acid ( hyaluronic acid )': 1, 'solanesol': 1, 'hyaluronic acid': 2, 'conjugate ( hyaluronic acid - Solanesyl thiosalicylate )': 1, 'hyaluronic acid - Solanesyl thiosalicylate nanoparticles': 1, 'hyaluronic acid - Solanesyl thiosalicylate - Doxorubicin showed superior tumor inhibition compared with free Doxorubicin , as well as lower cardiotoxicity and': 1, 'Rvlpulse': 1, 'ZebraLab': 1, 'Ticlopidine': 1, 'ADP': 4, 'adenosine diphosphate': 1, 'ticlopidine': 8, 'Astragali': 3, 'Trastuzumab': 2, 'dantrolene': 6, 'calcium': 1, 'fluorouracil': 1, 'valsartan': 2, 'amlodipine': 2, 'lisinopril': 3, 'rats': 1, 'LSP': 1, 'pretreatments': 1, 'mitoxantrone': 7, 'glutathione peroxidase ( GSH - Px )': 2, 'Mitoxantrone': 1, 'subchronic': 1, 'MTX': 12, 'disulfiram': 2, 'humanized monoclonal antibody that significantly improves metastatic and non - metastatic breast cancer therapeutic outcomes . This study compares': 1, 'Crocin': 3, 'milrinone': 1, 'III inhibitor in cynomolgus monkeys , and share': 1, 'interactions': 1, 'PD-1': 1, 'Prevotellaceae': 1, 'butyrate supplementation alleviated PD-1 / PD - L1 inhibitor': 1, 'chemo': 2, 'oseltamivir': 3, 'Coronaviridae': 1, 'Epirubicin': 1, 'Daunorubicin': 1, 'Imatinib Mesylate ( Imatinib Mesylate': 1, 'Imatinib Mesylate': 4, 'Imatinib': 2, 'Imatinib Mesylate - treated groups . Oil Red O staining suggested obvious cardiac lipid accumulation after': 1, 'monoclonal antibodies': 1, 'pertuzumab': 1, 'Fenitrothion': 8, 'resveratrol': 2, 'glutathione reductase ( glutathione reductase )': 1, 'superoxide dismutase ( superoxide dismutase )': 2, 'resveratrol complexes with protein and DNA sequences of SIRT1 were lower than docked complexes': 1, 'neoadjuvant chemotherapy': 3, 'mangostin': 3, 'vitamin E ( 200 IU / kg )': 1, 'vitamin E ( 19 days )': 1, 'intraperitoneally': 1, 'antiinflammatory': 1, 'antiapoptotic': 1, 'catecholaminergic hormone release': 1, 'free': 1, 'Dioscorea': 1, 'methotrexate': 2, 'Troxerutin': 2, 'AMPK': 1, 'superoxide dismutase antioxidants': 1, 'angiotensin receptor blockers (ARBs ( angiotensin receptor blockers )': 1, 'beta-blockers and angiotensin-converting enzyme inhibitors / angiotensin receptor blockers': 1, 'BB': 3, 'angiotensin': 1, 'beta-blockers or angiotensin-converting enzyme inhibitors / angiotensin receptor blockers were significantly associated with higher LVEFs . For anthracyclines': 1, 'Quercetin ( Quercetin )': 1, 'Quercetin': 1, 'Cisplatin': 1, 'monotherapy': 1, 'nivolumab': 3, 'pembrolizumab': 3, 'n=39': 1, 'arachidonic acid metabolism , linoleic acid metabolism': 1, 'dox': 2, 'mercapturic acid pathway enzyme': 1, 'Omega-6': 1, 'Rlip': 2, 'arachidonic acid': 3, 'antineoplastic': 1, 'Her2 inhibitors': 1, 'arachidonic acid increased lipid peroxidation': 1, 'Rlip inhibitors': 1, 'Chemotherapy': 3, 'ZM447439': 1, 'HDAC inhibitor': 1, 'regular blood transfusion': 1, 'iron': 1, 'antiseizure medications ( antiseizure medications': 1, 'antiseizure medications': 1, 'antiseizure medications should be considered ; cardiac monitoring of treatment': 1, 'EMBASE': 1, 'CINAHL': 1, 'carfilzomib': 1, 'proteasome inhibitor': 1, 'chalcone': 2, 'Ciprofloxacino': 1, 'Ethidium Bromide': 1, 'Coenzyme Q10': 1, 'histopathological': 3, 'Ultrastructurally': 1, 'corticosteroids': 2, 'corticosteroid': 15, 'Tofacitinib': 1, 'Herceptin': 7, 'ferroptosis inhibitor': 1, 'Deferoxamine': 1, 'DCFHDAA': 1, 'timedependent': 2, 'glutathione peroxidase ( glutathione peroxidase ) protein expression and the GSH/ GSSG ratio in H9c2 cells (WBC in a dose': 1, 'mitofusin': 1, 'Selenium plays crucial roles in maintaining the growth and development of vertebrates': 1, 'selenium': 1, 'Human': 1, 'Synthetic opioids': 1, 'morphine': 1, 'GSH': 2, 'interleukin': 2, 'VEGFR': 1, 'bevacizumab': 1, 'immunomodulation': 1, 'sodium chloride solution': 1, 'nicotinic receptor agonist ( PNU : PNU-282987': 1, 'muscarinic receptor agonist ( BET : bethanechol ,': 1, 'alpha7nAChR': 2, 'acetylcholine receptors agonists protected': 1, 'October': 1, 'Caffeic acid phenethyl ester ( Caffeic acid phenethyl ester )': 1, 'Caffeic acid phenethyl ester': 2, 'Caffeic acid phenethyl ester significantly ameliorated': 1, 'Mechanistically': 1, 'Caffeic acid phenethyl ester attenuated the': 1, 'Caffeic acid phenethyl ester significantly enhanced': 1, 'Benzofuran': 1, 'chemotypes': 1, 'Embase': 1, 'megestrol': 1, 'megestrol acetate': 1, 'fatty acid oxidation': 1, 'GRP78': 1, 'adenosine triphosphate ( adenosine triphosphate )': 1, 'Cardiotoxicity': 1, 'radiodensity': 1, 'asparaginase': 1, 'Perindopril': 1, 'perindopril': 1, 'CRISPR': 1, 'desipramine': 2, 'Anticancer': 1, 'proteasome inhibitors such as carfilzomib': 1, 'Carfilzomib': 2, 'adenosine triphosphate production': 1, 'Pegylated': 1, 'epirubicin': 5, 'Noninferiority': 1, 'periplocymarin': 3, 'pharmacokinetics': 1, 'nanoprobes': 1, 'antiplasmodial': 1, 'fluoride': 1, 'Doxorubicin chemotherapy': 1, 'myricetin': 4, 'adenosine triphosphate depletion': 2, 'glutathione peroxidase ( GSH - Px ) in intact cardiomyocytes': 1, 'agonists': 1, 'cardioactive therapies , possibly explaining the lack of association of risk categories with LVD occurrence .': 1, 'vincristine': 1, 'dexamethasone': 1, 'cytarabine': 1, 'hallucinogens': 1, 'diphenyltetrazolium bromide ( MTT )': 1, 'p21 CDC42': 3, 'February': 1, 'August': 1, 'Glutathione': 1, 'methoxy polyethylene glycol ( methoxy polyethylene glycol )': 1, 'methoxy polyethylene glycol - S - PBLG copolymer': 1, 'methoxy polyethylene glycol - S - PBLG micelles': 1, 'epinephrine': 2, 'propranolol': 1, 'carvedilol': 1, 'metoprolol': 1, 'labetalol': 1, 'curcumin': 1, 'CMN': 1, 'aspartate amino transaminase ( aspartate transaminase )': 1, 'Doxo': 4, 'Icariin': 2, 'antibiotics': 1, 'analgesics': 1, 'anesthetics': 1, 'opioids': 1, 'ropivacaine': 2, 'analgesia': 1, 'unsaturated phospholipid': 1, 'beta - sodium glycerophosphate ( beta - GP )': 1, 'Verapamil': 1, 'Lamotrigine': 2, 'levetiracetam': 5, 'lamotrigine': 3, 'valproic acid ( lamotrigine only )': 1, 'Levetiracetam Serum / Plasma Levels with Toxicity : A Long - Term Retrospective Review at an Academic Medical Center " [ K. E. Wood ,': 1, 'Cyclophosphamide': 1, 'Yohimbine': 6, 'HiPSC': 2, 'Yohimbine inhibited': 1, 'Whereas Yohimbine': 1}, 'osteoporosis': {'streptozotocin': 1, 'ferric ammonium citrate ( FAC , 200muM )': 1, 'denosumab': 12, 'UCHealth': 1, 'antiresorptive': 1, 'bisphosphonates': 4, 'anabolic': 7, 'bone anabolic': 1, 'Glucocorticosteroids': 11, 'mycophenolate mofetil': 1, 'Serum vitamin D': 1, 'vitamin D receptor genotyping': 1, 'vitamin D': 11, 'uric acid': 1, 'Vitamin D': 1, 'vitamin D receptor gene polymorphisms were not linked to rheumatoid arthritis . trabecular bone score and': 1, 'vitamin D receptor gene polymorphisms were not linked to rheumatoid arthritis': 1, 'silibinin': 4, 'selenium': 1, 'Folic acid ( Folic acid': 1, 'Folic acid': 8, 'Folic acid (': 1, 'Corynebacterium glutamate expression system': 1, 'Erzhi formula ( Erzhi formula': 1, 'Kyoto': 5, 'prednisolone': 3, 'dimethyl wedelolactone': 1, 'ursolic acid , acacetin , beta - sitosterol': 1, 'EGF': 1, 'IL-2': 1, 'glucocorticoid': 11, 'Erzhi': 1, 'raloxifene': 13, 'teriparatide': 19, 'chemotherapy': 3, 'sevelamer': 1, 'lanthanum': 1, 'adenosine triphosphate': 1, 'eldecalcitol': 6, 'vitamin D3': 1, 'rapamycin': 2, 'November': 1, 'methotrexate': 13, 'steroid': 2, 'warfarin': 3, 'EMBASE': 1, '13,906': 1, 'bone mineral density (': 1, 'eicosapentaenoic acid + docosahexaenoic acid supplementation': 1, 'linolenic acid supplementation': 1, '2,664,104': 1, 'abaloparatide': 7, 'January': 3, 'osteoclast precursor cells': 1, 'secretome': 1, 'intragastrically': 1, 'ovariectomized': 1, 'mRNAs': 3, 'FXR': 1, 'Mrp2': 1, 'estradiol': 2, 'ARV': 1, 'precursor cells': 1, 'ephrinA2': 1, 'Mechanistically': 1, 'exosomes': 3, 'Bglap': 1, 'nicotinamide mononucleotide ( nicotinamide mononucleotide': 1, 'osteopontin': 5, 'Col1a1': 1, 'osteoporosis medications': 2, 'analgesics': 1, 'nonsteroidal': 2, 'corticosteroids': 2, 'Visual Analog Scale': 1, 'GeneCards': 1, 'Cytoscape': 2, 'metformin': 7, 'alendronate': 6, 'Alendronate': 14, 'insulin': 3, 'nitro blue': 1, 'Glucocorticoid': 1, 'glucocorticoids': 6, 'Estrogen Receptor 1 ( Estrogen Receptor 1 )': 1, 'Glutathione Peroxidase': 1, 'bisphosphonate': 20, 'Bisphosphonate': 1, 'calcium': 2, 'Morinda': 1, 'epinephrine': 1, 'Embase': 1, 'Zoledronic acid ( Zoledronic acid )': 1, 'Zoledronic acid ( Yigu(R )': 1, 'Zoledronic acid ( Aclasta(R )': 1, 'bioequivalence': 1, 'Zoledronic acid': 1, 'Yigu(R': 1, 'Zoledronic acid treatment': 1, 'beta - CTX )': 1, 'zoledronic acid achieved the potent anti - resorptive': 1, 'sedentarism': 1, 'PJF': 1, '54,324': 1, 'Orthopantomograph': 1, 'Hypertriglyceridemia': 1, 'Baidu': 1, 'Weipu': 1, 'Wanfang': 1, 'implantology': 1, 'calcium ions': 1, 'risedronate': 2, 'calcium - RISNPs': 1, 'fisetin': 4, 'ovariectomy': 2, 'estrogen': 1, 'vitamin D receptors': 2, 'superoxide dismutase ( superoxide dismutase )': 1, 'Hormone': 9, 'vaginal Hormone therapy': 1, 'Receptor Activator': 4, 'osteoclastogenesis': 2, 'methylprednisolone': 1, 'vitamin D receptor': 1, 'isoflavones supplementation': 1, 'interactions': 2, 'probiotics': 1, 'plasminogen activators': 1, 'dexamethasone': 6, 'February': 2, 'estrogen receptor ( estrogen receptor )': 1, 'estrogen receptors': 1, 'tamoxifen': 2, 'bazedoxifene': 5, 'Raloxifene': 2, 'beta agonists': 1, 'ERbeta antagonist': 1, 'Risedronate': 1, 'beta - cyclodextrin - modified chitosan ( polylactic-co-glycolic acid - CS - CD )': 1, 'leflunomide': 1, 'vitamin D ( vit - D )': 1, 'chronic steroid': 1, 'humanized monoclonal anti - sclerostin antibody ( Scl - Ab )': 1, 'osteocyte': 1, 'blockade': 1, 'olive oil': 1, 'tocotrienols': 6, 'catabolites': 1, 'tryptophan': 1, 'steroids': 2, 'Zoledronic acid ( ZA )': 1, 'Bacteroidetes': 1, 'Actinobacteria': 1, 'Epsilonbacteraeota': 1, 'Photoacoustic': 1, 'zoledronic acid infusion': 3, 'bortezomib': 6, 'phenylpropanoids': 1, 'acetylcysteine': 1, 'Sarcopenia': 1, 'testosterone': 1, 'dehydroepiandrosterone sulphate ( dehydroepiandrosterone sulphate )': 1, 'dehydroepiandrosterone sulphate correlated negatively with the percentage of fat mass in men': 1, 'dehydroepiandrosterone sulphate': 1, 'Protocatechuic acid': 1, 'hypoparathyroidism': 2, 'calcitriol': 2, 'calcium carbonate supplementation': 1, 'calcium carbonate': 1, 'Teriparatide': 1, 'botulinum toxin injections': 1, 'alendronic acid': 1, 'Bangladesh': 1, 'vitamin D3 analogs': 1, 'ibandronate': 2, 'Glutamic acid': 1, 'amino acid': 1, 'glutamic acid': 1, 'amino acid compositions': 2, 'dirigent': 1, 'phenylpropanoid biosynthesis': 1, 'insulinotropic polypeptide )': 1, 'glucagon': 6, 'insulinotropic polypeptide': 5, 'glucose': 2, 'pharmacokinetic': 1, 'calcium supplementation': 1, 'phytochemical polyphenol avenanthramides ( avenanthramides )': 1, 'avenanthramides': 1, 'intermediate': 1, 'pharmacodynamics': 1, 'supplements': 1, 'statins': 5, 'statin': 5, 'bone mineral density - reducing drugs': 1, 'levothyroxine': 2, 'pump inhibitors': 1, 'Spondyloarthritis': 1, 'curdlan': 1, 'cholecalciferol': 6, 'PDGF': 1, 'Osteopontin': 1}, 'metastasis': {'FOLFIRINOX': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'January': 4, 'photothermal': 4, 'chemokine ligand': 1, 'LR': 1, 'nonadjacent': 1, 'nomogram': 2, 'September': 2, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'chemotherapy': 97, 'trifluridine': 2, 'tipiracil': 3, 'FTD': 1, 'fluorouracil': 4, 'October': 1, 'June': 1, 'Trifluridine': 1, 'oxaliplatin': 8, 'cisplatin': 3, 'irinotecan': 3, 'clinicopathological': 1, 'heparin': 1, 'warfarin': 1, 'vitamin K antagonist': 1, 'anticoagulation': 2, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'carboplatin': 1, 'TFEB': 6, 'pN': 2, 'Transendothelial': 1, 'Mir-155_5p': 1, 'Cytoscape': 1, 'ClueGO': 1, 'Kyoto': 8, 'palisading': 1, 'histopathological': 1, 'Clinicopathological': 1, 'Paris saponin': 2, 'nitric oxide synthase': 1, 'suramin': 4, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'Ursolic acid ( Ursolic acid': 1, 'anticancer': 2, 'Ursolic acid': 6, 'February': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'pseudoachalasia': 1, 'Linoleic acid ( Linoleic acid': 1, 'Linoleic acid': 6, 'Linoleic acid reduced GLI2': 1, 'Linoleic acid - mediated suppression of Sox17 expression . These results suggest that Linoleic acid promotes tumor cell stemness': 1, 'GLI2 fragments via': 1, 'GLI2': 2, 'doxorubicin': 1, 'anesthesia': 3, 'CNKI': 1, 'Wanfang': 1, 'anesthetics': 1, 'progesterone receptor (PR ( progesterone receptor )': 1, 'dimerization blocker , Stattic ( S )': 1, 'nanocarrier': 1, 'Stattic': 5, 'PLGA nanoparticles': 1, 'urothelial': 1, 'arginine methyltransferase': 1, "progesterone receptor (PR status . Rates of high Wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'letrozole': 1, 'steroid': 1, 'prednisolone': 1, 'Prednisolone': 1, 'progesterone receptor': 1, 'Fulvestrant': 1, 'antibiotic': 1, 'nivolumab': 11, 'paclitaxel': 4, 'S-1': 1, 'Ramucirumab': 1, 'opioids': 1, 'steroids': 1, 'cause(s)and': 1, 'anastrozole': 2, 'Paclitaxel': 1, 'Leucovorin': 1, 'irinotecan(FOLFOXIRI)plus': 1, 'panitumumab': 1, 'gemcitabine': 5, 'nab - paclitaxel': 3, 'pancreaticoduodenectomy': 1, 'chemoradiotherapy': 1, 'Adjuvant chemotherapy': 4, 'FOLFIRI': 5, 'progesterone': 3, 'docetaxel': 2, 'trastuzumab': 4, 'ramucirumab': 1, 'antibiotics': 1, 'bevacizumab': 5, 'capecitabine': 1, 'cetuximab': 2, 'RHV': 1, 'Chemotherapy': 1, 'Imatinib': 1, 'imatinib': 4, 'R - CHOP therapy achieved a complete response . A 21 - year - old female spotted seal ( Phoca largha': 1, 'Estrogen': 2, 'receptor alpha . TFEB - Estrogen-related receptor alpha axis enhanced generation of pseudopodia': 1, 'phosphatidylcholine': 2, 'Peptidyl arginine deiminase': 1, 'Lidocaine': 2, 'lidocaine': 6, 'SOX': 1, 'FOLFOX': 1, 'docetaxel(DTX)as': 1, 'chemotherapy(TC)and': 1, 'chemo': 2, 'fulvestrant)was': 1, 'immunochemotherapy': 1, 'GCS': 1, 'neo': 1, 'PALN': 2, 'FOLFOXIRI': 1, 'pegfilgrastim': 1, 'unresectable': 1, 'neoadjuvant chemotherapy': 2, 'epirubicin': 1, 'cyclophosphamide': 1, 'SSPPD': 1, 'ILNM(4': 1, 'Tamoxifen': 1, 'aromatase inhibitors': 1, 'CDK4/6 inhibitors': 1, 'nab - paclitaxel plus ramucirumab , then treated with nivolumab': 1}, 'inflammation': {'analgesia': 13, 'bupivacaine': 3, 'fentanyl': 2, 'saline': 1, 'intragastrically': 1, 'malondialdehyde': 9, 'January': 3, 'glucocorticoids': 1, 'Tribulus terrestris saponins ( terrestris saponins )': 1, 'terrestris saponins (': 1, 'insulin': 9, 'terrestris saponins , at': 1, 'terrestris saponins helped in alleviation of insulin': 1, 'terrestris saponins as a promising candidate that may alleviate the inflammatory burden , insulin resistance and adipokine': 1, 'gliosis': 1, 'chemometrics': 1, 'adipokines': 1, 'resistin': 1, 'esculetin': 1, 'albuminuria': 1, 'pyrrolizidine': 1, 'Folic acid': 12, 'Folic acid peroxisomal beta - oxidation': 1, 'mildronate': 1, 'Lachnoanaerobaculum': 1, 'hallii': 1, 'Bifidobacterium': 4, 'Rikinella': 1, 'Christensenellaceae': 1, 'nonmodel': 2, 'beta-blockers )': 1, 'beta-blockers in patients with ascites and discuss the complex interplay among their hepatic , systemic , and renal hemodynamic effects in this scenario . The aim of this study was to further elucidate the molecular mechanisms that mediate pathologic foreign body response ( foreign body response )': 1, 'steroid': 4, 'duration': 1, 'Lactobacillus': 2, 'eotaxin': 1, 'rupatadine': 3, 'peroxynitrite': 1, 'chemotherapy': 1, 'Annexin': 1, 'statin': 1, 'leucine': 1, 'isoleucine biosynthesis , glutathione metabolism': 1, 'beta - hydroxybutyrate ( beta-hydroxybutyrate )': 1, 'fatty acid': 4, 'beta-hydroxybutyrate': 1, 'quantitative insulin sensitivity check index RQUICKI - beta-hydroxybutyrate': 1, 'nitric oxide': 3, 'divalent cations ( magnesium , zinc': 1, 'Tamoxifen': 16, 'hydroethanolic': 2, 'glutathione peroxidase ( GSH - Px )': 1, 'Sargachromenol': 1, 'Potassium dichromate (': 1, 'selenium': 4, 'IL-2': 2, 'Veraflo': 1, 'Akaike': 1, 'antifungal': 2, 'lavage': 3, 'protease inhibitor': 1, 'bFGF': 1, 'chondral': 1, 'fibrinolysis': 1, 'Ctgf': 1, 'Caenorhabditis': 1, 'Oscillospiraceae': 1, 'Lachnoclostridium': 1, 'IL-5': 1, 'IL-9': 1, 'streptozotocin': 2, 'fasting insulin': 2, 'estradiol': 5, 'leptin': 3, 'antibiotics': 3, 'clindamycin': 1, 'rifampicin': 6, 'Immunohistochemistry': 1, 'bleomycin': 1, 'analgesic': 9, 'opiates': 1, 'tetrodotoxin': 1, 'corticosteroid': 2, 'corticosteroids': 1, 'rapamycin': 2, 'subgingival': 2, 'Desulfobulbaceae': 1, 'Mycoplasmataceae': 1, 'Campylobacteraceae': 1, 'Muribaculaceae': 1, 'Streptococcaceae': 1, 'Gemellaceae': 1, 'Megasphaera': 1, 'Romboutsia': 1, 'Rothia': 1, 'supragingival': 1, 'chemo': 1, 'pembrolizumab': 2, 'opioid analgesic dipeptide': 1, 'morphine': 1, 'infliximab': 7, 'royal jelly': 1, 'Il-2': 1, 'Folic acid ( Folic acid': 1, 'Folic acid (': 1, 'superoxide dismutase': 1, 'tPSA': 3, 'bevacizumab': 4, 'ranibizumab': 3, 'triamcinolone': 1, 'Folic acid revealed': 1, 'methylprednisolone': 2, 'cyclophosphamide': 1, 'ASD).Linoleic acid': 3, 'ASD).Linoleic acid reduced GLI2': 1, 'ASD).Linoleic acid -': 1, 'GLI2 fragments via': 1, 'GLI2': 2, 'ovalbumin': 2, 'aberrance': 1, 'pleiotrophin': 1, 'Jak1': 1, 'Faecalibaculum': 1, 'Dubosiella': 1, 'zymosan': 1, 'Dangshen Erling decoction ( Dangshen Erling decoction': 1, 'Dangshen Erling': 2, 'Dangshen Erling decoction': 4, 'Sebia': 1, 'Prevotella': 1, 'Porphyromonas': 1, 'Folic acid ( 22:4 )': 1, 'pyruvic acid': 1, 'amino acids': 1, 'succinate': 1, 'itaconic acid': 1, 'amino acid': 1, 'itaconic acid positively correlated with Streptococcus . Conclusion : In the lower respiratory tract microenvironment , shared and specific alterations occurred in community-acquired pneumonia and CTD - ILD patients , which were associated with inflammatory and immune reactions , which may provide a new direction for future studies aiming to elucidate the mechanism , improve the diagnosis , and develop therapies for different respiratory diseases . As a heterogeneous and wide inflammation ,': 1, 'antibiotic': 1, 'osteoarticular': 1, 'complexation': 1, 'ropivacaine': 1, 'sufentanil': 1, 'propofol': 1, 'analgesics': 1, 'IL-7': 1, 'metabolite taurine': 1, 'Erysipelotrichaceae': 2, 'taurine': 1, 'betaine': 1, 'colchicine': 10, 'Keratinocytes': 1, 'Trehangelins': 1, 'plasma': 1, 'Rituximab': 1, 'folic acid': 1, 'Folic acid - AKI )': 1, 'Folic acid - AKI but did not prevent kidney failure': 1, 'Folic acid - AKI': 1, 'vasoactive medications': 1, 'norepinephrine': 4, 'hypochlorous acid': 1, 'dimethyl fumarate ( dimethyl fumarate': 1, 'glatiramer acetate': 1, 'dimethyl fumarate': 9, 'microglial': 1, 'intraarticular': 1, 'antiinflammatory': 2, 'chondroprotective': 2, 'CCR4 antagonist': 1, 'September': 1, 'rhinosinusitis': 1, 'Bionorica': 1, 'ibuprofen': 1, 'Leukotriene': 1, 'zymozan': 1, 'BNO': 1, 'Ibuprofen': 1, 'metagenomic': 1, 'metaproteomic': 1, 'Blautia': 1, 'haematological': 1, 'PBS+AA': 2, 'phosphate - buffered saline ( phosphate-buffered saline ) liposomes': 1, 'EPO': 1, 'iron': 1, 'erythropoietin': 1, 'Anagliptin': 1, 'nitric oxide ( nitric oxide': 1, 'trehalose': 1, 'atherogenesis': 1, 'curcumin nanoparticles ( curcumin - nanoparticles ) against copper oxide nanoparticle ( CuO - NP)-mediated hepatorenal effects on behavioral performance , biochemical markers , antioxidants , inflammation , apoptosis , and histopathology in rats . STUDY DESIGN : Twenty Wistar adult male rats were randomly divided into four groups ( n=5 )': 1, 'IotaIota': 1, 'gavaged': 1, 'curcumin - nanoparticles (': 1, 'curcumin - nanoparticles': 1, 'histopathological': 2, 'uric acid': 1}, 'fracture': {'n=63': 1, '1.299': 1, 'denosumab': 7, 'UCHealth': 1, 'October': 2, 'antifouling': 1, 'antifouling sol - gel': 1, 'bisphosphonates': 2, 'anabolic': 6, 'steroid': 2, 'steroids': 3, 'exclusivity': 1, 'Serum vitamin D': 1, 'vitamin D receptor genotyping': 1, 'vitamin D': 2, 'uric acid': 1, 'Vitamin D': 1, 'vitamin D receptor gene polymorphisms were not linked to rheumatoid arthritis . trabecular bone score and': 1, 'vitamin D receptor gene polymorphisms were not linked to rheumatoid arthritis': 1, 'Medline': 1, 'CINAHL': 1, 'January': 4, 'Corynebacterium glutamate expression system': 1, 'chemotherapy': 8, 'raloxifene': 1, 'teriparatide': 1, 'antibiotics': 4, 'glucocorticoid': 2, 'sevelamer': 1, 'lanthanum': 1, 'antibiotic': 2, 'meropenem': 1, 'colistin': 1, 'ceftazidime': 1, 'avibactam': 1, 'anesthesia': 1, 'posttreatment': 1, 'Spain': 1, 'Finland': 1, 'eldecalcitol': 3, 'vitamin D3': 1, 'hypercalcaemia': 1, 'Cochrane library databases ( last update : May 2020 )': 1, '30(th': 1, 'September': 2, 'Kirschner': 1, 'KDMLI': 3, 'February': 2, 'methotrexate': 9, 'analgesic': 7, 'vitamin D analogs': 1, 'R3': 1, 'Truven': 1, 'August': 3, 'risedronate': 1, 'cyclophosphamide': 1, 'doxorubicin': 2, 'vincristine': 1, 'prednisone': 1, 'EuroQol': 1, 'microarchitectural': 1, 'Wilcoxon': 1, 'chondral': 1, 'methoxyflurane': 1, 'analgesics': 1, 'analgesia': 1, 'ARV': 1, 'Osteosynthesis': 1, 'QuickDASH': 2, 'pPOSSUM': 2, 'hydromechanical': 1, 'bone mineral density': 1, 'aspirin': 7, 'Aspirin': 1, 'photobiomodulation': 1, 'magnesium': 1, 'Serum Calcium and magnesium': 2, 'nonsteroidal': 2, 'corticosteroids': 2, 'Propofol': 1, 'remifentanil': 1, 'rocuronium': 1, 'magnesium - doped hydroxyapatite ( 1Mg - HAs )': 1, 'osteopontin': 1, 'Polyethylene glycol ( Polyethylene glycol )': 1, 'Polyethylene glycol polymers': 1, 'Polyethylene glycol blend': 1, 'Polyethylene glycol in the poly(lactic acid)': 1, 'endodontically': 1, 'mesiolingual': 7, 'distobuccal': 6, 'Arbeitsgemeinschaft': 1, 'Osteosynthesefragen': 1, 'nitro blue': 1, 'rapamycin': 1}, 'osteonecrosis': {'bisphosphonates': 7, 'denosumab': 18, 'Actinomyces': 6, 'chemotherapy': 9, 'Osteonecrosis': 1, 'Visual Analog Scale ( Visual Analog Scale )': 1, 'Visual Analog Scale': 6, 'antiresorptive': 2, 'Steroid': 25, 'eldecalcitol': 4, 'vitamin D3': 1, 'teriparatide': 5, 'Embase': 3, 'Kyoto': 10, 'Cytoscape': 2, '2,664,104': 1, 'corticosteroids': 17, 'zoledronic acid': 13, 'Zoledronic acid group ( 3 in mandible ,': 1, 'Zoledronic acid group ( 1 in maxilla , 2 in mandible )': 1, 'Zoledronic acid - treated and control groups 1': 1, 'Zoledronic acid treatment': 3, 'glucocorticoids': 4, 'glucocorticoid': 14, 'bisphosphonate': 40, 'methotrexate': 4, 'leflunomide': 1, 'Zoledronic acid ( Zoledronic acid )': 1, 'fluorescein diacetate ( FDA)-staining . We confirmed that Zoledronic acid treatment suppressed cell viability of osteoclasts': 1, 'glutathione peroxidase': 2, 'glutathione': 1, 'Zoledronic acid': 9, 'Protocatechuic acid': 1, 'vitamin D analogues': 2, 'antibiotics': 1, 'vitamin D analogue significantly inhibited elevation of serum inflammatory cytokine levels in mice in response to injection': 1, 'vitamin D': 6, 'TPTD': 3, 'steroid': 33, 'dexamethasone': 8, 'prosthodontic': 1, 'January': 12, 'Glucocorticoid': 2, 'zoledronic acid ( Zoledronic acid': 2, 'Zoledronic acid - mediated decrease in the protein expression of the osteogenic genes osteopontin': 1, 'EuroQol': 1, 'Visual Analog Scale ( 1.4 vs 2.4 , p=0.025 )': 1, 'EPCs': 2, 'methylprednisolone': 3, 'zoledronic acid ( Zoledronic acid )': 2, 'Zoledronic acid / saline administration': 1, 'Zoledronic acid - treated group': 2, 'Zoledronic acid - treated group had significantly higher incidence of osteonecrosis': 1, 'Zoledronic acid - treated rabbit model': 1, 'osteonecrosis': 4, 'zoledronic acid ( zoledronic acid )': 1, 'vitamin D supplementation only . ( c )': 1, 'steroids': 7, 'heparin': 1, 'alendronate': 4, 'February': 1, 'Visual Analog Scale )': 4, 'analgesia': 1, 'Cochrane January': 1, 'iodinated solution': 1, 'osseointegration': 1, 'corticosteroid': 21, 'prednisone': 4, 'Avascular': 1, 'Okinawa': 1, 'pravastatin': 1, 'September': 3, 'August': 2, 'platelet rich plasma': 1, 'CNKI': 1, 'Diels': 1, 'Pheretima aspergillum ( E.Perrier ) , Panax notoginseng ( Burk . )': 1, 'Bge': 1, 'bevacizumab': 1, 'October': 2, 'cyclophosphamide': 1, 'CY': 1, 'Zoledronic acid administration': 1, 'BFM95': 2, 'Zoledronic acid ( Zol )': 1, 'vitamin D influences Vascular Endothelial Growth Factor levels . The aim': 1, 'Zol': 1, 'serum calcium': 1, 'day-3': 1, 'dasatinib': 1, 'antileukemic': 2, 'osteonecrotic': 1, 'hyaluronic acid hydrogel': 1, 'Zoledronic Acid )': 1, 'Morphometry': 1, 'Histomorphometry': 1, 'imipenem': 1, 'cilastatin sodium': 1, 'edentulism': 1, 'anesthesia': 1, 'metabolomic': 1, 'lipidomic': 1, 'PUBMED': 1, 'chemotherapies': 1, 'chemo': 2, 'XGBoost': 1, 'MEDLINE': 1, 'circRNA': 1, 'Bisphosphonate': 1, 'osteocyte': 1, 'geranylgeraniol': 1, 'Zoledronic acid via': 1, 'Zoledronic acid impaired Rac1 migration to BMDM membrane': 1, 'Zoledronic acid simultaneously activated Rac1': 1, 'GGOH': 2, 'osteocytic': 1, 'sEHI': 1, '11,101': 1, 'Osterix': 1, 'Arthrex': 1, 'precollapse corticosteroid': 2, 'Zoledronic acid caused enhanced reactive oxygen': 1, 'arachidonic acid': 2, 'H2 O2 production': 1, 'H2 O2 production in isolated CYP2C8 enzymes': 1, 'H2 O2': 1, 'Zoledronic acid groups': 1, 'Zoledronic acid group ( 9.6': 1, 'Zoledronic acid or denosumab ( hazard ratio': 1, 'antibiotic': 1, 'Kummell': 1, 'analgesics': 2, 'zoledronic acid and zoledronic acid groups': 1, 'zoledronic acid combination': 1, 'hip corticosteroid/anesthetic': 1, 'Interobserver': 1, 'systemic corticosteroid': 1, 'clodronate inhibit NBP - binding to hemi-arthroplasty': 1, 'Corticosteroids': 2, 'antiresprotive medications': 1, 'antirresorptives': 1, 'zoledronic acid ( p>0.0001 )': 1, 'zoledronic acid administration': 1, 'sterile saline (': 1, 'Zoledronic acid - treated animals showed a larger radiolucent extraction site area compared to the saline group ( p = 0.007 )': 1, 'Heparin lithium': 1, 'lithium': 2, 'thrombophilias': 1, 'hUC': 3, 'zoledronic acid and/or denosumab': 1, 'zoledronic acid and/or denosumab ( odds ratio = 1.03': 2, 'arthrodesis': 2, 'blood': 1}, 'cancers': {'January': 6, 'September': 1, 'chemotherapy': 27, 'Histone deacetylase': 1, 'Human Histone Deacetylase': 1, 'Histone': 4, 'Deacetylase': 1, 'Paeoniaceae': 1, 'Cytotoxic': 1, 'antimalarials': 1, 'phosphodiesterase-5 inhibitors': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 5, 'ipilimumab': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'Sargachromenol': 1, 'chemoradiation': 2, 'arsenic trioxide': 2, 'retinoic acid': 2, 'arsenic trioxide combined': 1, 'anthracycline': 2, 'd1': 1, 'd18': 1, 'Ductal': 2, 'acinar': 1, 'clonally': 1, 'fasting insulin': 2, 'estradiol': 5, 'insulin': 4, 'paclitaxel': 5, 'heterotypic': 1, 'COX-2': 1, 'microsomal prostaglandin E': 1, 'Ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mPGES-1': 2, 'SPLC': 1, 'Interferon': 1, 'nomogram': 2, 'Krippendorff alpha': 2, 'February': 1, 'analgesic': 3, 'diclofenac': 7, 'opioid': 1, 'tramadol': 4, 'pain medication': 1, 'cisplatin': 9, 'docetaxel': 1, 'etoposide': 1, 'CRISPR': 2, 'antifungal': 2, 'anticancer': 2, 'anesthesia': 3, 'CNKI': 1, 'Wanfang': 1, 'anesthetics': 1, 'progesterone receptor (PR ( progesterone receptor )': 1, 'estrogen receptor': 1, 'Chemotherapy': 1, 'unresectable': 1, 'NAC': 1, 'BRAF inhibitors': 2, 'vitamin D supplementation': 1, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'Shokat': 1, 'BRAF': 5, 'HER3': 1, 'human monoclonal antibody': 1, 'vemurafenib': 1, 'gamma)153Sm': 1, 'Physicochemical': 1, 'chemotherapy(TC)and': 1, 'chemo': 8, 'anastrozole': 1, 'bevacizumab': 4, 'fulvestrant)was': 1, 'glucocorticoid': 1, 'trastuzumab': 1, 'immunoblotting': 1, 'intrapleurally': 1, 'Cholangiocarcinoma': 1, 'radioactive iodine ( radioiodine ) treatment increased markedly . radioiodine has been associated with an increased risk of leukemia , but risks of second solid malignancies remain unclear . We aimed to quantify risks of second malignancies associated with radioiodine treatment': 1, 'nonsignificantly': 1, 'carboplatin': 3, 'doxorubicin': 1, 'cyclophosphamide': 1, 'Chemo': 1, 'nanotherapeutics': 1, 'Folate Receptor': 1, 'folic acid': 1, 'intratumoral': 1, 'FLOT': 4, 'steroid': 1, 'thrombospondin': 4, 'radiosensitivity': 1, 'regulate thrombospondin': 1, 'rMATS': 1, 'LeafCutter': 1, 'CCL8': 1, 'CCL19': 1, 'nucleophosmin': 1, 'homodimerization': 1, 'Cochrane databases': 1, 'tsRNA': 1, 'Kyoto': 3, 'CDK4': 1, 'Bortezomib': 2, 'Nivolumab': 1, 'biocompatible sodium alginate': 1, 'Finland': 1, 'anticoagulation': 3, 'Splanchnic': 1, 'isoleucine': 2, 'Embase': 1, 'MEDLINE': 1, 'superoxide anions ( O2(- )': 1, 'allosteric inhibitor': 1, 'dermatomyositis': 1, 'autoantibody': 1, 'amino acids': 1, 'fisetin': 1, 'curcumin': 1, 'luteolin': 1, 'garcinol': 1, 'probiotics': 1, 'Immunohistochemistry': 1, 'ITPKB': 2, 'Histone deacetylase ( Histone deacetylase': 1, 'proteasome inhibitors': 1, 'Histone deacetylase inhibitor': 2, 'proteasome inhibitor': 2, 'ixazomib': 1, 'Histone deacetylase inhibitor romidepsin synergistically induce cell': 1}, 'tumour': {'Cytotoxic': 1, 'chemotherapy': 36, 'Immunostaining': 1, 'Tamoxifen': 16, 'hydroethanolic': 2, 'nitric oxide': 2, 'malondialdehyde': 1, 'glutathione peroxidase ( GSH - Px )': 1, 'trichogerminomas': 1, 'alizarin red stainings': 1, 'osteopontin': 1, 'antibiotics': 1, 'clindamycin': 1, 'rifampicin': 6, 'Immunohistochemistry': 1, 'chemo': 2, 'octreotide': 2, 'telotristat': 1, 'Amplatzer': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'urothelial': 1, 'arginine methyltransferase': 1, 'fluorouracil': 1, 'January': 5, 'August': 1, 'Peptidyl arginine deiminase': 1, 'Imatinib': 1, 'cisplatin': 15, 'agglutinin': 1, 'haematological': 2, 'inflammatories': 1, 'Cochrane databases': 1, 'vincristine': 2, 'actinomycin': 2, 'doxorubicin': 9, 'epirubicin': 1, 'ifosfamide': 1, 'carboplatin': 7, 'etoposide': 18, 'cyclophosphamide': 3, 'CCR6': 1, 'Embase': 1, 'MEDLINE': 1, 'Akaike': 1, 'pN': 1, 'tranexamic acid ( tranexamic acid )': 1, 'tranexamic acid': 1, 'tranexamic acid in haematuria': 1, 'polylactic acid filament': 1, 'sugemalimab': 6, 'paclitaxel': 8, 'pemetrexed': 1, 'bleomycin': 2, 'etoposide phosphate': 2, 'Bleomycin': 1, 'Etoposide': 1, 'hydrocortisone': 1, 'promethazine': 1, 'adrenaline': 1, 'fluids': 1, 'oxygen': 1, 'Spironolactone': 2, 'spironolactone': 4, 'steroid': 4, 'checkpoint inhibitor': 1, 'Chemotherapy': 1, 'taxane': 1, 'Centre': 1, 'TTK': 2, 'CDC20': 2, 'Abiraterone': 1, 'steroids': 1, 'G1': 1, 'Characterising': 1, 'multistructure': 1, 'Bromelain': 2, 'Acetylcysteine': 3, 'Gemcitabine': 2, 'chemoimmunotherapy': 1, 'pembrolizumab': 1, 'blockade': 1, 'CTCAE': 1, 'nitric oxide ( nitric oxide': 1, 'E)-9': 2, 'Cisplatin': 2, 'raloxifene': 4, 'nephrotoxicity': 1, 'Vitamin D': 1, 'Vitamin D synthesis': 1, 'vitamin D receptor ( vitamin D receptor )': 1, 'butyrate': 1, 'acetate': 1, 'chemoradiotherapy': 2, 'Fondazione': 1, 'Gemelli': 1, 'betegeknel': 1, 'gyakran nem lehetseges vagy nehezitette valik': 1, 'gasztroszkop': 1, 'szajon': 1, 'torteno': 1, 'rosszindulatu': 1, 'Orv Hetil': 2, 'trismus': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'fisetin': 2, 'PHF10': 5, 'Pyradiomics': 1, 'Wilcoxon': 2, 'tumourigenesis': 1, 'nivolumab': 4, 'cabozantinib': 5, 'SUVpeak': 3, 'SUVapex': 1, 'sorafenib': 3, 'antifibrotic': 1, 'proangiogenic': 1, 'telomerase inhibitors , anti - angiogenesis agents': 1, 'Bazedoxifene': 1, 'bazedoxifene': 5, 'imatinib': 2, 'panitumumab': 1, 'amino acid': 1, 'ipilimumab': 2, 'perfluorohexane': 7, 'Infliximab': 4, 'hypokalaemia': 1, 'Galectin-3 inhibitor': 2, 'tocilizumab': 1, 'rituximab': 5, 'methotrexate': 1, 'BRAF': 1, 'trametinib dimethyl sulfoxide (': 1, 'atezolizumab': 1, 'bevacizumab': 1, 'vinblastine': 3, 'Vinblastine': 1}, 'polycystic ovary syndrome': {'insulin': 91, 'glucose': 10, 'peak insulin': 1, 'fasting insulin': 7, 'Analgesics': 1, 'periodontopathogens': 1, 'letrozole': 42, 'adipocytokines': 1, 'Curcumin': 1, 'polyphenolic compound': 1, 'curcumin exhibits immobilizing action on sperms , and at': 1, 'curcumin': 11, 'chemotherapeutic': 1, 'Embase': 3, 'albuminuria': 1, 'hyperandrogenism': 10, 'flutamide': 1, 'Spironolactone': 1, 'spironolactone': 7, 'January': 11, 'September': 4, 'clomiphene': 16, 'Kuntai': 4, 'estradiol': 15, 'Berberis': 1, 'berberine': 2, 'dehydroepiandrosterone sulfate': 3, 'luteinizing hormone (LH / follicle - stimulating hormone (LH , testosterone': 2, 'antiandrogen': 2, 'adropin': 1, 'metatrim': 1, 'cholesterol': 2, 'fatty acid (TCA oxidation': 1, 'testosterone': 4, 'dehydroepiandrosterone - sulfate ( dehydroepiandrosterone - S )': 1, 'polyunsaturated fatty acids ( polyunsaturated fatty acids )': 1, 'NCT04738409.).Estradiol': 1, 'steroid': 5, 'ERbeta': 1, 'Letrozole': 3, 'metformin': 54, 'Metformin': 6, 'normal saline water ( 0.9': 1, 'malondialdehyde': 4, 'IL-6': 1, 'genistein': 4, 'gonadotropins': 2, 'diacerein': 2, 'serum insulin': 1, 'interleukin': 2, 'inflammasome': 1, 'valproate': 1, 'lamotrigine': 2, 'oxcarbazepine': 2, 'carbamazepine': 2, 'progesterone': 13, 'Gpx3': 1, 'mRNAs': 7, 'tamoxifen': 2, 'clomiphene citrate': 2, 'Tamoxifen': 1, 'dehydroepiandrosterone': 7, 'Androgens': 1, 'estrogens': 3, 'glucagon': 1, 'peripheral insulin resistance in the early phase of type 2 diabetes . In the skeletal muscle and liver , the ATP surplus contributes to insulin resistance': 1, 'donor breastmilk': 1, 'ovarian insulin resistance in polycystic ovary syndrome remain elusive . METHODS : Follicular fluid': 1, 'Electroacupuncture': 7, 'Indonesia': 1, 'Folliculogenesis': 2, 'resveratrol': 5, 'resveratrol potently': 1, 'November': 1, 'estrogen': 2, 'oxytocin': 5, 'arginine - vasopressin , AVP )': 1, 'phoenixin': 1, 'PNX': 1, 'lipidomic': 1, 'vitamin - like nutrients ( bioflavonoids and alpha - lipoic acid (TCA )': 1, 'selenium': 1, 'chromium': 1, 'omega-3 fatty acids': 1, 'probiotics': 4, 'androgens': 1, 'placentaspecific': 2, 'fasting insulin ( FINS : WMD -3.40': 1, 'Serum metformin concentrations': 1, 'kisspeptin': 1, 'receptor antagonist': 1, 'B analogs': 1, 'vitamin B12': 1, 'vitamin D': 3, 'prebiotics': 2, 'Cochrane databases': 1, 'synbiotics': 2, 'pioglitazone': 6, 'Ferriman - Gallwey score ( F - G )': 1, 'fasting insulin ( fasting insulin': 1, 'Insulin': 1, 'GeneCards': 1, 'Kyoto': 3, '13,823': 1, 'melatonin': 1, 'glucose transporter ( GLUT4 )': 1, 'palmitic acid (TCA ( physical activity )': 1, 'ESR2': 2, 'Latvia': 1, 'bile acid (TCA and 24 bile acid (TCA metabolites': 1, 'taurocholic acid (TCA ( taurocholic acid )': 1, 'glycochenodeoxycholic acid (TCA ( glycochenodeoxycholic acid )': 1, 'Resveratrol possesses anti - inflammatory , antioxidant and antidiabetic properties . The purpose of this study was to evaluate the potential effectiveness of resveratrol in polycystic ovary syndrome based': 1, 'ovariectomy': 1, 'ovulate': 1, 'dysglycemia': 1, 'fasting insulin resistance ( homeostatic model assessment of insulin': 1, 'psychiatric medication': 1, 'statins': 4, 'Statins': 1, 'statin': 1, 'Do insulin sensitizing agents such as': 1, 'myoinositol': 3, 'Ferriman': 1, 'Ferriman Gallwey': 2, 'Bushen': 3, 'cyproterone': 1, 'norepinephrine': 1, 'hydroxyindoleacetic acid (TCA (': 1, 'luteinizing hormone': 1, 'Bushen Jieyu Tiaochong Formula': 1, 'ATF4': 1, 'drospirenone': 1, 'Scopus': 1, 'Cochrane': 1, 'orlistat': 8, 'acarbose': 2, 'rosiglitazone': 2, 'sitagliptin': 1, 'lipotoxicity': 1, 'glycerophosphocholines': 1, 'sphingolipids': 1, 'rhamnosus GG': 1, 'free testosterone': 1, 'luteinizing hormone , luteinizing hormone': 1, 'February': 2, '17,076': 1, 'antioxidative vitamins ( vitamins )': 1, 'Cochrane Library databases': 1, 'CINAHL': 2, 'pipelle': 1, 'hormone agonist protocol': 2, 'hormone agonist': 1, 'hormone agonist cycles': 1, 'MDM2': 1, 'Hyperinsulinism': 1, 'Cytoscape': 2, 'EREG': 1, 'Wenshentiaojing': 1, 'luteinizing hormone (LH and follicle - stimulating hormone (LH , serum total cholesterol': 1, 'GPR120 agonist decreased insulin resistance in the polycystic ovary syndrome rat model but improved the ovarian function . It is suggested that GPR120 plays a vital role in suppressing insulin resistance , regulating ovary function and decreasing lipid accumulation in the liver , demonstrating that targeting GPR120 could be an effective method for the improvement of PCOS.Polycystic ovary syndrome (MS ( polycystic ovary syndrome )': 1, 'Merck': 2, 'cyclopamine': 1, 'allopregnanolone': 1, 'Serum leptin /': 1, 'Bacteroidetes': 1, 'Blautia': 3, 'butyric acid (TCA , reduced after Sleeve gastrectomy . Sleeve gastrectomy significantly ameliorated polycystic ovary syndrome - related symptoms such as hyperandrogenism': 1, 'Pentraxin': 2, 'lipid': 1, 'Drosha': 1, 'Glucose': 1, 'Anticoagulation': 1, 'apixaban': 2, 'vitamin D3 supplementation : either a microencapsulated liposomal': 1, 'immunoreactive insulin': 2, 'vitamin D supplementation': 1, 'vitamin D3': 2, 'dihydrotestosterone': 2, 'progesterone receptor (ER , homeobox A11 mRNA expression and placental estrogen - related receptor (ER beta and trophoblast - specific protein alpha mRNA expression . Collectively , our data provide insight into how N-acetylcysteine': 1, 'gonadotropin': 1, 'RBPMS': 1, 'leptin': 4, 'intracerebroventricular': 2, 'Extracellular glutathione peroxidase': 1, 'glutathione peroxidase': 2, 'Antibiotic': 1, 'Dorea': 1, 'dehydroepiandrosterone sulphate ( dehydroepiandrosterone sulphate )': 1, 'alpha - lipoic acid (TCA on clinical , endocrine and metabolic features of women affected by polycystic ovary syndrome . METHODS : In this pilot cohort study , 60 women ( 30 hyperinsulinemic and 30 normoinsulinemic patients ; age 15 - 34 years ) were enrolled and clinical , hormonal and metabolic parameters were evaluated before and after a six - months treatment with alpha - lipoic acid (TCA': 1, 'progestin': 1, 'synthetic oxytocin': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'GSH': 1}, 'ovarian cancer': {'chemotherapy': 110, 'Paclitaxel': 6, 'MSH6': 1, 'MSH2': 1, 'niraparib': 2, 'haematological': 1, 'paclitaxel': 24, 'carboplatin': 23, 'Adjuvant chemotherapy': 1, 'bevacizumab': 17, 'cisplatin': 58, 'neoadjuvant chemotherapy': 5, 'chemo': 9, 'Cisplatin': 3, 'February': 1, 'Kyoto': 7, 'TLR3 ligands': 1, 'rintatolimod': 1, 'celecoxib': 1, 'interferon-a was': 1, 'November': 1, 'MEST(high)BRCA1(high': 1, 'ITPKB': 2, 'poly adenosine diphosphate ribose polymerase )': 1, 'anticancer': 4, 'veliparib': 2, 'NEK4': 1, 'January': 5, 'alpha': 1, 'opioid agonist D': 1, 'methadone': 8, 'analgesic': 2, 'kinase inhibitor': 1, 'bazedoxifene': 5, 'nicotinamide adenine dinucleotide ( NADH )': 1, 'tamoxifen': 2, 'CRISPR': 1, 'fatty acid oxidation': 1, '12,337': 1, 'CAncer': 8, 'poly adenosine diphosphate ribose polymerase ) inhibitors': 1, 'poly adenosine diphosphate ribose polymerase inhibitors have been used in clinical practice . However , patients with platinum - resistant relapsed ovarian cancer cases still have a poor prognosis and there is an unmet need': 1, 'Wilcoxon': 1, 'Fe(III': 2, 'anesthesia': 1, 'exosomes': 1, 'rapamycin inhibitors': 1, 'nomogram': 4, 'GEPIA': 1, 'ropivacaine': 2, 'dexmedetomidine': 1, 'normal saline': 2, 'analgesia': 7, 'sufentanil': 1, 'ondansetron': 1, 'Flurbiprofen': 1, 'PLGA': 5, 'MEDLINE': 1, 'Scopus': 1, 'hexon': 1, 'CDDP': 1, 'AP-1': 1, 'camrelizumab': 1, 'famitinib': 1, 'HCG11': 1, 'daidzein': 5, 'genistein': 2, 'tertiles': 1, 'Breastfeeding': 1, 'PHY34': 4, 'poly adenosine diphosphate ribose polymerase cleavage and Annexin V staining . Compounds with a diphyllin structure similar to PHY34 have been shown to inhibit the ATP6V0A2 subunit of V(vacuolar)-ATPase . Therefore , ATP6V0A2 wild - type and ATP6V0A2 V823 mutant cell lines were tested with PHY34': 1, 'miR-133a': 1, 'miR-133a inhibitor': 1, 'Sapporo': 1, 'L - methionine': 1, 'miR-551b-5p': 1, 'vitamin D3': 1, 'calcitriol': 4, 'calcemic': 1, 'vitamin D analogs ( an1,25Ds )': 1, 'vitamin D receptor ( vitamin D receptor )': 1, 'Ang-(3': 1, 'Folate receptor ( Folate receptor ) alpha and': 1, 'amino acids': 1, 'folate transporter': 1, 'Hyperthermic': 7, 'ATF4': 1, 'CHOP': 1, 'Bax': 1, 'proteasome inhibitor': 1, 'bortezomib': 1, 'poly adenosine diphosphate ribose polymerase ) inhibitors ( poly (ADP-ribose) polymerase inhibitors )': 1, 'tricarboxylate': 1, 'molybdenum disulfide ( MoS2 )': 1, 'bovine serum albumin': 1, 'electroconductivity': 1, 'Adenosine': 1, 'intercellular interactions': 1, 'beta inhibitor': 2, 'Youden': 1, 'Fluorouracil': 1, 'carcinoembryonic': 1, 'mRNAs': 2, 'nivolumab': 3, 'steroid': 3, 'normothermic': 1, 'epinephrine': 5, 'platinum chemotherapy': 1, 'SKOV-3': 1, 'antitumor': 1, 'autophagy': 1, 'histone deacetylase': 7, 'Nagasaki': 1, 'ginkgolic acid': 5, 'DSMO': 1, 'Transwell': 1, 'August': 1, 'microRNA-30': 3, 'gemcitabine': 3, 'HCG18': 3, 'shRNA': 1, 'Lysophosphatidic acid': 6, 'Lysophosphatidic acid ( Lysophosphatidic acid': 1, 'Lysophosphatidic acid receptors (CARs ( LPA receptors )': 1, 'Lysophosphatidic acid receptor': 1}, 'B-cell lymphoma': {'Pixantrone': 3, 'chemotherapy': 47, 'Annexin': 1, 'p38 inhibitor': 1, 'Imatinib': 1, 'imatinib': 1, 'VIP152': 1, 'ovalbumin': 1, 'MTX': 6, 'Rituximab': 2, 'cyclophosphamide': 13, 'doxorubicin': 22, 'vincristine': 12, 'prednisolone': 4, 'bevacizumab': 1, 'immuno - chemotherapy': 1, 'pegylated': 1, 'methotrexate': 7, 'lenalidomide': 2, 'Tafasitamab': 1, 'loncastuximab': 3, 'mRNAs': 1, 'chemo': 1, 'January': 2, 'Lymphomapatients': 1, 'Rwanda': 1, 'rituximab': 17, 'prednisone': 8, 'lansoprazole': 1, 'LPZ': 1, 'HCl': 1, 'superoxide dismutase': 1, 'malondialdehyde': 7, 'nitric oxide': 2, 'proanthocyanidins': 1, 'TFBIP': 2, 'pharmacokinetics': 3, 'obinutuzumab': 1, 'atezolizumab': 3, 'tisagenlecleucel': 5, 'Lymph2Cx': 1, 'aspirin': 1, 'Honokiol': 1, 'CRISPR': 1, 'fludarabine': 1, 'SCT': 1, 'aromatase inhibitors': 1, 'tamoxifen': 8, 'Insulin': 1, 'Tamoxifen': 1, 'BCL3': 1, 'amino acid': 1, 'immunotherapy': 1, 'Bangkok': 1, 'Thailand': 1, 'normal saline': 2, 'myeloperoxidase': 1, 'aniliniumtype fullerene derivatives ( derivative # 4 )': 1, 'polyubiquitination': 1, 'NRMT': 4, 'cisplatin': 1, 'lisocabtagene': 2, 'bioavailable': 1, 'interferon gene agonists': 1, 'costimulatory molecule': 1, '1BB': 1, 'Fondazione Italiana Linfomi )': 1, 'liposomal': 1, 'doxorubicine': 1, 'ibrutinib': 1, 'dexamethasone': 3, 'etoposide': 3, 'September': 2, 'platelet': 1, 'zanubrutinib': 1, 'August': 2, 'bruton tyrosine kinase ( bruton tyrosine kinase ) inhibitor': 1, 'Ibrutinib': 2, '2,3,5 - Triphenyltetrazolium chloride ( Triphenyltetrazolium chloride': 1, 'bortezomib': 5, 'daratumumab': 1, 'STK11': 1, 'selenium nanoparticles ( prodigiosins - SeNPs )': 1, 'fluoxetine': 1, 'sodium selenite ( Na2SeO3 ,': 1, 'glutathione peroxidase': 1, 'Tisagenlecleucel': 1, 'methylprednisolone': 2, 'immunoglobulin': 1, 'anakinra': 1, 'Chemotherapy': 1, 'L1220Tfs*3': 1, 'EOT': 1, 'Atrazine': 4, 'atrazine': 1, 'LD50': 1, 'dopamine': 1, 'diacerein': 2, 'letrozole': 3, 'serum insulin': 1, 'interleukin': 2, 'insulin': 1, 'inflammasome': 1, 'Syk inhibitors': 1, 'corepressors': 1, 'Pegfilgrastim': 1, 'pegfilgrastim': 1, 'propofol': 8, 'consolidative': 2, 'immunochemotherapy': 1, 'Consolidative': 1, 'HD - MTX': 1, 'alphaOFF': 1, 'chemoimmunotherapy': 3, 'Tacrolimus': 1, 'mycophenolate mofetil': 1, 'Mycophenolate mofetil': 1, 'tacrolimus': 1, 'rapamycin': 1, 'oncofetal protein insulin - like growth factor 2 mRNA binding protein-3 ( IMP3 )': 1, 'bendamustine': 1, 'steroid': 3, 'Embase': 1, 'steroids': 1, 'CDK9 inhibitor': 2, 'pembrolizumab': 3, 'dinaciclib': 3, 'CDK9 inhibitor combinations': 1, 'statins': 6, 'lovastatin': 1, 'thalidomide': 11, 'Urine albumin': 1, 'patellectomy': 1, 'sirolimus': 1, 'GraphPad': 1, 'normal': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'glutathione peroxidase ( GSH - PX )': 1, 'reoxygenation': 1, 'Cytoscape': 1, 'Astragali': 1, 'Dioscoreae': 2, 'pharmacokinetic': 2, 'aducanumab': 1, 'Curcumin': 1, 'anticancer': 2, 'curcumin': 6, 'photodynamic': 2, 'flavonoids': 4, 'Drynariae': 4, 'intragastric': 1, 'Kangnaoshuai': 1, 'donepezil': 1, 'Rhizoma': 2, 'estrogen': 1, 'scopolamine': 2, 'CCAAT': 1, 'multiagent chemotherapy': 1, 'levetiracetam': 2, 'D18': 1, 'lorazepam': 1, 'phenobarbital': 1, 'midazolam': 1, 'tocilizumab': 1, 'antibiotics': 1, 'sedatives': 1, 'D19': 1, 'intravitreal': 1, 'RCHOP': 3, 'selinexor': 1, 'deregulation': 1, 'urothelial': 1, 'Aciclovir': 1}, 'ALI': {'mVOCs': 2, 'iodine complex': 2, 'ionic - iodine polymer complex with': 1, 'elemental iodine': 1, 'magnesium stearate ( magnesium stearate ) binary mixtures . Micronized fluticasone propionate': 1, 'magnesium stearate': 1, 'magnesium stearate mixing': 2, 'pharmacokinetics': 1, 'Shc4': 2, 'bleomycin': 2, 'JAK': 2, 'normal saline': 2, 'intragastric': 1, 'chemotherapy': 7, '21.3mo': 1, 'BB': 1, 'Xuanfei Baidu': 7, 'glycyrrhizic acid': 1, 'dapagliflozin': 1, 'malondialdehyde': 8, 'nitric oxide': 5, 'dapagliflozin antioxidant': 1, 'selenoprotein': 1, 'anticoagulant medication . Endovascular or open vascular revascularisation': 1, 'anticoagulation': 1, 'Fangfeng': 1, 'IL-5': 1, 'antiinflammatory': 1, 'ASA': 4, 'myeloperoxidase': 2, 'Kyoto': 7, 'Amadori compounds': 1, 'sodium adducting cations': 1, 'antibiotic': 16, 'ciprofloxacin': 3, 'Chloroquine': 4, 'rapamycin': 3, 'Isovitexin': 7, 'PTEN': 1, 'Vorapaxar': 1, 'aspirin': 1, 'analogues': 1, 'elastase inhibitor': 1, 'lenalidomide': 1, 'polymorphonuclear': 1, 'Qingwenzhike': 3, 'interleukin-18': 1, 'isoorientin': 2, 'Thalictrum': 3, 'IL-2': 1, 'Atg5': 1, 'sodium iodide': 2, 'radiopharmaceuticals': 1, 'Resveratrol ( Resveratrol )': 1, 'dexamethasone': 7, 'Intragastric': 1, 'Resveratrol': 6, 'lipopolysaccharide': 2, 'mRNAs': 5, 'interactions': 2, 'JHEP': 1, 'phosphoinositide': 3, 'Eurycoma longifolia ( Tongkat Ali )': 1, 'isoscopoletin': 1, 'Fluorofenidone': 1, 'melatonin receptor agonist with anti - inflammatory and antioxidant effects': 1, 'Autophagy': 1, 'Sirtuin': 6, 'thrombolytic': 1, 'Embase': 2, 'CINAHL': 1, 'beta inhibitor': 1, 'Mtor': 1, 'Hif1alpha': 1, 'Telocytes': 1, 'beta inhibitors': 1, 'Cochrane': 1, 'box-1': 1, 'PRF1': 1, 'GZMB': 1, 'OASL': 1, 'HSP90AA1': 1, 'Hydroxymethylfurfural': 1, 'fluticasone': 2, 'UFP': 2, 'NQO1': 1, 'propionate': 1, 'galactooligosaccharide': 1, 'flavonoid': 1, 'coumarin': 1, 'microg': 1, 'ABTS': 1, 'Trolox': 1, 'Terretonin': 4, 'Agrimonia pilosa ethanol extract': 1, 'nitrous oxide': 3, 'NAPDH oxidase ( DPI )': 1, 'hydrochloric acid ( hydrochloric acid )': 2, 'HCL': 1, 'Taurine': 1, 'nitrous': 5, 'dexmedetomidine': 2, 'chelerythrine': 1, 'TCMSP': 1, 'TCMIO': 1, 'K inhibitor': 1, 'cytokine storm injection': 1, 'fluids': 4, 'antibiotics': 9, 'hyperoxia': 1, 'cytokine storm': 1, 'Antibiotic': 2, 'Calycosin': 1, 'interferon genes inhibitor C-176 (': 1, 'interferon genes inhibitor': 2, 'interferon genes knockdown significantly decreased the phosphorylation of transcription factor': 1, 'interferon genes inhibitor can alleviate lipopolysaccharide - induced air-liquid': 1, 'acetaminophen': 1, 'insulin glargine': 1, 'detemir': 1, 'September': 1, 'insulin Glargine': 1, 'insulin': 3, 'Detemir': 3, 'Glargine': 1, 'leptin': 1, 'Streptozotocin': 1, 'broncho': 1, 'ZDP': 1, 'bifendate': 1, 'physiologic saline ( normal , negative control )': 1, 'antioxidants superoxide dismutase': 1, 'Vitamin D3': 1, 'calcitriol': 1, 'vitamin D3 supplementation prevents lipopolysaccharide - induced air-liquid': 1, 'vitamin D3': 1, 'antidepressants': 1, 'venlafaxine': 2, 'antipsychotic': 1, 'Anakinra': 4, 'IL-1 blockade': 1, 'Nervilia': 5, 'IL-6': 6, 'phytomedicine': 1, 'propionate receptor antagonist': 1, 'Intratracheal': 1, 'hydrochloric acid': 3, 'propionate receptors': 1, 'hydrogen': 2, 'TBI': 3, 'pyroptosis': 2, 'salicylic acid': 3, 'microparticle': 1, 'adipic acid - it is anticipated that the Poly - A particles represent a therapeutic strategy in acute respiratory distress syndrome with a rare opportunity': 1, 'metformin': 4, 'Metformin': 1, 'Ambroxol': 2, 'methylprednisolone': 2, 'January': 1, 'paraquat': 2, 'propofol': 6, 'oleic acid ( oleic acid )': 1, 'oleic acid group': 2, 'oleic acid': 2, 'oleic acid + IX group,': 1, 'Albumin': 1, 'LLDT-8': 4, 'Dexmedetomidine antagonist yohimbine ( yohimbine )': 1, 'catecholamine': 1, 'yohimbine': 1, 'AngioJet': 1, 'Maresin': 3, 'plasminogen activator inhibitor ( PAI)-1 ( SMD :': 1, 'ANG2': 1, 'interleukin': 1, 'IL-8': 4, 'Metrnbeta': 1, 'terbutaline': 3, 'transferase dUTP nick - end labeling': 1, 'Honokiol': 2, 'superoxide dismutase in bronchoalveolar lavage fluid ( bronchoalveolar lavage fluid': 1, 'superoxide dismutase': 2, '14(S)-HDHA': 2, 'prostaglandin': 2, 'linolenic acid': 1, 'DMEM': 1, 'peroxiredoxin': 2, 'abolishes': 1, 'dehydroepiandrosterone - sulfate': 1, 'omeprazole': 2, 'bergamottin': 1, 'Bergamottin': 1, 'tsRNA-5002b': 1, 'tsRNA-3045b': 1, 'tsRNA-5005b': 1, 'intratracheal': 2, 'Naboandelus': 1, 'citrate': 1, 'extracellular citrate': 2, 'pro - interleukin-1beta': 1, 'adenosine - triphosphate ( adenosine-triphosphate )': 1, 'red mitochondrial superoxide': 1, 'semisynthetic': 1, 'Plaur': 1, 'Syringaresinol': 1, 'lidocaine': 8, 'nivolumab': 1, 'Infliximab': 2, 'Lidocaine': 1, 'carbapenems': 2, 'Ali': 1, 'tigecyclin': 1, 'colistin': 1, 'streptozotocin': 1, 'analgesic': 1, 'interleukin ( IL)-1beta and prostaglandin E2 ( prostaglandin E2 )': 1, 'Antioxidant compounds': 1, 'Bronchoalveolar lavage fluid ( bronchoalveolar lavage fluid': 1, 'JAK2': 1, 'luteolin': 1, 'quercetin': 1, 'Coronavirus': 1, 'erythropoietin': 1, 'mitogen': 1, 'Palrnatine': 1, 'Dimethyl fumarate ( Dimethyl fumarate': 1, 'Dimethyl fumarate': 10, 'Dimethyl fumarate ( dissolved in': 1, 'zinc metalloproteinase': 1, 'polyanionic sodium alginate ( NaAIg )': 1, 'intratracheally': 1, 'Aldehyde': 5, 'Matrix': 1, 'glycocalyx': 1, 'acetylcysteine': 10, 'Canadian Acetaminophen Overdose': 1, 'paracetamol': 1, 'polyplexes': 1, 'hypochlorous acid ( hypochlorous acid': 1, 'hypochlorous acid concentration': 1, 'hypochlorous acid': 1, 'Osteoprotegerin': 1, 'microRNAs': 1, 'exosomes': 1, 'Exosomes': 1, 'Na(+),K(+)-ATPase': 2}, 'pain': {'opioids': 16, 'opioid': 30, 'Cochrane Llibrary': 1, 'analgesia': 16, 'baclofen': 7, 'LPB': 1, 'Morphine': 1, 'morphine': 7, 'pharmacokinetics': 1, 'chemoradiotherapy': 4, 'carboplatin': 3, 'paclitaxel': 2, 'trametinib': 2, '-1/1/2/3': 1, 'VRS': 17, 'corticosteroids': 7, 'corticosteroid': 4, 'February': 3, 'steroid': 11, 'concomitantly': 2, 'November': 1, 'Oswestry': 1, 'interlaminar': 2, 'Osteonecrosis': 1, 'Visual Analog Scale ( visual analog scale': 1, 'September': 6, 'gabapentin': 4, 'psychiatric medication': 1, 'Stimwave': 1, 'Methylene blue ( Methylene blue )': 1, 'nitric oxide synthesis': 2, 'analgesic': 15, 'Methylene blue': 2, 'Methylene blue group included 53 patients . In both groups , the Numeric Rating Scale': 1, 'Methylene blue group were also respective significantly lower than that of the control group at 3 months': 1, 'Methylene blue injection': 1, 'Methylene blue can significantly reduce pain intensity , improve patient lumbar function: p = 0.018': 1, 'lidocaine': 5, 'diazepam': 5, 'ultrasonographic': 1, 'antihistamines': 1, 'January': 6, 'October': 2, 'botulinum toxin injection': 2, 'botulinum toxin injections': 1, 'CGX': 1, 'syngeneic': 1, 'ProQuest': 1, 'nitrous': 2, 'interactions': 1, 'oxygen': 1, 'N2O': 1, 'EMONO': 3, 'Weierkang': 1, 'Kyoto': 2, 'endotheliitis': 1, 'benzodiazepine': 2, 'nonsteroidal': 2, 'colchicine': 1, 'chemotherapy': 11, 'CCRT': 1, 'cisplatin': 1, 'narcotic analgesics': 1, 'spasmolytics': 1, 'analgesics': 2, 'antibiotics': 4, 'methylene blue dye ( 1.25 mL': 1, 'irinotecan': 1, 'CBDCA': 3, 'fentanyl': 3, 'Transmucosal': 2, 'Curcuma longa ( curcumin )': 1, 'mefenamic': 1, 'mefenamic acid': 2, 'curcumin': 2, 'mefenamic acid (': 1, 'antibiotic': 1, 'amoxicillin': 1, 'metronidazole': 1, 'Tongsayobang': 2, 'heparin': 1, 'warfarin': 1, 'vitamin K antagonist': 1, 'anticoagulation': 1, 'albumin': 1, 'glucocorticoid': 1, 'platelet rich plasma ( platelet rich plasma )': 1, 'PF.BACKGROUND': 1, 'Remimazolam': 1, 'benzodiazepines': 1, 'propofol': 5, 'remimazolam': 1, 'propionate receptor antagonists': 1, 'propionate receptor antagonist': 1, 'pregabalin': 5, 'tramadol': 6, 'acetaminophen': 1, 'nortriptyline': 1, 'prednisolone': 1, 'perampanel': 2, 'Arabia': 1, 'duloxetine': 1, 'amitriptyline': 1, 'Pregabalin': 1, 'etomidate': 4, 'intraperitoneally': 1, 'Propofol': 1, 'detortion': 1, 'buprenorphine': 16, 'methadone': 1, 'IQR': 3, 'progestin': 5, 'levonorgestrel': 1, 'Diazepam': 1, 'glucocorticoids': 1, 'Firmicutes': 2, 'Bacteroidetes': 2, 'Osaka': 1, 'tetrodotoxin': 1, 'glutamate': 2, 'serratiopeptidase': 3, 'dexamethasone': 3, 'chymotrypsin': 1, 'opioid analgesic dipeptide': 1, 'Versius': 1, 'cannabis': 1, 'Wilcoxon': 2, 'lysine': 1, 'methionine': 1, 'sedative medications': 1, 'chronic opioid': 1, 'Opioid': 2, 'chronic opioid administration': 1, 'contrast': 1, 'diclofenac': 7, 'pain medication': 1, 'chemoradiation': 1, 'intracerebroventricular': 1, 'cysteine protease': 1, 'amantadine': 1, 'selegiline': 1, 'levodopa': 2, 'benserazide': 1, 'carbidopa': 1, 'GeneCards': 1, 'tamoxifen': 1, 'synovectomy': 1, 'Suboxone': 3, 'naloxone': 1, 'Sandoz': 1, 'Alvogen': 1, 'ropivacaine': 1, 'sufentanil': 1}, 'fractures': {'September': 3, 'denosumab': 7, 'UCHealth': 1, 'October': 2, 'bisphosphonates': 2, 'anabolic': 3, 'Visual Analog Scale ( visual analog scale': 1, 'bone anabolic': 1, 'Serum vitamin D': 1, 'vitamin D receptor genotyping': 1, 'vitamin D': 4, 'uric acid': 1, 'Vitamin D': 1, 'vitamin D receptor gene polymorphisms were not linked to rheumatoid arthritis . trabecular bone score and': 1, 'vitamin D receptor gene polymorphisms were not linked to rheumatoid arthritis': 1, 'Medline': 1, 'CINAHL': 1, 'Cointegrator': 5, 'January': 9, 'raloxifene': 1, 'teriparatide': 1, 'glucocorticoid': 2, 'chemotherapy': 5, 'Greulich': 1, 'opioid': 4, 'analgesics': 3, 'opioids': 2, 'antibiotics': 3, 'Cochrane library databases ( last update : May 2020 )': 1, '30(th': 1, 'KDMLI': 3, 'February': 2, 'decompressive craniectomy': 1, 'methotrexate': 9, 'steroid': 1, 'Osteoporotic': 1, 'R3': 1, 'August': 4, 'risedronate': 1, 'Oswestry': 1, 'sodium bicarbonate therapy': 1, 'lactulose': 1, 'vitamin D3 supplements': 1, 'EuroQol': 1, 'microarchitectural': 1, 'Wilcoxon': 1, 'chondral': 1, 'anesthetics': 1, 'epinephrine': 3, 'dexamethasone': 4, 'supraclavicular': 1, 'interscalene': 1, 'lidocaine': 3, 'bupivacaine': 1, 'Epinephrine': 1, 'Osteosynthesis': 1, 'QuickDASH': 1, 'doxorubicin': 1, 'magnesium': 1, 'Serum Calcium and magnesium': 2, 'Propofol': 1, 'remifentanil': 1, 'rocuronium': 1, 'Polyethylene glycol ( Polyethylene glycol )': 1, 'Polyethylene glycol polymers': 1, 'Polyethylene glycol blend': 1, 'Polyethylene glycol in the poly(lactic acid)': 1, 'enoxaparin': 3, 'Comfrey': 3, 'testosterone': 1, 'estradiol': 1, 'sclerostin': 1, 'Arbeitsgemeinschaft': 1, 'Osteosynthesefragen': 1, 'antibiotic': 8, 'calcium sulphate': 2, 'Stimulan': 1, 'Antibiotic': 1, 'blood': 2, 'asfotase alfa': 3, 'pseudofracture': 1, 'Embase': 1, 'ilioinguinal': 1, 'parathyroidectomy': 2, 'cinacalcet': 1, 'calcium': 2, 'Morinda': 1, 'normal saline': 2, 'bisphosphonate': 1, 'criteriea': 1, 'orthogeriatric': 2, 'CTX': 1, 'November': 1}, 'pancreatic cancer': {'chemotherapy': 53, 'inhalational anesthetics': 1, 'anesthesia': 10, 'inhalational': 1, 'inhalational anesthetics at Kyushu University hospital between December': 1, 'gemcitabine': 45, 'capecitabine': 6, 'STK11': 1, 'nab - paclitaxel': 7, 'nab - paclitaxel combination': 1, 'nab-paclitaxel': 5, 'chemoradiation': 2, 'S-1': 1, 'neoadjuvant chemotherapy': 6, 'VIP152': 1, 'circRNA': 1, 'anticoagulation': 1, 'fluorouracil': 2, 'epirubicin': 1, 'cyclophosphamide': 1, 'anticancer': 3, 'resveratrol ( resveratrol ) inhibits cancer (AsPC-1 cell proliferation , migration , and invasion and promotes apoptosis . Elevated expression of ryanodine receptor type 2 ( ryanodine receptor type 2 )': 1, 'resveratrol anticancer effects with ryanodine receptor type': 1, 'resveratrol': 2, 'resveratrol inhibits proliferation , migration , and invasion and suppresses ryanodine': 1, 'January': 7, 'carboplatin': 1, 'doxorubicin': 3, '2ClIBMECA': 1, 'A3ARspecific': 1, 'Gemcitabine': 10, 'nab - paclitaxel ( Gemcitabine plus nab-paclitaxel )': 1, 'FOLFIRINOX': 5, 'nab-paclitaxel chemotherapy combinations': 1, 'nab-paclitaxel regimens as a first - line treatment of metastatic Pancreas cancer . In clinical routine , it is still unclear which regiment is more effective . The present study showed increased survival (OS parameters with FOLFIRINOX': 1, 'paclitaxel': 2, 'NEK4': 1, '22-': 1, 'UBL3': 1, 'Bromelain': 2, 'Acetylcysteine': 3, 'erlotinib': 2, 'chemoradiotherapy': 3, 'Erlotinib': 1, 'Tregulatory': 1, 'October': 1, 'fisetin': 2, 'PHF10': 5, 'resectable': 2, 'monotherapy': 1, 'gliomaassociated': 3, 'fluorescein isothiocyanate ( CS /': 1, 'nomogram': 4, 'Perfluorooctanoic acid ( Perfluorooctanoic acid': 1, 'Perfluorooctanoic acid': 2, 'nitric oxide synthase': 1, 'Amanita': 1, 'silymarin compounds': 1, 'KRAS': 1, 'heterotypic': 1, 'soluble ALCAM': 1, 'ABR': 1, 'HDAC inhibitors ( HDAC inhibitors ) in Pancreatic ductal adenocarcinoma . This review summarizes the mechanisms associated with success and failure of HDAC inhibitors in Pancreatic ductal adenocarcinoma and discusses': 1, 'antecolic': 2, 'Embase': 1, 'pancreaticoduodenectomy': 2, 'September': 1, 'AG': 1, 'albumin': 1, 'adenosine triphosphate binding pocket . Therefore , we assessed its ability to induce apoptosis ( which increased 1.5-': 1, 'BIK': 1, 'desmoplastic': 1, 'unresectable': 2, 'mitomycin C': 1, 'epirubicin hydrochloride': 1, 'farnesyl transferase inhibitor': 1, 'photothermal': 3, 'boronic acid ( boronic acid )': 1, 'boronic acid - ligand fluorescence conjugate can effectively target multiple cancer stem cells': 1, 'chemo': 1, 'hydrogel precursor solution': 1, 'analgesia': 9, 'ADP': 1, 'adenosine triphosphate': 2, 'August': 1, 'posttreatment': 1, 'erastin': 1, 'RSL3': 1, 'HPA': 1, 'PD-1': 1, 'Proton Boron Fusion Therapy ( Proton Boron Fusion Therapy )': 1, 'Proton Boron Fusion Therapy in pancreatic cancer (AsPC-1 . The ( 19)F - BPA carrier': 1, 'Fatty acid binding protein 4 or the - single - point mutant Fatty acid binding protein 4 ( R126Q , fatty acid binding site mutant )': 1, 'Clinicopathological': 1, 'Adjuvant': 1, 'pancreatogastrostomy': 1, 'Dindo': 1, 'nab': 1, 'Medtronics': 1, 'opioid': 5, 'opioids': 2, 'OMPs': 3, 'doxorubicin hydrochloride': 1, 'Chitinase': 5, 'chemosensitivity': 1, 'multiagent chemotherapy ( multiagent chemotherapy )': 1, 'multiagent chemotherapy': 2, 'durvalumab': 1, 'adenosine triphosphate ( adenosine triphosphate ) production in a galactose - containing medium resulting in significant cytotoxicity . Importantly , 64 ( DX3 - 234 )': 1, 'dihydrofuran': 1, 'doublecortinlike': 2, 'CDK inhibitors': 1, 'miR1291': 2, 'nab - paclitaxel (': 1, 'nab-paclitaxel )': 1, 'Fluorouracil': 1, 'anabolic': 1, 'prodrugs': 1, 'osteopontin': 5, 'shRNA': 1, 'fatty acid': 1, 'asparaginase': 16}, 'colorectal cancer': {'chemotherapy': 53, 'propofol': 6, 'sevoflurane': 2, 'Propofol': 1, 'anesthesia': 2, 'multitesting': 1, 'NCTN': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'irinotecan': 4, 'conatumumab': 1, 'quercetin': 1, 'fasting insulin': 4, 'fasting insulin ( n = 34 )': 1, 'circulating insulin': 1, 'intratumoral': 2, 'estradiol': 6, 'insulin': 5, 'Mir-155_5p': 1, 'PPI': 1, 'nomogram': 3, 'ketamine': 1, 'COX-2': 1, 'microsomal prostaglandin E': 1, 'Ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mPGES-1': 2, 'taTME.Linoleic acid ( taTME.Linoleic acid )': 1, 'taTME.Linoleic acid': 1, 'taTME.Linoleic acid treatment': 1, 'taTME.Linoleic acid reduced GLI2 ubiquitination': 1, 'taTME.Linoleic acid - induced cleaved GLI2': 1, 'taTME.Linoleic acid - mediated suppression of Sox17 expression . These results suggest that taTME.Linoleic acid promotes tumor cell stemness': 1, 'GLI2 fragments via': 1, 'GLI2': 2, 'taTME.Linoleic acid -': 1, 'antifungal': 1, 'anticancer': 2, 'SCFAs': 1, 'fluorouracil': 1, 'chemo': 2, 'anticoagulant': 1, 'Warfarin': 1, 'SOX': 2, 'bevacizumab': 5, 'IRIS': 1, 'FOLFIRI': 1, 'August': 1, 'Australasia': 1, 'honokiol': 1, 'Lidocaine': 2, 'lidocaine': 6, 'Gemcitabine': 1, 'cisplatin': 1, 'January': 3, 'chemotherapy(ACT)in': 1, 'oxaliplatin': 9, 'analgesia': 8, 'laparotomies': 1, 'Interquartile': 1, 'anticoagulants': 1, 'EuroQol': 1, 'October': 1, 'selenium': 1, 'panitumumab': 1, 'erlotinib': 1, 'gefitinib': 1, 'CellSeg': 1, 'CCR6': 1, 'anthraquinone laxatives': 2, 'laxatives': 1, 'Wnt ligands': 1, 'PORCN inhibitor': 1, '23/174': 1, 'probiotics': 1, 'dihydroartemisinin': 4, 'circRNA': 2, 'Cochrane Library databases': 1, 'nonpharmacologic': 2, 'mesalamine': 2, 'Embase': 1, 'CINAHL': 1, 'curcumin': 4, 'methotrexate': 5, 'fatty acid synthase ( fatty acid synthase )': 1, 'pelareorep': 1, 'Oncolytic': 1, 'reovirus': 1, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 1, 'neoadjuvant chemotherapy': 1, 'Overexpression': 1, 'cetuximab': 6, 'Transwell': 1, 'bile acid receptor TGR5': 1, 'doublet chemotherapy': 3, 'doublet chemotherapy + anti - epidermal growth factor receptor ( vs doublet chemotherapy': 1, 'AOM': 1, 'amino acid': 1, 'doublet chemotherapy immunotherapywith': 1, "Peyer 's patches ( Peyer's patches": 1, 'TLR6': 1, 'NHSII': 1, 'estrogens': 2, 'ATCC': 1, 'beta inhibitors': 1, 'ZNF384 knockdown models were established in colorectal cancers cells': 1, 'cancerassociated': 2, 'lactic acid efflux': 1, 'Antibiotic': 1, 'antibiotic': 5, 'ANCOVA': 1, 'carcinoembryonic': 1, 'brivanib': 1, 'axitinib': 1, 'Glutamine': 1, 'GLS': 1, 'JMJD2D inhibitor': 1, 'glucosamine': 3, 'Fluorouracil': 1, 'Influencers': 1, 'Alvoxal': 2, 'lactic acid efflux inhibition': 1, 'mitoxantrone': 2, 'doxorubicin': 2, 'rhodamine': 1, 'PD-1 inhibitors': 1, 'neurotoxin rotenone': 1}, 'Breast cancer': {'January': 4, 'September': 2, 'bisphosphonates': 1, 'denosumab': 1, 'Actinomyces': 4, 'chemotherapy': 50, 'estradiol': 8, 'testosterone': 1, 'progesterone': 2, 'AKT inhibitor': 1, 'paclitaxel': 8, 'FoundationOne': 1, 'PUPOSE': 1, 'multitesting': 1, 'MSH6': 1, 'MSH2': 1, 'amino acid ( amino acid': 1, 'amino acid': 5, 'deregulation': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'Tamoxifen': 18, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 9, 'glutathione peroxidase ( GSH - Px )': 1, 'trastuzumab': 14, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'cisplatin': 4, 'nanogels': 2, 'curcumin': 7, 'anticancer': 3, 'glutathione ( GSH )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 11, 'ovulation': 1, 'letrozole': 12, 'clomiphene citrate': 3, 'clomiphene': 6, 'livebirth': 5, 'Takeda': 1, 'Roche': 1, 'estrogen receptor / progesterone receptor / human epidermal growth factor receptor': 1, 'fasting insulin': 2, 'insulin': 3, 'tamoxifen': 16, 'antineoplastic': 1, 'Chemotherapy': 7, 'suramin': 3, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'Ursolic acid ( Ursolic acid': 1, 'Ursolic acid': 6, 'artemisinin': 1, 'dihydroartemisinin': 3, 'neoadjuvant chemotherapy': 8, 'PARP inhibitor': 1, 'PARP inhibitors': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'Kyoto': 1, 'compound Kushen': 2, 'November': 1, 'chemotherapies': 1, 'nomogram': 1, 'CRISPR': 2, 'progesterone receptor (PR ( progesterone receptor )': 2, 'estrogen receptor': 3, 'Herceptin': 13, 'dimerization blocker , Stattic ( S )': 1, 'nanocarrier': 1, 'Stattic': 5, 'PLGA nanoparticles': 1, "progesterone receptor (PR status . Rates of high Wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'steroid': 2, 'prednisolone': 1, 'Prednisolone': 1, 'progesterone receptor': 1, 'eribulin': 1, 'Fulvestrant': 1, 'EC': 1, 'capecitabine': 1, 'docetaxel': 4, 'nivolumab': 3, 'anastrozole': 2, 'epirubicin': 5, 'cyclophosphamide': 6, 'fructose': 1, 'pertuzumab': 5, 'fluorouracil': 5, 'NeoSphere': 1, 'TRYPHAENA': 1, 'imatinib': 4, 'fulvestrant': 2, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'antifungal': 1, 'chemotherapy(TC)and': 1, 'chemo': 2, 'bevacizumab': 4, 'fulvestrant)was': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'ICG': 1, 'October': 2, 'intratumorally': 1, 'photodynamic': 1, 'aromatase inhibitors': 1, 'CDK4/6 inhibitors': 1, 'glucocorticoid': 1, 'anthracycline': 1, 'Progesterone receptor (PR membrane component': 1, 'Progesterone receptor membrane component': 7, 'FPR2': 1, 'GPR37': 1, 'CCR5': 1, 'radioactive iodine ( radioactive iodine ) treatment increased markedly . radioactive iodine': 1, 'radioactive iodine treatment': 2, 'radioactive iodine ( yes v no or unknown ) using Poisson regression among > /= 5-': 1, 'radioactive iodine treatment ( 45': 1, 'nonsignificantly': 1, 'radioactive iodine': 2, 'carboplatin': 3, 'blebbing': 1, 'psychotropics': 1, 'doxycycline': 1, 'citrate ions': 1, 'anticancer compounds': 1, 'herceptin': 1, 'PSN': 1, 'CAncer': 1, 'progesterone receptor ) receptor (PR - negative human breast cancer (BC . Here , we show that reverting the high LIP': 1, 'NMYC': 1, 'PsycINFO': 1, 'hormone binding globulin ( sex hormone binding globulin )': 1, 'hormone binding globulin': 1, 'hormone binding globulin by suppression status . Conclusions : There were no differences in FE2 but significantly lower E2 and higher sex hormone binding globulin among women with HIV versus without HIV . Further research is merited in a large contemporary sample': 1, 'Adjuvant': 1, 'bisphosphonate': 6, 'ibandronate': 1, 'zoledronic acid': 1, 'glutathione peroxidase': 2, 'iRGD': 1, 'ferroptosis': 1, 'postmastectomy': 1, 'Clinicopathological': 1, 'progesterone receptor (PR ( PgR ) status , in which ER-/PgR + tended to present the worst prognosis . CONCLUSION : This study revealed profound heterogeneity associated with hazard ratios status in the clinical outcomes of human epidermal growth factor receptor 2 - positive breast cancer (BC regarding clinicopathological': 1, 'Ado - trastuzumab emtansine ( T - DM1 )': 1, 'monoclonal antibody': 1, 'microtubule inhibitor emtansine': 1, 'L1CAM': 1, 'shRNA': 1, 'Oncomine': 1, 'Aurein': 1, 'aromatase inhibitors ( aromatase inhibitors )': 1, 'NSAIDs': 1, '2012.PURPOSE': 1, '12,907': 1, 'CHOP': 1, 'pAMPK': 2, 'GRP78': 2, 'Bax': 2, 'valrubicin': 1, 'antibiotics': 1, 'steroids': 2, 'leuprorelin': 1, 'Fluorouracil': 2}, 'lung cancer': {'January': 7, 'September': 3, 'intratumoral': 1, 'cisplatin': 18, 'gemcitabine': 8, 'pemetrexed': 8, 'bevacizumab': 6, 'chemotherapy': 61, 'pharmacokinetics': 2, 'chemoradiotherapy': 4, 'carboplatin': 6, 'paclitaxel': 3, 'trametinib': 2, '-1/1/2/3': 1, 'chloroisopropyl': 2, 'phosphate': 1, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - progressive disease - L1 therapy': 1, 'OPTN': 1, 'atezolizumab': 2, 'docetaxel': 4, 'AVENIO': 1, 'Cobas': 1, 'osimertinib': 13, 'BRAF': 1, 'Glyco disulfide acted as reducing and capping agents of gold ions': 1, 'October': 1, 'linalool oxide': 1, 'fatty acid biosynthesis': 1, 'chemoradiation': 1, 'Akaike': 1, 'alectinib': 8, 'CBDCA': 3, 'Clinicopathological': 1, 'PKLR': 1, 'amino acid': 1, 'anthracyclines': 2, 'phosphate buffered saline . Anti - cancer (A549 effects of extracts': 1, 'SPLC': 1, 'Interferon': 1, 'nomogram': 1, 'checkpoint inhibitor': 3, 'pseudoprogression': 1, 'Ocimum': 1, 'methylprednisolone': 1, 'pembrolizumab': 8, 'microCi': 2, 'cholesterol biosynthesis': 1, 'poly adenosine diphosphate ribose polymerase inhibition . Inhibition of Squalene epoxidase interrupted homologous recombination by suppressing ATM activity via': 1, 'epoxidase inhibitors': 1, 'antifungal': 1, 'opioids': 2, 'benzodiazepines': 1, 'antidepressants': 1, 'opioid': 1, 'benzodiazepine': 1, 'August': 2, 'chemoimmunotherapy': 3, 'anticoagulation': 2, 'hyperpolarized': 2, 'Osimertinib': 5, 'thrombospondin': 4, 'radiosensitivity': 1, 'regulate thrombospondin': 1, 'Oct4': 1, 'PTPRD': 1, 'authorisation': 1, 'biotransformation': 1, 'microg': 5, 'saline': 1, 'malondialdehyde': 1, 'chemo': 5, 'CDK4': 1, 'Bortezomib': 2, 'crizotinib': 1, 'brigatinib': 2, 'Niementowski': 1, 'anthranilic acid ( 1a )': 1, 'Physicochemical': 1, 'ADMET': 1, 'caspases activators': 1, 'EC chemotherapy': 1, 'SCLC.PURPOSE': 1, 'Aprepitant': 2, 'dexamethasone': 2, 'antiemetic': 2, 'antiemetics': 1, 'aprepitant': 1, 'Metformin': 1, 'metformin': 1, 'valrubicin': 1, 'cabozantinib': 1, 'chemical inhibitors': 1, 'CRISPR': 1, 'mannitol': 1, 'corticosteroids': 1, 'EGFRtyrosine kinase inhibitor': 1, 'Bufotalin': 11, 'glutathione peroxidase': 3, 'ferroptosis': 1, 'sugemalimab': 10, 'CStone Pharmaceuticals': 1, 'Etoposide': 9, 'Hoechst': 1, 'Annexin': 1, 'TNS1': 1, 'Overexpression': 1, 'steroids': 3, 'beta blockers': 1, 'diuretics': 2, 'ACE inhibitors': 1, 'oxygen': 1, 'poly adenosine diphosphate ribose polymerase ( poly adenosine diphosphate ribose polymerase )': 1, 'anticancer': 1, 'veliparib': 1, 'Immunohistochemistry': 1, 'serine': 1, 'NEK4': 1, 'follistatin': 1, 'fenbendazole': 1, 'FBZ': 1, 'albendazole': 1, 'Transwell': 1, 'Matrigel': 1, 'antivirals': 1, 'antimalarials': 1, 'antibiotics': 1, 'steroid': 1, 'immunoglobulins': 1, 'poly adenosine diphosphate ribose polymerase )': 1, 'poly adenosine diphosphate ribose polymerase': 1, 'Youden': 1, 'CA125': 1, 'fentanyl': 7, 'analgesia': 3, 'Docetaxel': 1, 'antimitotic chemotherapy medication': 1, 'Labeled docetaxel': 1, 'Alvotere': 4, 'NanoAlvand': 1, 'chemotherapeutic': 1, '21.3mo': 1, 'BB': 1, 'durvalumab': 3, 'nivolumab': 1, 'Taxol': 2, 'estradiol': 1, 'miR-96': 1, 'doxorubicin': 1, 'kinase inhibitors': 1, 'CCRT': 8, 'lymphocyte': 1, 'aldehyde hyaluronic acid': 1, 'Anticancer': 1, 'Cisplatin': 1, 'CDDP': 1, 'Doxorubicin': 1, 'hyponatraemia': 1, 'PD(L)-1': 1}, 'HER2-positive breast cancer': {'trastuzumab': 282, 'pertuzumab': 27, 'chemotherapy': 61, 'neoadjuvant chemotherapy': 6, 'fluorouracil': 7, 'epirubicin': 8, 'cyclophosphamide': 11, 'docetaxel': 13, 'NeoSphere': 2, 'TRYPHAENA': 1, 'Herceptin': 40, 'citrate ions': 1, 'Clinicopathological': 1, 'estrogen receptor (PgR ( estrogen receptor )': 1, 'progesterone receptor (PgR ( progesterone receptor ) status , in which ER-/PgR + tended to present the worst prognosis . CONCLUSION : This study revealed profound heterogeneity associated with hormone receptor status in the clinical outcomes of human epidermal growth factor receptor 2 - positive breast cancer regarding clinicopathological': 1, 'capecitabine': 17, 'deruxtecan': 7, 'zenocutuzumab': 1, 'emtansine': 13, 'Docetaxel': 3, 'carboplatin': 6, 'August': 2, 'Primaquine': 2, 'November': 1, 'TTRE': 1, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 2, 'FTY720': 1, 'taxane': 8, 'tucatinib': 2, 'arachidonic acid': 2, 'anthracycline': 13, 'Trastuzumab': 13, 'neoadjuvant anti - human epidermal growth factor receptor': 1, 'HER2DX': 1, 'paclitaxel': 17, 'neoadjuvant': 3, '1BB monoclonal antibody': 6, 'TUBO': 1, '1BB monoclonal antibody combination therapy had a synergistic antitumor effect at the initial treatment': 1, '1BB monoclonal antibody combination therapy': 1, 'fulvestrant': 5, 'pyrotinib': 10, 'rapamycin': 10, 'lapatinib': 45, 'horseradish peroxidase ( horseradish peroxidase )': 1, 'anastrozole': 3, 'Neoadjuvant': 6, 'Lapatinib': 8, 'hsa': 1, 'hormone receptor': 1, 'September': 2, 'margetuximab': 1, 'IRRs': 1, 'Ado - trastuzumab emtansine ( T - DM1 )': 1, 'kinase inhibitors': 1, 'Nanobodies': 1, 'amino acid': 1, 'CDR1': 1, 'doxorubicin': 2, 'MSNs': 1, 'TZMSC': 1, 'DOTA': 1, 'HER2])-based': 1, 'MMP2': 1, 'uridylyl phosphate adenosine': 1, 'lysine': 1, 'Vojvodina': 1, 'Bengbu': 1, 'Neoadjuvant chemotherapy': 1, 'Affibody molecule ( 6 - 7 kDa )': 1, 'Affibody': 3, 'estrogen receptor )': 4, 'pembrolizumab': 1, 'atezolizumab': 2, 'durvalumab': 1, 'nivolumab': 1, 'antidiarrheal': 1, 'loperamide': 2, 'colestipol': 1, 'antidiarrheal medications in a real - world clinical setting': 1, 'ACE inhibitors': 1, 'beta - blockers': 1, 'statins': 1, 'anticancer': 2, 'diphenyltetrazolium bromide': 1, 'Everolimus': 1, 'dasatinib': 2, 'ACE - I': 1, 'progesterone': 2, 'estrogen receptor / progesterone positivity rate (DCR was 72': 1, 'nab - paclitaxel was preferred': 1, 'cetuximab': 2, 'peg - filgrastim was prophylactically administered': 1, 'oligometastatic': 1, 'Ado - trastuzumab ( T - DM1 )': 1, 'oleanolic acid ( oleanolic acid )': 1, 'oleanolic acid': 2, 'everolimus': 1, 'pharmacodynamics': 1, 'pharmacokinetics': 1, 'Cytotoxic': 1, 'PD-1': 1, 'RXR agonist': 1, 'concomitantly': 1, 'October': 1, 'Pertu': 1, 'pharmacokinetic': 1, 'Letrozole': 1, 'aromatase inhibitor ( aromatase inhibitor': 1, 'letrozole': 3, 'nomogram': 1, 'alpha ( estrogen receptor )': 1, 'progesterone receptor (PgR ( progesterone )': 3, 'estrogen receptor - progesterone - human epidermal growth factor receptor': 1, 'CDK4/6 inhibitors': 1, 'bioequivalence': 1, 'humanized Mucin': 1, 'Margetuximab': 1, 'dodecyl sulfate - polyacrylamide gel': 1, 'neoadjuvant pertuzumab': 1, 'her-2 blockade and taxanes': 1, 'January': 4, 'Thermotoga': 1, 'thalidomide': 5, 'cereblon': 1, 'recombinant humanized anti - human epidermal growth factor receptor 2 monoclonal antibody (nAb': 1, 'Tz': 1, 'beclin': 1, 'selenite': 1, 'TTFields': 1, 'docked ligands': 1, 'ofdocetaxel': 1, 'Pertuzumab': 2, 'eugenol': 1, 'threonine kinase': 1, 'progesterone receptor (PgR status [ hormone receptor , 3.12 ; 95 % confidence interval ( confidence intervals )': 1, 'TIL': 1, 'tyrosine kinase inhibitor ( tyrosine kinase inhibitor ) with promising efficacy in the human epidermal growth factor receptor-2 ( human epidermal growth factor receptor 2 ) positive breast cancer . The phase III PHOEBE study proved that pyrotinib plus capecitabine': 1, 'vinorelbine': 1, 'biosimilars': 1, '95%CI': 1, 'estrogen': 1, 'progesterone receptor (PgR negativity and human epidermal growth factor receptor-2 positivity . After neoadjuvant therapy , the tumor in her left breast reduced in size , but the lymph nodes remained swollen . Mastectomy and axillary lymph node dissections were performed . In the pathological findings , epithelioid cell granuloma was observed in the lymph nodes . Based on these findings , lymph node swelling was attributed to a sarcoid - like reaction . CLINICAL DISCUSSION : SLRs have been reported in 4 - 14': 1, 'rapamycin inhibitors': 1, 'cisplatin': 4, 'Alamar Blue': 1, 'Annexin': 1, 'HER3': 1, 'Ado - trastuzumab': 1, 'ribociclib': 5, 'ado': 1, 'February': 2, 'IRCCS': 1, 'Gemelli': 1, 'Polyclinic': 1, 'dendrimers functionalized with anti - human epidermal growth factor receptor 2 VHHs': 1, 'Adjuvant chemotherapy': 1, 'neoadjuvant chemotherapy with PH - FECH': 1, 'noncardiac': 1, 'nab - paclitaxel plus': 1, 'estrogen receptor ( p =': 1, 'progesterone receptor ( p = 1.0 )': 1, 'Adjuvant': 1, 'Pim1': 1, 'Pim1 inhibitor': 3, 'Cardiotoxicity': 2, "humanized monoclonal antibody (nAb against CD47 , blocks CD47 's": 1, 'rituximab': 3, 'estrogen receptor / progesterone levels': 1, 'estrogen receptor / progesterone level might be associated with better DFS.Intercellular mechanisms by which the stromal microenvironment contributes to solid tumor progression and targeted therapy resistance remain poorly understood , presenting significant clinical hurdles': 1, 'Bioinformatic': 1}, "Alzheimer's disease": {'AMPK': 2, 'thiocholine': 2, 'Schisandrae': 2, 'F%': 1, 'ketamine': 1, 'amino acid tryptophan': 1, 'dantrolene': 4, 'beta-site': 1, 'Epling': 1, 'Donepezil': 1, 'phellandrene': 1, 'quinazolinones': 1, 'benzothiadiazine': 1, 'Cladosporium': 1, 'streptozotocin': 7, 'curcumin nanoparticles ( curcumin nanoparticles': 1, 'curcumin': 11, 'nitric oxide ( nitric oxide': 1, 'curcumin nanoparticles': 1, 'opioid analgesic dipeptide': 1, 'morphine': 2, 'intracerebroventricular': 3, 'cysteine protease': 1, 'hydroxy - alpha)': 1, 'Hydroxy-alpha-sanshool - LP': 1, 'asparagine endopeptidase inhibitors': 2, 'asparagine endopeptidase inhibitor': 1, 'doxycycline': 2, 'scopolamine': 6, 'gst-4': 1, 'Bacopa': 8, 'asiatic acid': 1, 'quercetin': 1, 'hypocretins': 1, 'suvorexant': 1, 'lemborexant': 1, 'dysregulate': 1, 'avicularin': 1, 'October': 2, 'Fluoxetine': 3, 'fluoxetine': 3, 'super oxide dismutase': 1, 'sialic acid moiety': 1, 'alprazolam': 1, 'Ferulic acid': 1, 'Ferulic acid exhibits various therapeutic actions by modulation of various signal transduction pathways such as Nrf2': 1, 'ferulic acid include anti - apoptosis , antioxidant , anti - inflammatory , antidiabetic': 1, 'ferulic acid': 1, 'Curcumin': 1, 'insulin': 1, 'DMSO': 1, 'intrahippocampal': 1, 'OpenGrey': 1, 'nitric oxide': 1, 'Vitamin B12 supplementation . Results : Out of 2920 study eligible subjects ,': 1, 'Vitamin B12 supplementation . BACKGROUND : Chronic alcohol consumption can alter the structure of the central nervous system': 1, 'neprilysin': 1, 'retinoic acid': 5, 'diphenyltetrazolium bromide': 1, 'resveratrol': 7, 'polyphenol antioxidant found in plants': 1, 'JOTROLTM': 1, 'JOTROL': 4, 'neuromodulator norepinephrine': 1, 'normal saline': 1, 'Saponins': 1, 'flavonoids': 2, 'crude saponins and flavonoids from Basal forebrain were able': 1, 'saponins': 1, 'flavonoid': 1, 'nitric oxide synthase inhibitor': 1, 'vitagenes': 1, 'neuropathogenesis': 1, 'Gingipains': 1, 'Cannabidiol': 6, 'opioid': 1, 'psychostimulant': 1, 'nicotine': 2, 'opioids': 1, 'psychostimulants': 1, 'neuroradiologists': 1, 'ESCI': 1, 'Quercetin ( Quercetin )': 1, 'neuroinflammation': 1, 'Quercetin': 3, 'https://github.com/zhangpl109/DeepMGT-DTI.Both Curcuma longa ( Curcuma longa )': 1, 'Curcuma longa extract': 1, 'aducanumab': 1, 'levodopa': 1, 'annexins': 1, 'EWAS': 1, 'Colocalisation': 1, 'rosiglitazone': 5, 'NSC': 1, 'histone deacetylase inhibition , rescued the deficits in gamma oscillations in PSAPP mice': 1, 'dimethyl fumarate ( DMF)-induced anti - inflammatory and neuroprotective effects in the brain along with improvement in cognitive functions in rats with the Intracerebroventricular - streptozotocin': 1, 'DMF rat chow': 1, 'Scopus': 1, 'January': 1, 'August': 1, 'Proteobacteria': 1, 'Bifidobacterium': 1, 'Phascolarctobacterium': 1, 'Clostridiaceae': 1, 'Lachnospiraceae': 1, 'Rikenellaceae': 1, 'ghrelin receptor agonist': 1, 'Montine': 3, 'oxytosis': 1, 'diacetylbritannilactone': 1, 'malondialdehyde': 2, 'super oxide dismutase ( super oxide dismutase )': 1, 'metals chelator': 1, 'steroids': 1, 'estrogens': 1, 'rapamycin': 2, 'KLVFF': 1, 'Honokiol': 1, 'superoxide dismutase ( super oxide dismutase': 1, 'photothermal': 1, 'GADA': 2, 'Zn': 2, 'vitamin D': 2, 'Pb': 1, '32,761': 1, 'Mitophagy': 1}, 'diabetes': {'glucose': 7, 'Cochrane Llibrary': 1, 'insulin': 49, 'fasting insulin ( fasting insulin': 1, 'fasting insulin ( beta = -1.348': 1, 'fasting insulin': 5, 'hoxy)phenoxy)acetic acid (ARA ( lead compound': 1, 'n=63': 1, '1.299': 1, 'APO': 1, 'streptozotocin': 11, 'ferric ammonium citrate ( FAC , 200muM )': 1, 'fluoxetine': 5, 'norepinephrine': 1, 'Fluoxetine': 1, 'vasopressor': 1, 'carboxyethyl lysine': 1, 'macroalbuminuria': 1, 'linoleic acid (ARA ( linoleic acid )': 1, 'arachidonic acid (ARA ( arachidonic acid )': 1, 'linoleic acid': 3, 'arachidonic acid': 2, 'linoleic acid - enriched media': 1, 'Methylene blue ( Methylene blue )': 1, 'nitric oxide synthesis': 1, 'analgesic': 1, 'Methylene blue': 3, 'Methylene blue group included 53 patients . In both groups , the Numeric Rating Scale': 1, 'Methylene blue group were also respective significantly lower than that of the control group at 3 months': 1, 'Methylene blue injection': 1, 'Methylene blue can significantly reduce pain intensity , improve patient lumbar function , pain - related depression and sleep quality , increase total effective rate with no severe adverse side effects . Rapid identification of patients likely': 1, 'Allyl isothiocyanate ( Allyl isothiocyanate )': 1, 'Allyl isothiocyanate': 4, 'Allyl isothiocyanate action': 1, 'intragastrically': 1, 'Irrespectively': 1, 'Allyl isothiocyanate considerably lowered thyroid hormones ( fT4 , fT3 )': 1, 'Allyl isothiocyanate at': 2, 'blood insulin': 1, 'chemotherapy': 9, 'fluorouracil': 1, 'leucovorin': 1, 'irinotecan': 5, 'oxaliplatin': 1, 'serine hydrolase carboxylesterase': 1, 'FOLFIRINOX': 1, 'anticoagulation': 1, 'Microaneurysm': 4, 'statin': 4, 'lysophosphatidylcholines': 2, 'hydroxysphingomyelins': 2, 'acarbose': 1, 'Amylase inhibitors': 1, 'vitamin B12': 1, 'glucagon': 13, 'dipeptidyl peptidase 4 inhibitors ( dipeptidyl peptidase 4 inhibitors )': 1, 'Acyclic': 2, 'apelin': 1, 'matrix metalloproteinases': 1, 'iron': 1, 'chelation': 1, 'steroids': 2, 'amino acids': 1, 'imidazoles': 1, 'hydroxy acids': 2, 'choline plasmalogens': 1, 'polyunsaturated fatty acids , carotenoids ,': 1, 'nonesterifed fatty acids , phospholipids and carnitines in blood serum using liquid chromatography - tandem mass spectrometry': 1, 'nitric oxide': 2, 'divalent cations ( magnesium , zinc': 1, 'antifungal': 1, 'corticosteroids': 1, 'epithelialization': 1, 'hydroxyproline': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'glutathione peroxidase ( glutathione peroxidase': 1, 'malondialdehyde': 3, 'antidepressants': 1, 'antipsychotics': 1, 'thymoquinone': 2, 'hyaluronate ( hyaluronate ) group ( n = 30 eyes )': 1, 'hydrocortisone': 1, 'January': 4, 'Embase': 1, 'AMED': 1, 'Pregabalin': 3, 'bioactive analogues': 1, 'palmitic acid (ARA ( physical activity ) played a synergistic role in the pathogenesis of Diabetic peripheral neuropathy . MATERIALS AND METHODS : The proliferation rate of Rat Schwann cell line RSC96 cells': 1, 'September': 1, 'fasting insulin ( n = 34 )': 1, 'circulating insulin': 1, 'canagliflozin': 4, 'Amino acids': 1, 'ovulation': 1, 'letrozole': 11, 'clomiphene citrate': 3, 'clomiphene': 6, 'livebirth': 5, 'Takeda': 1, 'Roche': 1, 'uric acid , allantoin': 1, 'uric acid': 1, 'red blood cells ( red blood cells': 1, 'high insulin': 1, 'propionate': 1, 'butyrate': 1, 'Metformin': 2, 'metformin': 13, 'receptor agonists': 1, 'lifelong insulin': 1, 'rapamycin': 2, 'November': 2, 'empagliflozin': 1, 'Quercetin': 3, 'vitamin E': 2, 'spectrophotometrically': 1, 'vitamin E treatment reversed these effects , suggestive of their anti - apoptotic effect': 1, 'IGHM': 1, 'Analgesics': 1, 'Leptotricia': 1, 'periodontopathogens': 1, 'antibiotic': 2, 'anesthesia': 1, 'lidocaine': 1, 'propofol': 2, 'rocuronium bromide': 1, 'royal jelly': 1, 'Il-2': 1, 'sodium nitroprusside ( sodium nitroprusside': 1, 'oxidative': 1, 'antibiotics': 1, 'corticosteroid': 1, 'SCOPUS': 1, 'Machakos': 3, 'sodium ozagrel': 2, 'atorvastatin': 5, 'February': 2, 'linagliptin': 1, 'vildagliptin': 3, 'maspin': 4, 'oxygen': 1, 'phosphate buffered saline': 1, 'sulfonylurea': 1, 'myelosuppression': 1, 'Astragaloside': 2, 'uric acid - induced pancreatic beta - cell damage need': 1, 'uric acid - induced pancreatic beta - cell dysfunction in T2D. Methods : uric acid - treated Min6 cells': 1, 'uric acid - stimulated Min6 cells': 1, 'compromised insulin': 1, 'ZFP161': 1, 'valine': 1, 'leucine': 1, 'isoleucine biosynthesis , serine': 1, 'circRNA': 3, 'mRNA interactions': 1, 'isoleucine': 1, 'hippurate': 1, 'proanthocyanidins': 6, 'UDCA': 1, 'GUDCA': 1, 'Tetraspanins': 2, 'desmopressin': 1, 'Indonesia': 1, 'resistin': 1, 'Cleaved': 1, 'superoxide dismutase and glutathione peroxidase': 1, 'HADHA': 3, 'opioids': 1, 'cause(s)and': 1, 'carboplatin': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'blood': 1, 'Prevalences': 1}, 'Polycystic ovary syndrome': {'insulin': 91, 'glucose': 10, 'peak insulin': 1, 'fasting insulin': 7, 'Analgesics': 1, 'periodontopathogens': 1, 'letrozole': 42, 'adipocytokines': 1, 'Curcumin': 1, 'polyphenolic compound': 1, 'curcumin exhibits immobilizing action on sperms , and at': 1, 'curcumin': 11, 'chemotherapeutic': 1, 'Embase': 3, 'albuminuria': 1, 'hyperandrogenism': 10, 'flutamide': 1, 'Spironolactone': 1, 'spironolactone': 7, 'January': 11, 'September': 4, 'clomiphene': 16, 'Kuntai': 4, 'estradiol': 15, 'Berberis': 1, 'berberine': 2, 'dehydroepiandrosterone sulfate': 3, 'luteinizing hormone (LH / follicle - stimulating hormone (LH , testosterone': 2, 'antiandrogen': 2, 'adropin': 1, 'metatrim': 1, 'cholesterol': 2, 'fatty acid (TCA oxidation': 1, 'testosterone': 4, 'dehydroepiandrosterone - sulfate ( dehydroepiandrosterone - S )': 1, 'polyunsaturated fatty acids ( polyunsaturated fatty acids )': 1, 'NCT04738409.).Estradiol': 1, 'steroid': 5, 'ERbeta': 1, 'Letrozole': 3, 'metformin': 54, 'Metformin': 6, 'normal saline water ( 0.9': 1, 'malondialdehyde': 4, 'IL-6': 1, 'genistein': 4, 'gonadotropins': 2, 'diacerein': 2, 'serum insulin': 1, 'interleukin': 2, 'inflammasome': 1, 'valproate': 1, 'lamotrigine': 2, 'oxcarbazepine': 2, 'carbamazepine': 2, 'progesterone': 13, 'Gpx3': 1, 'mRNAs': 7, 'tamoxifen': 2, 'clomiphene citrate': 2, 'Tamoxifen': 1, 'dehydroepiandrosterone': 7, 'Androgens': 1, 'estrogens': 3, 'glucagon': 1, 'peripheral insulin resistance in the early phase of type 2 diabetes . In the skeletal muscle and liver , the ATP surplus contributes to insulin resistance': 1, 'donor breastmilk': 1, 'ovarian insulin resistance in polycystic ovary syndrome remain elusive . METHODS : Follicular fluid': 1, 'Electroacupuncture': 7, 'Indonesia': 1, 'Folliculogenesis': 2, 'resveratrol': 5, 'resveratrol potently': 1, 'November': 1, 'estrogen': 2, 'oxytocin': 5, 'arginine - vasopressin , AVP )': 1, 'phoenixin': 1, 'PNX': 1, 'lipidomic': 1, 'vitamin - like nutrients ( bioflavonoids and alpha - lipoic acid (TCA )': 1, 'selenium': 1, 'chromium': 1, 'omega-3 fatty acids': 1, 'probiotics': 4, 'androgens': 1, 'placentaspecific': 2, 'fasting insulin ( FINS : WMD -3.40': 1, 'Serum metformin concentrations': 1, 'kisspeptin': 1, 'receptor antagonist': 1, 'B analogs': 1, 'vitamin B12': 1, 'vitamin D': 3, 'prebiotics': 2, 'Cochrane databases': 1, 'synbiotics': 2, 'pioglitazone': 6, 'Ferriman - Gallwey score ( F - G )': 1, 'fasting insulin ( fasting insulin': 1, 'Insulin': 1, 'GeneCards': 1, 'Kyoto': 3, '13,823': 1, 'melatonin': 1, 'glucose transporter ( GLUT4 )': 1, 'palmitic acid (TCA ( physical activity )': 1, 'ESR2': 2, 'Latvia': 1, 'bile acid (TCA and 24 bile acid (TCA metabolites': 1, 'taurocholic acid (TCA ( taurocholic acid )': 1, 'glycochenodeoxycholic acid (TCA ( glycochenodeoxycholic acid )': 1, 'Resveratrol possesses anti - inflammatory , antioxidant and antidiabetic properties . The purpose of this study was to evaluate the potential effectiveness of resveratrol in polycystic ovary syndrome based': 1, 'ovariectomy': 1, 'ovulate': 1, 'dysglycemia': 1, 'fasting insulin resistance ( homeostatic model assessment of insulin': 1, 'psychiatric medication': 1, 'statins': 4, 'Statins': 1, 'statin': 1, 'Do insulin sensitizing agents such as': 1, 'myoinositol': 3, 'Ferriman': 1, 'Ferriman Gallwey': 2, 'Bushen': 3, 'cyproterone': 1, 'norepinephrine': 1, 'hydroxyindoleacetic acid (TCA (': 1, 'luteinizing hormone': 1, 'Bushen Jieyu Tiaochong Formula': 1, 'ATF4': 1, 'drospirenone': 1, 'Scopus': 1, 'Cochrane': 1, 'orlistat': 8, 'acarbose': 2, 'rosiglitazone': 2, 'sitagliptin': 1, 'lipotoxicity': 1, 'glycerophosphocholines': 1, 'sphingolipids': 1, 'rhamnosus GG': 1, 'free testosterone': 1, 'luteinizing hormone , luteinizing hormone': 1, 'February': 2, '17,076': 1, 'antioxidative vitamins ( vitamins )': 1, 'Cochrane Library databases': 1, 'CINAHL': 2, 'pipelle': 1, 'hormone agonist protocol': 2, 'hormone agonist': 1, 'hormone agonist cycles': 1, 'MDM2': 1, 'Hyperinsulinism': 1, 'Cytoscape': 2, 'EREG': 1, 'Wenshentiaojing': 1, 'luteinizing hormone (LH and follicle - stimulating hormone (LH , serum total cholesterol': 1, 'GPR120 agonist decreased insulin resistance in the polycystic ovary syndrome rat model but improved the ovarian function . It is suggested that GPR120 plays a vital role in suppressing insulin resistance , regulating ovary function and decreasing lipid accumulation in the liver , demonstrating that targeting GPR120 could be an effective method for the improvement of PCOS.Polycystic ovary syndrome (MS ( polycystic ovary syndrome )': 1, 'Merck': 2, 'cyclopamine': 1, 'allopregnanolone': 1, 'Serum leptin /': 1, 'Bacteroidetes': 1, 'Blautia': 3, 'butyric acid (TCA , reduced after Sleeve gastrectomy . Sleeve gastrectomy significantly ameliorated polycystic ovary syndrome - related symptoms such as hyperandrogenism': 1, 'Pentraxin': 2, 'lipid': 1, 'Drosha': 1, 'Glucose': 1, 'Anticoagulation': 1, 'apixaban': 2, 'vitamin D3 supplementation : either a microencapsulated liposomal': 1, 'immunoreactive insulin': 2, 'vitamin D supplementation': 1, 'vitamin D3': 2, 'dihydrotestosterone': 2, 'progesterone receptor (ER , homeobox A11 mRNA expression and placental estrogen - related receptor (ER beta and trophoblast - specific protein alpha mRNA expression . Collectively , our data provide insight into how N-acetylcysteine': 1, 'gonadotropin': 1, 'RBPMS': 1, 'leptin': 4, 'intracerebroventricular': 2, 'Extracellular glutathione peroxidase': 1, 'glutathione peroxidase': 2, 'Antibiotic': 1, 'Dorea': 1, 'dehydroepiandrosterone sulphate ( dehydroepiandrosterone sulphate )': 1, 'alpha - lipoic acid (TCA on clinical , endocrine and metabolic features of women affected by polycystic ovary syndrome . METHODS : In this pilot cohort study , 60 women ( 30 hyperinsulinemic and 30 normoinsulinemic patients ; age 15 - 34 years ) were enrolled and clinical , hormonal and metabolic parameters were evaluated before and after a six - months treatment with alpha - lipoic acid (TCA': 1, 'progestin': 1, 'synthetic oxytocin': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'GSH': 1}, 'cognitive impairment': {'Ketamine': 2, 'anesthesia': 1, 'nonopioid analgesic': 1, 'ketamine': 13, 'January': 4, 'F%': 1, 'cholinesterase inhibitors': 1, 'memantine': 5, 'Embase': 5, 'donepezil': 8, 'galantamine': 1, 'rivastigmine': 3, 'Donepezil': 2, 'streptozotocin': 4, 'curcumin nanoparticles ( curcumin nanoparticles': 1, 'curcumin': 1, 'nitric oxide ( nitric oxide': 1, 'curcumin nanoparticles': 1, 'malondialdehyde': 2, 'October': 4, 'tramadol': 1, 'Tramadol': 1, 'chemotherapy': 8, 'necrostatin-1': 1, 'Turkey': 1, 'nonsteroidal': 1, 'aspirin': 7, 'aspirin nonsteroidal anti-inflammatory drugs from 3 months': 1, 'aspirin nonsteroidal anti-inflammatory drugs dispensed': 1, 'aspirin nonsteroidal anti-inflammatory drugs': 1, 'phytanic acid': 2, 'C26:0': 2, 'OpenGrey': 1, 'amyloid beta': 1, 'nitric oxide': 1, 'sphingolipids': 2, 'lipidomic': 1, 'Alzheimer Nederland': 1, 'analgesic': 1, 'PAINAD': 1, 'folic acid ( odds ratio = 0.59': 1, 'folic acid': 1, 'GABAergic': 1, 'excitatory glutamate': 1, 'aminobutyric acid': 1, 'neuroradiologists': 1, 'liposomal complexes carrying': 1, 'CRISPR': 1, 'Physicochemical': 1, 'cannabidiol': 10, 'Forkhead': 1, 'levodopa': 1, 'annexins': 1, "Hydrogen sulfide ( H2S ) plays an important role in cognitive function . Therefore , this work is aimed at investigating whether H2S attenuates the cognitive impairment in Parkinson's disease and the underlying mechanisms . In the rotenone- ( rotenone- )": 1, 'clozapine': 1, 'histone deacetylase inhibition , rescued the deficits in gamma oscillations in PSAPP mice': 1, 'Scopus': 4, 'August': 1, 'Proteobacteria': 1, 'Bifidobacterium': 1, 'Phascolarctobacterium': 1, 'Clostridiaceae': 1, 'Lachnospiraceae': 1, 'Rikenellaceae': 1, 'phosphate transporter (': 1, 'Immunohistochemistry': 1, 'vitamin D supplementation . METHODS : Forty male Wistar rats were divided into 4 groups . Control , metabolic syndrome ( 20': 1, 'vitamin D supplemented (': 1, 'vitamin': 1, 'VAMP': 1, 'Vitamin D supplementation mitigated alterations': 1, 'Vitamin D supplementation offered neuroprotective effects': 1, 'CNKI': 2, 'SinoMed': 1, 'Wanfang': 2, 'VIP': 2, 'Sishencong': 3, 'acupoint': 1, 'Apolipoprotein': 2, 'clonazepam': 5, 'CINAHL': 3, 'thrombolytics': 2, 'extraventricular': 1, 'neuroendoscopic lavage': 1, 'MEDLINE': 1, 'testosterone': 1, 'androgens': 1, 'sodium nitroprusside': 2, 'wars': 1, 'antidepressants': 1, 'insulin': 1, 'PsychINFO': 1, 'PsycINFO': 1, 'antivirals': 1, 'BCRSS': 1, '1OR': 1, 'polytherapy': 1, 'Qingxiang Tiguanyin ( Tgy - Q )': 1, 'Nongxiang Tieguanyin ( Tgy - N )': 1, 'oxcarbazepine': 1, 'acetaminophen': 1, 'cortical norepinephrine': 1, 'Clemastine fumarate': 1, 'clemastine': 1, 'neurofilament': 1, 'steroids': 1, 'cyclophosphamide': 1, 'acetylcholinesterase inhibitors ( acetylcholinesterase inhibitors )': 1, 'dysexecutive': 2, 'nicotine': 4}, 'non-small cell lung cancer': {'intratumoral': 1, 'cisplatin': 27, 'gemcitabine': 9, 'pemetrexed': 4, 'bevacizumab': 13, 'chemotherapy': 81, 'pharmacokinetics': 3, 'chemoradiotherapy': 11, 'carboplatin': 5, 'paclitaxel': 6, 'trametinib': 2, '-1/1/2/3': 1, 'chloroisopropyl': 2, 'phosphate': 1, 'MEK inhibitor ( MEK inhibitor': 1, 'MEK inhibitor / anti - progressive disease - L1 therapy': 1, 'OPTN': 1, 'atezolizumab': 1, 'docetaxel': 13, 'AVENIO': 1, 'January': 5, 'TKIs inhibitors': 7, 'BRAF': 1, 'chemoradiation': 1, 'TKIs inhibitors ( tyrosine kinase inhibitors )': 3, 'Akaike': 1, 'alectinib': 8, 'Clinicopathological': 1, 'PKLR': 1, 'amino acid': 2, 'anthracyclines': 2, 'phosphate buffered saline . Anti - cancer effects of extracts': 1, 'Interferon': 1, 'nomogram': 1, 'TKIs inhibitor ( tyrosine kinase inhibitor ) resistance , epidermal growth factor receptor - tyrosine kinase inhibitor': 1, 'osimertinib': 18, 'pembrolizumab': 14, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'antifungal': 1, 'TKIs inhibitor ( tyrosine kinase inhibitor )': 2, 'chemoimmunotherapy': 3, 'TKIs inhibitors ( tyrosine kinase inhibitors': 2, 'hyperpolarized': 2, 'Osimertinib': 5, 'thrombospondin': 4, 'radiosensitivity': 1, 'regulate thrombospondin': 1, 'PTPRD': 1, 'authorisation': 1, 'chemo': 4, 'CDK4': 1, 'Bortezomib': 2, 'crizotinib': 1, 'dexamethasone': 2, 'antiemetic': 2, 'Aprepitant': 1, 'antiemetics': 1, 'aprepitant': 1, 'cabozantinib': 1, 'mannitol': 1, 'corticosteroids': 1, 'EGFRtyrosine kinase inhibitors (TKIs inhibitor': 1, 'Bufotalin': 11, 'glutathione peroxidase': 3, 'ferroptosis': 1, 'sugemalimab': 10, 'CStone Pharmaceuticals': 1, 'steroids': 2, 'beta blockers': 1, 'diuretics': 2, 'ACE inhibitors': 1, 'TKIs inhibitor ( tyrosine kinase inhibitor': 2, 'oxygen': 1, 'Immunohistochemistry': 1, 'serine': 1, 'September': 2, 'checkpoint inhibitor': 8, 'follistatin': 1, 'Docetaxel': 1, 'antimitotic chemotherapy medication': 1, 'Labeled docetaxel': 1, 'Alvotere': 4, 'NanoAlvand': 1, 'chemotherapeutic': 1, '21.3mo': 1, 'BB': 1, 'durvalumab': 6, 'nivolumab': 2, 'miR-96': 1, 'doxorubicin': 1, 'lymphocyte': 1, 'hyponatraemia': 1, 'PD(L)-1': 1, 'budigalimab': 2, 'neoadjuvant chemotherapy': 2, 'gefitinib': 6, 'erlotinib': 15, 'TKIs inhibitors ( epidermal growth factor receptor - tyrosine kinase inhibitors )': 2, 'PPI': 1, 'interactions': 1, 'glycyrrhetinic acid derivative': 1, 'TKIs inhibitor': 5, 'neoadjuvant immunotherapy with sintilimab': 1, 'brigatinib': 1, 'Ramucirumab': 1, 'anticancer': 1, 'etoposide': 3, 'August': 1, 'dacomitinib': 1, 'prednisolone': 2, 'lorlatinib': 3, 'Lorlatinib': 1, 'CLINICALTRIALS': 1, 'veliparib': 2, 'TKIs inhibitors ( epidermal growth factor receptor - tyrosine kinase inhibitors': 1, 'pyrotinib': 2, 'February': 1, 'normal albumin': 1, 'albumin': 1, 'Erufosine': 1, 'Cisplatin': 1, 'resectable': 1, 'biopolymer': 1, 'nanocarrier': 1, 'aminolevulinic acid ( aminolevulinic acid ) prodrug )': 1, 'nintedanib': 5, 'Nintedanib': 1, 'Scopus': 1, 'demethylase': 4, 'Thrombospondin': 2}, 'pancreatic ductal adenocarcinoma': {'chemotherapy': 67, 'fluorouracil': 4, 'leucovorin': 2, 'irinotecan': 7, 'oxaliplatin': 7, 'serine hydrolase carboxylesterase': 2, 'opioid': 1, 'gemcitabine': 86, 'circRNA': 1, 'SSPPD': 1, 'PALN': 1, 'Adjuvant chemotherapy': 2, 'January': 4, 'Tregulatory': 1, 'Interleukin-2': 1, 'nab - paclitaxel (': 1, 'nab': 3, 'nab - paclitaxel': 5, 'fisetin': 2, 'PHF10': 5, 'nitric oxide synthase': 1, 'pancreatoduodenectomy': 2, 'PGRN blockade': 1, 'adenosine triphosphate binding pocket . Therefore , we assessed its ability to induce apoptosis ( which increased 1.5-': 1, 'desmoplastic': 1, 'farnesyl transferase inhibitor': 1, '12,018': 1, 'ADP': 1, 'gadoxetic acid - enhanced magnetic resonance imaging': 1, 'Ductal': 7, 'rapamycin': 4, 'insulin': 6, 'PCNA': 1, 'IDH1': 1, 'erastin': 1, 'RSL3': 1, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 1, 'resectable': 1, 'unresectable': 2, 'Clinicopathological': 2, 'Adjuvant': 1, 'pancreaticoduodenectomy': 2, 'osteopontin': 7, 'shRNA': 2, 'Gli1': 2, 'sAXL': 1, 'farnesyl diphosphate synthase (': 1, 'farnesyl diphosphate synthase': 4, 'zoledronic acid )': 2, 'farnesyl diphosphate synthase overexpression in pancreatic ductal adenocarcinoma tissues and cells (ICs ( P <': 1, 'CRISPR': 2, 'zoledronic acid exerts radiosensitization': 1, 'zoledronic acid': 1, 'carboxylesterase': 1, 'sEH inhibitors': 1, 'anabolic': 1, 'thrombospondin': 1, 'autophagy': 2, 'macropinocytosis': 1, 'HER2 inhibitor': 1, 'lapatinib': 3, 'sphingosine analog fingolimod ( FTY720 )': 1, 'Lapatinib': 1, 'FTY720': 2, 'hydroxychloroquine': 4, 'KLK10': 1, 'nomogram': 3, 'panitumumab': 2, 'methylcytosine': 1, 'Gemcitabine': 1, 'unresecable': 1, 'exosomes': 1, 'albumin': 1, 'polyamine blockade therapy ( polyamine blockade therapy ) strategy for inhibiting pancreatic tumor progression . Moreover , polyamine blockade therapy treatment': 1, 'syngeneic': 2, 'polyamine blockade therapy - treated tumors revealed macrophage presence and significantly increased expression of CD86 , a T cell co - stimulatory marker . Collectively , therapies which target polyamine metabolism can': 1, 'amino acid': 1, 'retinoic acid ( retinoic acid': 1, 'cisplatin': 4, 'HSP90 inhibitors . Mechanistic explanations of this synergy include the degradation of Fanconi anemia pathway factors upon HSP90 inhibition . Treatment with the drug combination resulted in increased DNA damage and chromosome fragmentation , as we have reported previously for ovarian cancer cells (ICs . On top of this , HSP90 inhibition also enhanced the accumulation of DNA - bound platinum . We next investigated an orthotopic syngeneic animal model consisting of tumors arising from Kras(G12D/+);p53(flox/flox);Pdx1-Cre(ERT2) cells (ICs ( LSL - KrasG12D/+ ; LSL - Trp53R172H/+': 1, 'HSP90 inhibitor onalespib': 1, 'Zeste Homolog': 1, 'Zeste Homolog 2 complex and reveal posttranslational Enhancer of Zeste Homolog': 1, 'Zeste Homolog 2 complex formation in PDAC.Pancreatic ductal adenocarcinoma ( pancreatic ductal adenocarcinoma )': 1, 'chemokine ligand': 1, 'XGBoost': 2, 'capecitabine': 12, 'Insulin': 1, 'foradjuvant': 1, 'Acinar': 3, 'heterocellular interactions': 1, 'lysosomal inhibitor': 1, 'RTKs': 1, 'autophagy inhibitors in PDAC.BACKGROUND': 1, 'rocaglamide': 1, 'cadmium chloride ( CdCl2 )': 1, 'splanchnicectomy': 3, 'histone deacetylase': 4, 'PDGFRbeta': 1, 'amino acid glycine': 1, 'KRAS': 1, 'cobimetinib': 2, 'FOLFIRINOX': 1, 'UnderweightWHO': 1, 'NormalWHO': 1, 'OverweightWHO': 1, 'Peptidic': 1, 'paclitaxel': 5, 'pancreatospheres': 1, 'cytopathologists': 1, 'chemo': 1, 'Transcriptomic': 1, 'epigenomic': 1, 'Scopus': 1, 'Embase': 1, 'Notch3 plays': 1, 'Notch3': 1, 'chemosensitivity': 1, 'checkpoint inhibitors in pancreatic cancer has been unsuccessful .': 1, 'Glucocorticoids': 1, 'glucocorticoid receptor ( glucocorticoid receptor ) signaling are long thought to suppress immunity by acting on immune cells (ICs . Here we demonstrate a previously undescribed tumor cell - intrinsic role for glucocorticoid receptor in activating pancreatoduodenectomy - L1 expression and repressing the major histocompatibility complex class I ( MHC - I ) expression in pancreatic ductal adenocarcinoma ( pancreatic ductal adenocarcinoma ) cells (ICs through transcriptional regulation . In mouse models of pancreatic ductal adenocarcinoma , either tumor cell - specific depletion or pharmacologic inhibition of glucocorticoid receptor leads to pancreatoduodenectomy - L1 downregulation and MHC - I upregulation in tumor cells (ICs , which in turn promotes the infiltration and activity of cytotoxic T cells (ICs , enhances anti - tumor immunity , and overcomes resistance to immune checkpoint blockade therapy': 1, 'ProMeta': 1, 'autophagy inhibitor': 1, 'chemoresistance': 1, 'Rosmarinic acid ( retinoic acid': 1, 'retinoic acid': 10, 'retinoic acid restrained': 1}, 'NACT': {'chemotherapy': 285, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 39, 'neoadjuvant chemotherapy': 173, 'chemoradiation': 17, 'cisplatin': 38, 'paclitaxel': 36, 'docetaxel': 19, 'carboplatin': 30, 'Neo': 3, 'chemo': 7, 'trastuzumab': 14, 'anthracycline': 6, 'progesterone receptors (PR ( pathological response )': 1, 'platinum compounds': 1, 'Carboplatin': 2, 'Chemotherapy': 13, 'neoadjuvant chemotherapy ( docetaxel ,': 1, 'fluorouracil': 1, 'Wilcoxon': 1, '8.7%]and': 1, 'Ductal': 1, 'immunohistochemical': 1, 'epirubicin': 12, 'cyclophosphamide': 14, 'doxorubicin': 14, 'neoadjuvant chemotherapy ( group A )': 1, 'neoadjuvant chemotherapy ( group B )': 1, 'neoadjuvant chemotherapy ( group C )': 1, 'trachelectomy': 4, 'neoadjuvant chemotherapy - concurrent chemoradiation': 1, 'Neoadjuvant chemotherapy': 2, 'loplatin': 2, 'Akaike': 1, 'nomogram': 1, '01/01/2003': 1, 'PFS': 2, 'peg - filgrastim was prophylactically administered': 1, 'oligometastatic': 1, 'Nomograms': 1, 'Neoadjuvant': 1, 'Autophagy': 1, 'Scopus': 1, 'extracellular citrate': 1, 'September': 1, 'etoposide': 1, 'Teleconsultation': 1, 'January': 8, 'neoadjuvant chemotherapy protocols implemented': 1, 'UFT': 1, 'neo': 6, 'Neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 4, 'estrogen receptors': 1, 'citrate transporter ( NaCT )': 2, 'citrate': 1, 'Exogenous citrate': 1, 'citrate supplementation increases de novo lipogenesis and (delta- growth of hepatocellular carcinoma cells': 1, 'Citrate supplementation rescues Huh7 cell (IC viability in response to glutamine deprivation or Zn(2 + ) treatment , and (delta- NaCT deficiency mitigates these effects . Collectively , these findings demonstrate that NaCT - mediated citrate uptake': 1, 'bevacizumab': 7, 'Formalin': 1, 'mucinous': 1, 'chemoradiotherapy': 2, 'NACT+CCRT': 2, 'chemotherapeutics': 1, 'gemcitabine': 3, 'blue dye': 1, 'progesterone receptor (PR ( pathological response )': 1, 'infusional': 1, 'methotrexate': 1, 'divalent anion sodium symporter ( divalent anion sodium symporter': 1, 'antibiotic': 1, 'anion sodium symporter': 1, 'dicarboxylate transporter': 1, 'divalent anion sodium symporter protein structures': 1, 'divalent anion sodium symporter proteins': 1, 'ethyl sulfate': 1, 'oxaliplatin': 8, 'albumin': 1, 'Adjuvant chemotherapy': 1, 'anthracyclines': 4, 'anticoagulation': 2, 'methylene blue dye': 1, 'ifosfamide': 1, 'heparin': 1, 'NACT+IDS': 1, 'adnexa': 1, 'pertuzumab': 1, 'February': 1, 'Embase': 1, 'Anthracycline': 2, 'Nagelkerke': 1, 'CDK inhibitors': 1, 'Convolutional': 1, 'analgesia': 1, 'Porphyromonas': 3, 'October': 1, 'postmastectomy': 1, 'NACT.BACKGROUND': 1, 'sodium citrate ( NaCt )': 1, 'NaCt': 1, '46,274': 1, 'emtansine': 1, 'Rishikesh': 2, 'Sonomammography': 1, 'neoadjuvant chemotherapy containing anti - human epidermal growth factor receptor 2 reagent': 1, 'nucleic acid sampling (': 1, 'nucleic acid sampling following neoadjuvant': 1, 'nucleic acid sampling': 1, 'neoadjuvant chemotherapy - interval debulking': 1, 'November': 1}, 'peripheral neuropathy': {'PES': 1, 'chemotherapy': 185, 'covalent inhibitor': 1, 'GSH': 1, 'Embase': 1, 'AMED': 1, 'immunoglobulin': 2, 'palmitic acid ( palmitic acid ) played a synergistic role in the pathogenesis of Diabetic peripheral neuropathy . MATERIALS AND METHODS : The proliferation rate (DCR of Rat Schwann cell line RSC96 cells': 1, 'glucose': 3, 'palmitic acid': 7, 'bevacizumab': 2, 'FOLFIRI': 2, 'cosegregation': 1, 'spiropyran': 1, 'paclitaxel': 70, 'duvelisib inhibited paclitaxel': 1, 'Wuguchong': 10, 'Genecards': 1, 'peptide compounds': 1, 'immunotherapy': 1, 'checkpoint inhibitor': 1, 'delamanid': 1, 'linezolid': 4, 'injectables': 2, 'injectable': 1, 'epineurium': 1, 'Neurolysis': 1, 'CNW': 1, 'levodopa': 7, 'October': 1, 'January': 4, 'analgesic': 2, 'Unani': 1, 'analgesics': 2, 'platinumcomplex': 1, 'oxaliplatin': 56, 'fatty acid betaoxidation': 1, 'fatty acid beta - oxidation cycle': 1, 'glutathione peroxidase ( glutathione peroxidase': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'Intecc': 1, 'nab - paclitaxel plus programmed cell death protein 1 inhibitor ( sintilimab )': 1, 'February': 2, 'nab - paclitaxel plus sintilimab were enrolled in this study . The objective response rate (DCR was': 1, 'epithelioid': 1, 'glutathione': 1, 'mecobalamin': 2, 'bortezomib': 9, 'Oxaliplatin': 2, 'streptozotocin': 2, 'potentiate': 1, 'antiproliferative': 1, 'empagliflozin': 2, 'vitamin D supplementation': 1, 'vitamin': 1, 'vitamin D supplementation significantly controlled or reduced hemoglobin A1C': 1, 'Chemotherapy': 7, 'systemic anticancer treatment': 1, 'auriculotherapy': 1, 'intraplantar': 1, 'vitamin B supplementation': 2, 'Vitamin B supplementation could improve many symptoms and signs of DPN.For': 1, 'pregabalin': 12, 'sphingolipids': 1, 'calpain': 1, 'carbidopa': 2, "carbidopa - levodopa . However , his blood work was consistent with a significant increase in lambda light chain levels and the presence of an M spike in serum protein electrophoresis . Based on the presentation and clinical workup , he was finally found to have both multiple myeloma and Waldenstrom 's macroglobulinemia . Underlying malignancy was treated with chemotherapy": 1, 'dopamine': 2, 'vitamin D': 4, 'vitamin D supplementation in patients with diabetic peripheral neuropathy in addition to standard treatment': 1, 'gabapentin': 4, 'amitriptyline': 2, 'Vitamin D': 1, 'nitrous': 3, 'rituximab': 1, 'ixazomib': 1, 'lenalidomide': 1, 'dexamethasone': 1, 'Cyrillicligoarginines': 1, 'nicotinic acetylcholine receptors ( nicotinic acetylcholine receptors ) inhibitors': 1, 'octaoligoarginine': 1, 'analogs': 1, 'electromyographic': 2, '36(47': 1, 'neurotoxic chemotherapy': 1, 'Paclitaxel': 2, 'Duloxetine': 3, 'reuptake inhibitor': 1, 'duloxetine': 11, 'opioids': 2, 'boric acid in cisplatin - induced neuropathy , in which oxidative stress is also effective in its pathophysiology . In this study , 8 - 10 weeks old , 170 - 190 g': 1, 'boric acid groups': 1, 'cisplatin': 27, 'boric acid': 2, 'intragastric': 1, 'boric acid ( p <': 1, 'Boric acid significantly alleviated this condition ( p <': 1, 'histone deacetylase': 1, 'organophosphates': 1, 'carmabates': 1, 'phosphinic acid': 1, 'paraquat': 2, 'phosphinic acid (': 1, 'Vincristine': 7, 'pharmacokinetics': 1, 'pharmacodynamics': 1, 'CAPG': 1, 'Mecobalamin': 1, 'iron': 1, 'corticosteroids': 1, 'cyclophosphamide': 3, 'Coenzyme Q10 ( Coenzyme Q10 Q10 )': 1, 'vincristine': 17, 'intraperitoneally': 1, 'Mycophenolate mofetil ( Mycophenolate mofetil': 1, 'Mycophenolate': 1, 'Adjuvant chemotherapy ( Adjuvant chemotherapy': 1, 'Adjuvant chemotherapy': 4, 'Adjuvant': 1, 'capecitabine': 1, 'fluorouracil': 1, 'leucovorin': 4, 'chemotherapies': 1, 'propylthiouracil': 1, 'Adelta': 4, 'Fluticasone': 1, 'pyridoxine': 1, 'vitamin B6': 1, 'thymidine phosphorylase activity': 1, 'normal saline': 1, 'doxorubicin': 2, 'prednisone': 2, 'brentuximab vedotin': 2, 'alpha - tocopherol against different toxins are assumed , therefore , it is discussed as a possible protective factor for adverse effects in cancer treatment . In July 2020 , a systematic search was conducted searching five databases ( Embase , Cochrane , PsychInfo , Cinahl , Medline )': 1, 'alpha - tocopherol as complementary treatment for cancer patients is not possible . Despite findings regarding reduction of oral side effects , usage of alpha - tocopherol during therapy or visceral crisis must be discouraged because of potential negative influence on survival (OS rates . INTRODUCTION : Oxaliplatin utilized': 1, 'trastuzumab': 1, 'September': 2, 'margetuximab': 1, 'IRRs': 1, 'Histone deacetylase': 6, 'Histone': 7, 'mannosylated clodronate liposomes': 1, 'Cisplatin': 2, 'ovariectomy': 1, 'oligodeoxynucleotide': 1, 'estrogen receptor (': 1, 'August': 1, 'taxane': 1, 'mepolizumab': 4, 'chemobrain': 1, 'antineoplastic': 1, 'ADRIAMYCIN': 1, 'CYCLOPHOSPHAMIDE': 1, 'CISPLATIN': 1, 'METHOTREXATE': 1, 'chemotherapeutic': 2, 'cannabidiol': 4, 'cannabidiol fluorinated analog': 1, 'fluorinated cannabidiol analog': 1, 'Vaxzevria': 1, 'AstraZeneca': 1, 'glomus': 1, 'proband': 1, 'acetylcholinesterase inhibitor': 1, 'thiodiazole': 3, 'acetylcholinesterase': 1, 'Budapest': 1, 'steroid': 2, 'nonsteroidal': 1, 'tricyclic': 1, 'antidepressants': 1, 'irinotecan': 2, 'FOLFIRINOX': 1, 'gemcitabine': 4, 'nab - paclitaxel (': 1, 'nab-paclitaxel ) ) . Unfortunately , chemotherapy - induced peripheral neuropathy ( chemotherapy': 1, 'mirogabalin': 5, 'nab-paclitaxel': 1, 'retinoic acid': 1, 'morphine': 2, 'serotonin': 1, 'norepinephrine reuptake inhibitor': 1, 'corticosterone': 1, 'epinephrine': 1, 'analgesia': 1, 'CIPN.SIGNIFICANCE': 1, 'purine biosynthesis': 1, 'dihydroceramides': 1, 'antibiotic': 1, 'Steroid': 1, 'antibiotics': 2, 'Azathioprine': 1, 'lycorine': 2, 'FOLFOX': 1, 'GP': 1, 'June': 1, 'ipatasertib': 5, 'protein inhibitor of activated': 2, 'metabolomic': 1, 'dronabinol': 1, 'nabilone': 1, 'opioid': 1, 'neuromodulation': 1, 'cannabinoids': 1, 'Kampo': 2, 'Tocovid': 1, 'cetuximab': 1, 'Cmab': 2, 'Ramulus': 1, 'Spatholobi': 1, 'steroids': 1, 'neuroactive steroids': 1, 'progesterone': 1, 'tetrahydroprogesterone': 1, 'Inception': 1, 'Densenet': 1}, 'neutropenia': {'January': 12, 'chemotherapy': 195, 'trifluridine': 3, 'tipiracil': 4, 'FTD': 5, 'fluorouracil': 6, 'October': 2, 'June': 1, 'Trifluridine': 3, 'niraparib': 2, 'haematological': 2, 'carboplatin': 23, 'CBDCA': 3, 'pemetrexed': 6, 'bevacizumab': 18, 'osimertinib': 3, 'antibiotics': 21, 'VIP152': 1, 'FOLFOXIRI': 6, 'cetuximab': 1, 'pegfilgrastim': 7, 'neoadjuvant chemotherapy': 1, 'docetaxel': 10, 'cisplatin': 34, 'chemoradiotherapy': 2, 'pharmacokinetics': 8, 'cytarabine': 3, 'LDAC': 1, 'human Citomegalovirus ( human Citomegalovirus )': 1, 'Citomegalovirus': 3, 'Letermovir': 1, 'delays human Citomegalovirus': 1, 'antifungal': 7, 'Toranomon': 1, 'Kajigaya': 1, 'micafungin': 1, 'voriconazole': 2, 'itraconazole': 1, 'amphotericin': 7, 'Magnusiomyces': 1, 'steroid': 6, 'fungemia': 1, 'steroids': 4, 'R - CHOP regimen of pegylated liposomal': 1, 'doxorubicin': 21, 'sugemalimab': 6, 'paclitaxel': 40, 'Chemotherapy': 18, 'taxane': 2, 'Azathioprine': 2, 'mercaptopurine': 1, 'Pegfilgrastim - cbqv ( UDENYCA((R ) ) )': 1, 'pharmacodynamics': 5, 'bioequivalence': 1, 'antidrug': 2, 'February': 3, 'dexamethasone': 14, 'pomalidomide': 3, 'lenalidomide': 17, 'proteasome inhibitor': 1, 'Melphalan': 1, 'Oncopeptides': 1, 'bendamustine': 1, 'oxaliplatin': 10, 'nivolumab': 13, 'capecitabine': 2, 'Nivolumab': 1, 'Antibiotic': 1, 'levofloxacin': 9, 'Pegylated': 1, 'Cisplatin': 1, 'purine nucleoside analogs': 1, 'camrelizumab': 1, 'nab - paclitaxel': 4, 'September': 3, 'albumin': 3, 'nab - paclitaxel plus Programmed cell': 1, 'nab - paclitaxel plus sintilimab were enrolled in this study . The objective response rate (DCR was': 1, 'epithelioid': 1, 'crizotinib': 1, 'mecapegfilgrastim': 1, 'August': 2, 'anthracycline': 5, 'platinum': 1, 'gemcitabine': 14, 'nucleoside diphosphate - linked moiety X - type motif 15 ( nucleoside diphosphate-linked moiety X-type motif 15 )': 1, 'nucleoside diphosphate-linked moiety X-type motif 15 ( * )': 3, 'nucleoside diphosphate-linked moiety X-type motif 15 variants as well as in patients with thiopurine S-methyltransferase': 1, 'nucleoside diphosphate-linked moiety X-type motif 15 polymorphisms particularly , nucleoside diphosphate-linked moiety X-type motif 15 ( * )': 1, 'antibiotic': 16, 'vancomycin': 23, 'Vancomycin': 3, 'cefepime': 2, 'piperacillin': 5, 'Enterobacterales bacteraemia': 1, 'VDLP': 1, 'vincristine': 11, 'daunorubicin': 1, 'asparaginase': 1, 'prednisone': 3, 'triplet combination chemotherapy': 1, 'nanoparticle albumin - bound ( nab)-paclitaxel , has shown promising results': 1, 'doublet chemotherapy': 1, 'Gemcitabine': 1, 'chemo': 3, 'chemoradiation': 5, 'Human serum albumin ( Human serum albumin )': 1, 'irinotecan': 14, 'pharmacokinetic': 2, 'tocilizumab': 7, 'corticosteroids': 12, 'anakinra': 3, 'dasatinib': 1, 'cyclophosphamide': 17, 'tisagenlecleucel': 1, 'CDK4/6 inhibitor': 1, 'eflapegrastim': 3, 'postdose': 1, 'microg': 2, 'Eflapegrastim': 1, 'ixazomib': 4, 'stem cell infusion': 1, 'pembrolizumab': 2, 'doxycycline': 1, 'rituximab': 11, 'prednisolone': 7, 'R - CHOP': 2, 'Pegfilgrastim': 1, 'nephrotoxicity': 1, 'corticosteroid': 3, 'HER2 blockade': 1, 'trastuzumab': 4, 'neoadjuvant': 1, 'epirubicin': 2, 'Janus kinase inhibitor upadacitinib in combination with topical': 1, 'upadacitinib': 6, 'sintilimab': 2, 'letrozole': 5, 'fulvestrant': 2, 'mycophenolic acid': 1, 'valganciclovir': 3, 'monotherapy': 3, 'brodalumab': 2, 'ribociclib': 1, 'hyaluronic acid - polyvinyl alcohol - polyvinyl pyrrolidone': 1, 'microneedle': 1, 'amphotericin B liposomes': 2, 'ramucirumab': 1, 'atezolizumab': 2, 'nab - paclitaxel regimen': 1, 'nab - paclitaxel regimen as front - line management for treatment - naive , metastatic nonsquamous': 1, 'nab - paclitaxel ( ACN ) regimen': 1, 'nab - paclitaxel ( CN ) regimen were retrospectively identified in two medical institutions from 2017 to 2020 . The co - primary end points were overall survival (OS ( overall survival )': 1, 'Janus kinase 1 inhibitor': 1, 'itacitinib': 7, 'hyperglycaemia': 1, 'antithymocyte globulin': 1, 'cyclosporine': 1, 'eltrombopaq': 1, 'azacitidine': 2, 'CRISPR': 2, 'CTCAE': 1, 'Russian blue cat with idiopathic epilepsy was diagnosed with neutropenia .': 1, 'mycophenolate mofetil': 1, 'trimethoprim - sulfamethoxazole': 1, 'ceftriaxone': 1, 'PFS': 1, 'TAS-102+B': 1, 'durvalumab': 3, 'Trabectedin': 1, 'trabectedin': 2, 'n=9': 1, 'folinic acid ( FOLFIRI )': 1, 'DLT': 1, 'antiemetics': 1, 'Karyopharm Therapeutics': 1, 'Cefazolin': 1, 'Cephalosporins': 1, 'cefazolin': 1, 'eribulin': 4, 'thiotepa': 2, 'etoposide': 2, 'melphalan': 2, 'opioid': 1, 'Brucea': 5, 'Yadanzi': 1, 'FOLFIRI': 1, 'enoxaparin': 1, 'ganciclovir': 1, 'Antibiotics': 1, 'Voriconazole': 1, 'frontline': 2, 'fluconazole': 2, 'ciprofloxacin': 4, 'Levofloxacin': 1, 'albuminuria': 1, 'vinsristine': 1, 'meropenem': 9, 'colistin': 1, 'Wilcoxon': 1, 'tazobactam': 5, 'Pip - Taz )': 1, 'RSSC': 1, 'Taz': 1, 'carbapenem': 1, 'Pip - Taz therapy in ESBL - positive patients did not prolong': 1, 'Pip - Taz': 1, 'RCCS': 1, 'P=.78': 1, 'ceftaroline': 3, 'Obinutuzumab': 1, '8/15/22': 1, 'intradermally': 1, 'veliparib': 3, 'metagenomic': 1, 'red blood cell': 2, 'myelosuppressive': 5, 'Weipu': 1, 'Wanfang': 1, 'DHP107': 1, 'Embase': 1, 'nucleoside diphosphate-linked moiety X-type motif 15': 6, 'nucleoside diphosphate-linked moiety X-type motif 15 genetic polymorphisms was performed . Results : A total': 1, 'nucleoside diphosphate-linked moiety X-type motif 15 genetic polymorphisms and thiopurine': 1, 'nucleoside diphosphate-linked moiety X-type motif 15 polymorphisms , nucleoside diphosphate-linked moiety X-type motif 15': 1, 'normal saline': 1, 'Oxaliplatin': 1, 'bortezomib': 3, 'filanesib': 3, 'GOFL': 1, 'Chemo': 1, 'antipseudomonal beta - lactams were selected . Data synthesis': 1, 'ceftazidime': 1, 'cefoperazone': 1, 'sulbactam': 1, 'Meropenem': 1, 'Leiomyosarcoma': 2, 'zanubrutinib': 2, 'blinatumomab': 1, 'red blood cell ( red blood cell': 1, 'Linkoping': 1, 'Jonkoping': 1, 'Kalmar': 1, 'mucormycosis': 1, 'Coronavirus': 1, 'Steroids': 1, 'palbociclib': 1, 'Diplopia': 1, 'urothelial': 1, 'immunosuppressants': 1, 'filgrastim': 2, 'leucopenia': 2, 'Psl': 1, 'rabbits': 1, 'rapamycin inhibitor': 1, 'antihyperglycemic': 1, 'insulin': 1, 'Colchicine': 3, 'colchicine': 5, 'gimeracil': 1, 'CDDP': 1, 'IPTG': 1, 'lysates': 1, 'PEGylated': 1, 'Hematological': 1, 'decitabine': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, '99,681': 1, 'anticancer': 2, 'Sabouraud dextrose agar': 1, 'subculturing': 1, 'Shimotsuke': 1, 'Filgrastim': 1, 'red cell': 1, 'cytopenias': 1, 'gamma globulin': 1, 'multilineage': 1, 'Methotrexate': 1, 'methotrexate': 3, 'erythromycin': 1, 'leucocyte': 1, 'platelet': 1, 'Ligue Nationale Contre le': 1, 'xentuzumab': 3, 'Xentuzumab': 2, 'bioactive insulin': 1, 'zidovudine': 2, 'plasma': 1, 'enzalutamide': 1, 'Cochrane databases': 1, 'ABVD': 3, 'procarbazine': 1, 'bleomycin': 1, 'vinblastine': 1, 'dacarbazine': 1}, 'malignancy': {'FOLFIRINOX': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'MAGL': 1, 'chemotherapy': 21, 'Isavuconazole': 7, 'Mucormycosis': 1, 'January': 10, 'antifungal': 1, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'carboplatin': 3, 'October': 2, 'progestin': 9, 'levonorgestrel': 1, 'GnRH': 3, 'miR-133b': 7, 'shrewd immunohistochemical': 1, 'chemo': 1, 'postsurgery': 1, 'presurgery': 2, 'corticosteroid': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'steroid': 2, 'Imatinib': 1, 'imatinib': 1, 'R - CHOP therapy achieved a complete response . Background : Breast cancer ( Breast cancer )': 1, 'September': 1, 'Chondrosarcoma': 1, 'opioid': 3, 'remifentanil': 3, 'propofol': 5, 'midazolam': 1, 'Bispectral': 1, 'opioids': 1, 'alfentanil': 2, 'Mecoli': 1, 'dermatomyositis': 1, 'perflutren lipid microsphere or sulfur hexafluoride lipid - type A microspheres': 1, 'glutathione peroxidase': 1, 'cisplatin': 4, 'R - CHOP': 1, 'methotrexate': 1, 'somatostatin analogue': 1, 'August': 1, 'paclitaxel': 2, 'trastuzumab': 5, 'chemoradiotherapy': 7, 'neoadjuvant chemoradiotherapy': 1, 'Pegylated': 4, 'doxorubicin': 5, 'Kyoto': 3, 'flunarizine': 1, 'chemotherapies': 1, 'palisading': 1, 'EGR1': 1, 'ZFP36': 2, 'CFD': 1, 'steroids': 1, 'immunosuppressants': 1, 'infliximab': 1, 'cyclophosphamide': 1, 'vincristine': 1, 'prednisone': 1, 'miR-20a-5p inhibitor': 1, 'Overexpression': 1, 'thyroxine': 1, 'Taxol': 2, 'estradiol': 1, 'neuraminidase inhibitors': 1, 'dyspnoea': 1, 'Multimodality': 1, 'Chemotherapy': 1, 'antiseizure medication ( ASM': 1, 'lycopene': 1, 'asparaginase': 5, 'CALGB': 1, 'anticoagulation': 2, 'copanlisib': 1, 'glucocorticoid': 1, 'entropion': 2, 'antihistamines': 1, 'corticosteroids': 1, 'hyaluronic acid ( hyaluronic acid )': 1, 'hyaluronic acid': 2, 'cancerassociated': 2, 'lactic acid efflux': 1, 'anticancer': 1, 'Antibiotics': 1, 'oxacillin': 1, 'teicoplanin': 1, 'daptomycin': 1, 'fosfomycin': 1, 'antibiotics': 6, 'Midkine': 4, 'heparin': 1, 'Transwell': 1, 'urticaria annulare': 1, 'somatostatin analogues': 1, 'SpyGlass DS': 1, 'Antibiotic': 1, 'antibiotic': 4, 'form': 1, 'deregulation': 1, 'KRAS': 1, 'NRAS': 1, 'BRAF': 1, 'antiandrogens': 1, 'anticoagulants': 2, 'AnTicoagulation': 1, 'vitamin K antagonist': 2, 'Apatinib': 1, 'anticoagulant': 4, 'vitamin K antagonist ( vitamin K antagonist )': 1, 'diuretic': 1}}

